US 20120246747A1

(19) **United States**

(12) **Patent Application Publication**

TUSCHL et al.

(10) **Pub. No.: US 2012/0246747 A1**

(43) **Pub. Date: Sep. 27, 2012**

(54) **RNA-INTERFERENCE BY SINGLE-STRANDED RNA MOLECULES**

(75) Inventors: **Thomas TUSCHL**, New York, NY (US); **Javier Martinez**, New York, NY (US); **Agnieszka Patkaniowska**, New York, NY (US); **Henning Urlaub**, Goettingen (DE); **Reinhard Lührmann**, Marburg-Michelbach (DE)

(73) Assignee: **Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.**, Muenchen (DE)

(21) Appl. No.: **13/329,710**

(22) Filed: **Dec. 19, 2011**

Related U.S. Application Data

(62) Division of application No. 10/520,470, filed on Jan. 7, 2005, now Pat. No. 8,101,348, filed as application No. PCT/EP2003/007516 on Jul. 10, 2003.

(30) **Foreign Application Priority Data**

Jul. 10, 2002 (EP) 02015532.1
Aug. 23, 2002 (EP) 02018906.4

Publication Classification

(51) **Int. Cl.**

C07H 21/02	(2006.01)
C12N 5/02	(2006.01)
A01K 67/027	(2006.01)
C12N 5/10	(2006.01)

(52) **U.S. Cl.** **800/13**; 435/325; 435/375; 536/24.5

(57) **ABSTRACT**

The present invention relates to sequence and structural features of single-stranded (ss)RNA molecules required to mediate target-specific nucleic acid modifications by RNA-interference (RNAi), such as target mRNA degradation and/or DNA methylation.

Figure 1


A
cleavage site
32
GpppG AACAUCACGUACGCGGAAUACUUCGAAAUGUCCGU
51 nt
126 nt
5′ CGUACGCGGAAUACUUCGAUU
UUGCAUGCGCCUUAUGAAGCU 5′
siRNA duplex
B
D. mel.
HeLa
T1 OH - + - +
siRNA duplex
antisense siRNA

Figure 2



Figure 3


A
HOCGUACGCGGAAUACUUCGAAAOH 3′
Y–Cp32UGCAUGCGCCUUAUGAAGCU–X 5′
B
X P OH P OH
Y OH OH P P
time (min) 0 15 120 0 15 120 0 15 120 0 15 120
ligation product
5'OH/3'OH
5'P/3'OH
5'OH/3'P
5'P/3'P

Figure 4


time point of competitor siRNA addition (min)
0
15
siRNA duplexes
competitor (nM)
100 0 0 1000 10 1000
specific (nM)
0 100 10
HeLa S100
T1 - - + + + + + + +

Figure 5


A
UV
Bt
L3
L3
Bt
UV
B
Superdex 200
aldolase
BSA
T1 UV elu 2 4 6 8 10 11 12 13 14 15
C
glycerol gradient 5-20%
aldolase
BSA
OH T1 S100 UV elu 1 3 5 7 9 11 13 15 17 19 20

Figure 6



Figure 7


A
HeLa S100
c (nM)
100
10
1
siRNA
T1 s as ds s as ds s as ds
B
Drosophila embryo
c (nM)
100
10
1
siRNA
T1 s as ds s as ds s as ds

Figure 8


A
lamin A/C siRNAs
GL2
5'P s
5'OH as
5'P as
5'OH ds
lamin A/C ab
Hoechst
ph. contr.
B
norm. lamin A/C protein (%)
100
80
60
40
20
0
GL2
5'P s
5'OH as
5'P as
5'OH ds
siRNAs
lamin A/C

Figure 9


A
serie 1
20-25 nt
as
3'
5'
20-25 nt
serie 2
20-23 nt
20-23 nt
3'
5'
as
B
serie 1
serie 2
T1 ds 20 21 22 23 24 25 20 21 22 23
length (nt)
5'
series 1
as siRNA
3'
5'
series 2
as siRNA
3'

Figure 10


5' and 3' modified as and ds siRNAs
sequence of as 3' terminal nts
as siRNA
as siRNA
ds siRNA
65°C 1 min
65°C 1 min
length (nt)
15 21 25 27 29 15 21 25 27 29
UG tg UU tt UG tg UU tt UG tg UU tt
t—UULB
t—UULB dsRNA
P-t—ttLB
P-t—ttLB dsRNA
P-t—ttL
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Figure 11


norm. lamin A/C protein (%)
150
100
50
0
21 TT
21 TT
21 TT
13 15 17 19 21 21 TT 23 25 27 29
13 15 17 19 21 21 TT 23 25 27 29
ds
s ds
5' OH antisense
5' P antisense
GL2
lamin A/C siRNA

Figure 12


A
glycerol gradient 5-20%
M 1 2 3 4 5* 6 7 8 9 10
kDa
250
150
100
75
50
37
25
B
T1 bu
3 4 5 6 7 8 9 10

Figure 13 A



Observed	Mr(expt)	Mr(calc)	Delta	Position	Miss	Peptide
1299.67	1298.67	1298.73	-0.07	413 - 424	0	VLQPPSILYGGR
1402.64	1401.64	1401.74	-0.10	637 - 648	0	QEIIQDLAAMVR Oxidation(M)
1413.62	1412.61	1412.73	-0.12	169 - 180	1	HLPSMRYTPVGR
1423.60	1422.59	1422.71	-0.12	356 - 367	1	KLTDNQTSTMIR Oxidation(M)
1486.56	1485.56	1485.66	-0.10	495 - 507	0	YAQGADSVEPMFR Oxidation(M)
1513.71	1512.70	1512.80	-0.10	112 - 125	1	DKVELEVTLPGEGK
1608.67	1607.66	1607.69	-0.03	481 - 494	0	DAGMPIQGQPCFCK
1635.84	1634.83	1634.85	-0.02	85 - 98	1	TQIFGDRKPVFDGR
1658.85	1657.85	1657.84	0.01	368 - 382	2	ATARSAPDRQEEISK
1663.85	1662.85	1662.91	-0.06	698 - 711	1	DYQPGITFIVVQKR
1675.79	1674.78	1674.84	-0.06	372 - 385	2	SAPDRQEEISKLMR Oxidation(M)
1696.77	1695.76	1695.84	-0.08	323 - 336	0	YPHLPCLQVGQEQK
1743.75	1742.74	1742.77	-0.03	181 - 197	0	SFFTASEGCSNPLGGGR
2511.07	2510.06	2510.12	-0.05	816 - 838	1	YHLVDKEHDSAEGSHTSGQSNGR

Figure 13 B

B



eukaryotic translation initiation factor 2C1

Observed	Mr(expt)	Mr(calc)	Delta	Position	Miss	Peptide
1283.66	1282.65	1282.74	-0.09	410 - 421	0	VLPAPILQYGGR
1294.65	1293.64	1293.67	-0.03	794 - 805	0	SVSIPAPAYYAR
1361.61	1360.60	1360.70	-0.10	553 - 564	0	TSPQTLSNLCLK
1486.56	1485.56	1485.66	-0.10	492 - 504	0	YAQGADSVEPMFR Oxidation(M)
1560.76	1559.75	1559.83	-0.08	97 - 110	0	NIYTVTALPIGNER
1561.76	1560.75	1560.78	-0.02	111 - 124	1	VDFEVTIPGEGKDR
1608.67	1607.66	1607.69	-0.03	478 - 491	0	DAGMPIQGQPCFCK
1640.74	1639.73	1639.82	-0.08	240 - 253	0	NIDEQPKPLTDSQR
1675.79	1674.78	1674.84	-0.06	369 - 382	2	SAPDRQEEISRLMK Oxidation(M)
1679.86	1678.85	1678.90	-0.05	695 - 708	1	DYQPGITYIVVQKR
1696.77	1695.76	1695.84	-0.08	320 - 333	0	YPHLPCLQVGQEQK
1867.85	1866.85	1866.87	-0.02	178 - 194	0	SFFSPPEGYYHPLGGGR

Fig.13C


C
eIF2C2
eIF2C1
eIF2C peptides
oxidized
eIF2C1 peptides
oxidized
PAZ domain
PIWI domain

Figure 14

>eIF2C1, predicted protein sequence
MEAGPSGAAAGAYLPPLQQVFQAPRRPGIGTVGKPIKLLANYFEVDIPKIDVYHYEVDIKPD
KCPRRVNREVVEYMVQHFKPQIFGDRKPVYDGKKNIYTVTALPIGNERVDFEVTIPGEGKDR
IFKVSIKWLAIVSWRMLHEALVSGQIPVPLESVQALDVAMRHLASMRYTPVGRSFFSPPEGY
YHPLGGGREVWFGFHQSVRPAMWKMMLNIDVSATAFYKAQPVIEFMCEVLDIRNIDEQPKPL
TDSQRVRFTKEIKGLKVEVTHCGQMKRKYRVCNVTRRPASHQTFPLQLESGQTVECTVAQYF
KQKYNLQLKYPHLPCLQVGQEQKHTYLPLEVCNIVAGQRCIKKLTDNQTSTMIKATARSAPD
RQEEISRLMKNASYNLDPYIQEFGIKVKDDMTEVTGRVLPAPILQYGGRNRAIATPNQGVWD
MRGKQFYNGIEIKVWAIACFAPQKQCREEVLKNFTDQLRKISKDAGMPIQGQPCFCKYAQGA
DSVEPMFRHLKNTYSGLQLIIVILPGKTPVYAEVKRVGDTLLGMATQCVQVKNVVKTSPQTL
SNLCLKINVKLGGINNILVPHQRSAVFQQPVIFLGADVTHPPAGDGKKPSITAVVGSMDAHP
SRYCATVRVQRPRQEIIEDLSYMVRELLIQFYKSTRFKPTRIIFYRDGVPEGQLPQILHYEL
LAIRDACIKLEKDYQPGITYIVVQKRHHTRLFCADKNERIGKSGNIPAGTTVDTNITHPFEF
DFYLCSHAGIQGTSRPSHYYVLWDDNRFTADELQILTYQLCHTYVRCTRSVSIPAPAYYARL
VAFRARYHLVDKEHDSGEGSHISGQSNGRDPQALAKAVQVHQDTLRTMYFA

>eIF2C2, predicted protein sequence
MGVLSAIPALAPPAPPPPIQGYAFKPPPRPDFGTSGRTIKLQANFFEMDIPKIDIYHYELDI
KPEKCPRRVNREIVEHMVQHFKTQIFGDRKPVFDGRKNLYTAMPLPIGRDKVELEVTLPGEG
KDRIFKVSIKWVSCVSLQALHDALSGRLPSVPFETIQALDVVMRHLPSMRYTPVGRSFFTAS
EGCSNPLGGGREVWFGFHQSVRPSLWKMMLNIDVSATAFYKAQPVIEFVCEVLDFKSIEEQQ
KPLTDSQRVKFTKEIKGLKVEITHCGQMKRKYRVCNVTRRPASHQTFPLQQESGQTVECTVA
QYFKDRHKLVLRYPHLPCLQVGQEQKHTYLPLEVCNIVAGQRCIKKLTDNQTSTMIRATARS
APDRQEEISKLMRSASFNTDPYVREFGIMVKDEMTDVTGRVLQPPSILYGGRNKAIATPVQG
VWDMRNKQFHTGIEIKVWAIACFAPQRQCTEVHLKSFTEQLRKISRDAGMPIQGQPCFCKYA
QGADSVEPMFRHLKNTYAGLQLVVVILPGKTPVYAEVKRVGDTVLGMATQCVQMKNVQRTTP
QTLSNLCLKINVKLGGVNNILLPQGRPPVFQQPVIFLGADVTHPPAGDGKKPSIAAVVGSMD
AHPNRYCATVRVQQHRQEIIQDLAAMVRELLIQFYKSTRFKPTRIIFYRDGVSEGQFQQVLH
HELLAIREACIKLEKDYQPGITFIVVQKRHHTRLFCTDKNERVGKSGNIPAGTTVDTKITHP
TEFDFYLCSHAGIQGTSRPSHYHVLWDDNRFSSDELQILTYQLCHTYVRCTRSVSIPAPAYY
AHLVAFRARYHLVDKEHDSAEGSHTSGQSNGRDHQALAKAVQVHQDTLRTMYFA

>eIF2C3, predicted protein sequence
SRSRVPVPGPGAAAAPCPAPASPRRHPSANIPEIKRYAAAAAAAAGPGAGGAGDRGEAAPAA
AMEALGPGPPASLFQPPRRPGLGTVGKPIRLLANHFQVQIPKIDVYHYDVDIKPEKRPRRVN
REVVDTMVRHFKMQIFGDRQPGYDGKRNMYTAHPLPIGRDRVDMEVTLPGEGKDQTFKVSVQ
WVSVVSLQLLLEALAGHLNEVPDDSVQALDVITRHLPSMRYTPVGRSFFSPPEGYYHPLGGG
REVWFGFHQSVRPAMWNMMLNIDVSATAFYRAQPIIEFMCEVLDIQNINEQTKPLTDSQRVK
FTKEIRGLKVEVTHCGQMKRKYRVCNVTRRPASHQTFPLQLENGQAMECTVAQYFKQKYSLQ
LKYPHLPCLQVGQEQKHTYLPLEVCNIVAGQRCIKKLTDNQTSTMIKATARSAPDRQEEISR
LVKSNSMVGGPDPYLKEFGIVVHNEMTELTGRVLPAPMLQYGGRNKTVATPNQGVWDMRGKQ
FYAGIEIKVWAVACFAPQKQCREDLLKSFTDQLRKISKDAGMPIQGQPCFCKYAQGADSVEP
MFKHLKMTYVGLQLIVVILPGKTPVYAEVKRVGDTLLGMATQCVQVKNVVKTSPQTLSNLCL
KINAKLGGINNVLVPHQRPSVFQQPVIFLGADVTHPPAGDGKKPSIAAVVGSMDGHPSRYCA
TVRVQTSRQEISQELLYSQEVIQDLTNMVRELLIQFYKSTRFKPTRIIYYRGGVSEGQMKQV
AWPELIAIRKACISLEEDYRPGITYIVVQKRHHTRLFCADKTERVGKSGNVPAGTTVDSTIT
HPSEFDFYLCSHAGIQGTSRPSHYQVLWDDNCFTADELQLLTYQLCHTYVRCTRSVSIPAPA
YYARLVAFRARYHLVDKDHDSAEGSHVSGQSNGRDPQALAKAVQIHHDTQHTMYFA

Figure 14

>eIF2C4, predicted protein sequence
AGPAGAQPLLMVPRRPGYGTMGKPIKLLANCFQVEIPKIDVYLYEVDIKPDKCPRRVNREVV
DSMVQHFKVTIFGDRRPVYDGKRSLYTANPLPVATTGVDLDVTLPGEGGKDRPFKVSIKFVS
RVSWHLLHEVLTGRTLPEPLELDKPISTNPVHAVDVVLRHLPSMKYTPVGRSFFSAPEGYDH
PLGGGREVWFGFHQSVRPAMWKMMLNIDVSATAFYKAQPVIQFMCEVLDIHNIDEQPRPLTD
SHRVKFTKEIKGLKVEVTHCGTMRRKYRVCNVTRRPASHQTFPLQLENGQTVERTVAQYFRE
KYTLQLKYPHLPCLQVGQEQKHTYLPLEVCNIVAGQRCIKKLTDNQTSTMIKATARSAPDRQ
EEISRLVRSANYETDPFVQEFQFKVRDEMAHVTGRVLPAPMLQYGGRNRTVATPSHGVWDMR
GKQFHTGVEIKMWAIACFATQRQCREEILKGFTDQLRKISKDAGMPIQGQPCFCKYAQGADS
VEPMFRHLKNTYSGLQLIIVILPGKTPVYAEVKRVGDTLLGMATQCVQVKNVIKTSPQTLSN
LCLKINVKLGGINNILVPHQRPSVFQQPVIFLGADVTHPPAGDGKKPSIAAVVGSMDAHPSR
YCATVRVQRPRQEIIQDLASMVRELLIQFYKSTRFKPTRIIFYRDGVSEGQFRQVLYYELLA
IREACISLEKDYQPGITYIVVQKRHHTRLFCADRTERVGRSGNIPAGTTVDTDITHPYEFDF
YLCSHAGIQGTSRPSHYHVLWDDNCFTADELQLLTYQLCHTYVRCTRSVSIPAPAYYAHLVA
FRARYHLVDKEHDSAEGSHVSGQSNGRDPQALAKAVQIHQDTLRTMYFA

>HILI, predicted protein sequence
ISSGDAGSTFMERGVKNKQDFMDLSICTREKLAHVRNCKTGSSGIPVKLVTNLFNLDFPQDW
QLYQYHVTYIPDLASRRLRIALLYSHSELSNKAKAFDGAILFLSQKLEEKVTELSSETQRGE
TIKMTITLKRELPSSSPVCIQVFNIIFRKILKKLSMYQIGRNFYNPSEPMEIPQHKLSLWPG
FAISVSYFERKLLFSADVSYKVLRNETVLEFMTALCQRTGLSCFTQTCEKQLIGLIVLTRYN
NRTYSIDDIDWSVKPTHTFQKRDGTEITYVDYYKQQYDITVSDLNQPMLVSLLKKKRNDNSE
AQLAHLIPELCFLTGLTDQATSDFQLMKAVAEKTRLSPSGRQQRLARLVDNIQRNTNARFEL
ETWGLHFGSQISLTGRIVPSEKILMQDHICQPVSAADWSKDIRTCKILNAQSLNTWLILCSD
RTEYVAESFLNCLRRVAGSMGFNVMCILPSNQKTYYDSIKKYLSSDCPVPSQCVLARTLNKQ
GMMMSIATKIAMQMTCKLGGELWAVEIPLKSLMVVGIDVCKDALSKDVMVVGCVASVNPRIT
RWFSRCILQRTMTDVADCLKVFMTGALNKWYKYNHDLPARIIVYRAGVGDGQLKTLIEYEVP
QLLSSVAESSSNTSSRLSVIVVRKKCMPRFFTEMNRTVQNPPLGTVVDSEATRNEWQYDFYL
ISQVACRGTVSPTYYNVIYDDNGLKPDHMQRLTFKLCHLYYNWPGIVSVPAPCQYAHKLTFL
VAQSIHKEPSLELANHLFYL

>HIWI, predicted protein sequence
MTGRARARARGRARGQETAQLVGSTASQQPGYIQPRPQPPPAEGELFGRGRQRGTAGGTAKS
QGLQISAGFQELSLAERGGRRRDFHDLGVNTRQNLDHVKESKTGSSGIIVRLSTNHFRLTSR
PQWALYQYHIDYNPLMEARRLRSALLFQHEDLIGKCHAFDGTILFLPKRLQQKVTEVFSKTR
NGEDVRITITLTNELPPTSPTCLQFYNIIFRRLLKIMNLQQIGRNYYNPNDPIDIPSHRLVI
WPGFTTSILQYENSIMLCTDVSHKVLRSETVLDFMFNFYHQTEEHKFQEQVSKELIGLVVLT
KYNNKTYRVDDIDWDQNPKSTFKKADGSEVSFLEYYRKQYNQEITDLKQPVLVSQPKRRRGP
GGTLPGPAMLIPELCYLTGLTDKMRNDFNVMKDLAVHTRLTPEQRQREVGRLIDYIHKNDNV
QRELRDWGLSFDSNLLSFSGRILQTEKIHQGGKTFDYNPQFADWSKETRGAPLISVKPLDNW
LLIYTRRNYEAANSLIQNLFKVTPAMGMQMRKAIMIEVDDRTEAYLRVLQQKVTADTQIVVC
LLSSNRKDKYDAIKKYLCTDCPTPSQCVVARTLGKQQTVMAIATKIALQMNCKMGGELWRVD
IPLKLVMIVGIDCYHDMTAGRRSIAGFVASINEGMTRWFSRCIFQDRGQELVDGLKVCLQAA
LRAWNSCNEYMPSRIIVYRDGVGDGQLKTLVNYEVPQFLDCLKSIGRGYNPRLTVIVVKKRV
NTRFFAQSGGRLQNPLPGTVIDVEVTRPEWYDFFIVSQAVRSGSVSPTHYNVIYDNSGLKPD
HIQRLTYKLCHIYYNWPGVIRVPAPCQYAHKLAFLVGQSIHREPNLSLSNRLYYL

Fig.15



Fig.15 (cont.)



Figure 16

>eIF2C1, cDNA sequence of predicted ORF

ATGGAAGCGGGACCCTCGGGAGCAGCTGCGGGCGCTTACCTGCCCCCCCTGCAGCAGGTGTT
CCAGGCACCTCGCCGGCCTGGCATTGGCACTGTGGGGAAACCAATCAAGCTCCTGGCCAATT
ACTTTGAGGTGGACATCCCTAAGATCGACGTGTACCACTACGAGGTGGACATCAAGCCGGAT
AAGTGTCCCCGTAGAGTCAACCGGGAAGTGGTGGAATACATGGTCCAGCATTTCAAGCCTCA
GATCTTTGGTGATCGCAAGCCTGTGTATGATGGAAAGAAGAACATTTACACTGTCACAGCAC
TGCCCATTGGCAACGAACGGGTCGACTTTGAGGTGACAATCCCTGGGGAAGGGAAGGATCGA
ATCTTTAAGGTCTCCATCAAGTGGCTAGCCATTGTGAGCTGGCGAATGCTGCATGAGGCCCT
GGTCAGCGGCCAGATCCCTGTTCCCTTGGAGTCTGTGCAAGCCCTGGATGTGGCCATGAGGC
ACCTGGCATCCATGAGGTACACCCCTGTGGGCCGCTCCTTCTTCTCACCGCCTGAGGGCTAC
TACCACCCGCTGGGGGGTGGGCGCGAGGTCTGGTTCGGCTTTCACCAGTCTGTGCGCCCTGC
CATGTGGAAGATGATGCTCAACATTGATGTCTCAGCCACTGCCTTTTATAAGGCACAGCCAG
TGATTGAGTTCATGTGTGAGGTGCTGGACATCAGGAACATAGATGAGCAGCCCAAGCCCCTC
ACGGACTCTCAGCGCGTTCGCTTCACCAAGGAGATCAAGGGCCTGAAGGTGGAAGTCACCCA
CTGTGGACAGATGAAGAGGAAGTACCGCGTGTGTAATGTTACCCGTCGCCCTGCTAGCCATC
AGACATTCCCCTTACAGCTGGAGAGTGGACAGACTGTGGAGTGCACAGTGGCACAGTATTTC
AAGCAGAAATATAACCTTCAGCTCAAGTATCCCCATCTGCCCTGCCTACAAGTTGGCCAGGA
ACAAAAGCATACCTACCTTCCCCTAGAGGTCTGTAACATTGTGGCTGGGCAGCGCTGTATTA
AAAAGCTGACCGACAACCAGACCTCGACCATGATAAAGGCCACAGCTAGATCCGCTCCAGAC
AGACAGGAGGAGATCAGTCGCCTGATGAAGAATGCCAGCTACAACTTAGATCCCTACATCCA
GGAATTTGGGATCAAAGTGAAGGATGACATGACGGAGGTGACAGGGCGAGTGCTGCCGGCGC
CCATCTTGCAGTACGGCGGCCGGAACCGGGCCATTGCCACACCCAATCAGGGTGTCTGGGAC
ATGCGGGGGAAACAGTTCTACAATGGGATTGAGATCAAAGTCTGGGCCATCGCCTGCTTCGC
ACCCCAAAAACAGTGTCGAGAAGAGGTGCTCAAGAACTTCACAGACCAGCTGCGGAAGATTT
CCAAGGATGCGGGGATGCCTATCCAGGGTCAACCTTGTTTCTGCAAATATGCACAGGGGGCA
GACAGCGTGGAGCCTATGTTCCGGCATCTCAAGAACACCTACTCAGGGCTGCAGCTCATTAT
TGTCATCCTGCCAGGGAAGACGCCGGTGTATGCTGAGGTGAAACGTGTCGGAGATACACTCT
TGGGAATGGCTACGCAGTGTGTGCAGGTGAAGAACGTGGTCAAGACCTCACCTCAGACTCTG
TCCAACCTCTGCCTCAAGATCAATGTCAAACTTGGTGGCATTAACAACATCCTAGTCCCACA
CCAGCGCTCTGCCGTTTTTCAACAGCCAGTGATATTCCTGGGAGCAGATGTTACACACCCCC
CAGCAGGGGATGGGAAAAAACCTTCTATCACAGCAGTGGTAGGCAGTATGGATGCCCACCCC
AGCCGATACTGTGCTACTGTGCGGGTACAGCGACCACGGCAAGAGATCATTGAAGACTTGTC
CTACATGGTGCGTGAGCTCCTCATCCAATTCTACAAGTCCACCCGTTTCAAGCCTACCCGCA
TCATCTTCTACCGAGATGGGGTGCCTGAAGGCCAGCTACCCCAGATACTCCACTATGAGCTA
CTGGCCATTCGTGATGCCTGCATCAAACTGGAAAAGGACTACCAGCCTGGGATCACTTATAT
TGTGGTGCAGAAACGCCATCACACCCGCCTTTTCTGTGCTGACAAGAATGAGCGAATTGGGA
AGAGTGGTAACATCCCAGCTGGGACCACAGTGGACACCAACATCACCCACCCATTTGAGTTT
GACTTCTATCTGTGCAGCCACGCAGGCATCCAGGGCACCAGCCGACCATCCCATTACTATGT
TCTTTGGGATGACAACCGTTTCACAGCAGATGAGCTCCAGATCCTGACGTACCAGCTGTGCC
ACACTTACGTACGATGCACACGCTCTGTCTCTATCCCAGCACCTGCCTACTATGCCCGCCTG
GTGGCTTTCCGGGCACGATACCACCTGGTGGACAAGGAGCATGACAGTGGAGAGGGGAGCCA
CATATCGGGGCAGAGCAATGGGCGGGACCCCCAGGCCCTGGCCAAAGCCGTGCAGGTTCACC
AGGATACTCTGCGCACCATGTACTTCGCT

Figure 16

>eIF2C2, cDNA sequence of predicted ORF

ATGGGTGTTCTCTCTGCCATTCCCGCACTTGCACCTCCTGCGCCGCCGCCCCCCATCCAAGG
ATATGCCTTCAAGCCTCCACCTAGACCCGACTTTGGGACCTCCGGGAGAACAATCAAATTAC
AGGCCAATTTCTTCGAAATGGACATCCCCAAAATTGACATCTATCATTATGAATTGGATATC
AAGCCAGAGAAGTGCCCGAGGAGAGTTAACAGGGAAATCGTGGAACACATGGTCCAGCACTT
TAAAACACAGATCTTTGGGGATCGGAAGCCCGTGTTTGACGGCAGGAAGAATCTATACACAG
CCATGCCCCTTCCGATTGGGAGGGACAAGGTGGAGCTGGAGGTCACGCTGCCAGGAGAAGGC
AAGGATCGCATCTTCAAGGTGTCCATCAAGTGGGTGTCCTGCGTGAGCTTGCAGGCGTTACA
CGATGCACTTTCAGGGCGGCTGCCCAGCGTCCCTTTTGAGACGATCCAGGCCCTGGACGTGG
TCATGAGGCACTTGCCATCCATGAGGTACACCCCCGTGGGCCGCTCCTTCTTCACCGCGTCC
GAAGGCTGCTCTAACCCTCTTGGCGGGGGCCGAGAAGTGTGGTTTGGCTTCCATCAGTCCGT
CCGGCCTTCTCTCTGGAAAATGATGCTGAATATTGATGTGTCAGCAACAGCGTTTTACAAGG
CACAGCCAGTAATCGAGTTTGTTTGTGAAGTTTTGGATTTTAAAAGTATTGAAGAACAACAA
AAACCTCTGACAGATTCCCAAAGGGTAAAGTTTACCAAAGAAATTAAAGGTCTAAAGGTGGA
GATAACGCACTGTGGGCAGATGAAGAGGAAGTACCGTGTCTGCAATGTGACCCGGCGGCCCG
CCAGTCACCAAACATTCCCGCTGCAGCAGGAGAGCGGGCAGACGGTGGAGTGCACGGTGGCC
CAGTATTTCAAGGACAGGCACAAGTTGGTTCTGCGCTACCCCCACCTCCCATGTTTACAAGT
CGGACAGGAGCAGAAACACACCTACCTTCCCCTGGAGGTCTGTAACATTGTGGCAGGACAAA
GATGTATTAAAAAATTAACGGACAATCAGACCTCAACCATGATCAGAGCAACTGCTAGGTCG
GCGCCCGATCGGCAAGAAGAGATTAGCAAATTGATGCGAAGTGCAAGTTTCAACACAGATCC
ATACGTCCGTGAATTTGGAATCATGGTCAAAGATGAGATGACAGACGTGACTGGGCGGGTGC
TGCAGCCGCCCTCCATCCTCTACGGGGGCAGGAATAAAGCTATTGCGACCCCTGTCCAGGGC
GTCTGGGACATGCGGAACAAGCAGTTCCACACGGGCATCGAGATCAAGGTGTGGGCCATTGC
GTGCTTCGCCCCCCAGCGCCAGTGCACGGAAGTCCATCTGAAGTCCTTCACAGAGCAGCTCA
GAAAGATCTCGAGAGACGCTGGCATGCCCATCCAGGGCCAGCCGTGCTTCTGCAAATACGCG
CAGGGGGCGGACAGCGTGGAGCCCATGTTCCGGCACCTGAAGAACACGTATGCGGGCCTGCA
GCTGGTGGTGGTCATCCTGCCCGGCAAGACGCCCGTGTACGCCGAGGTCAAGCGCGTGGGAG
ACACGGTGCTGGGGATGGCCACGCAGTGCGTGCAGATGAAGAACGTGCAGAGGACCACGCCA
CAGACCCTGTCCAACCTTTGCCTGAAGATCAACGTCAAGCTGGGAGGCGTGAACAACATCCT
GCTGCCCCAGGGCAGGCCGCCGGTGTTCCAGCAGCCCGTCATCTTTCTGGGAGCAGACGTCA
CTCACCCCCCCGCCGGGGATGGGAAGAAGCCCTCCATTGCCGCCGTGGTGGGCAGCATGGAC
GCCCACCCCAATCGCTACTGCGCCACCGTGCGCGTGCAGCAGCACCGGCAGGAGATCATACA
AGACCTGGCCGCCATGGTCCGCGAGCTCCTCATCCAGTTCTACAAGTCCACGCGCTTCAAGC
CCACCCGCATCATCTTCTACCGCGACGGTGTCTCTGAAGGCCAGTTCCAGCAGGTTCTCCAC
CACGAGTTGCTGGCCATCCGTGAGGCCTGTATCAAGCTAGAAAAAGACTACCAGCCCGGGAT
CACCTTCATCGTGGTGCAGAAGAGGCACCACACCCGGCTCTTCTGCACTGACAAGAACGAGC
GGGTTGGGAAAAGTGGAAACATTCCAGCAGGCACGACTGTGGACACGAAAATCACCCACCCC
ACCGAGTTCGACTTCTACCTGTGTAGTCACGCTGGCATCCAGGGGACAAGCAGGCCTTCGCA
CTATCACGTCCTCTGGGACGACAATCGTTTCTCCTCTGATGAGCTGCAGATCCTAACCTACC
AGCTGTGTCACACCTACGTGCGCTGCACACGCTCCGTGTCCATCCCAGCGCCAGCATACTAC
GCTCACCTGGTGGCCTTCCGGGCCAGGTACCACCTGGTGGATAAGGAACATGACAGTGCTGA
AGGAAGCCATACCTCTGGGCAGAGTAACGGGCGAGACCACCAAGCACTGGCCAAGGCGGTCC
AGGTTCACCAAGACACTCTGCGCACCATGTACTTTGCT

Figure 16

>eIF2C3, cDNA sequence of predicted ORF

AGCCGGAGCCGGGTCCCTGTCCCCGGGCCGGGCGCCGCCGCCGCCCCCTGCCCAGCGCCCGC
GTCTCCGCGGCGCCACCCCAGCGCCAATATTCCGGAGATCAAGCGTTACGCGGCGGCGGCGG
CGGCGGCGGCGGGGCCCGGAGCGGGAGGCGCCGGGGACCGGGGCGAGGCGGCCCCCGCCGCC
GCCATGGAGGCGCTGGGACCCGGACCTCCGGCTAGCCTGTTTCAGCCACCTCGTCGTCCTGG
CCTTGGAACTGTTGGAAAACCAATTCGACTGTTAGCCAATCATTTTCAGGTTCAGATTCCTA
AAATAGATGTGTATCACTATGATGTGGATATTAAGCCTGAAAAACGGCCTCGTAGAGTCAAC
AGGGAGGTAGTAGATACAATGGTGCGGCACTTCAAGATGCAAATATTTGGTGATCGGCAGCC
TGGGTATGATGGCAAAAGAAACATGTACACAGCACATCCACTACCAATTGGACGGGATAGGG
TTGATATGGAGGTGACTCTTCCAGGCGAGGGTAAAGACCAAACATTTAAAGTGTCTGTTCAG
TGGGTGTCAGTTGTGAGCCTTCAGTTGCTTTTAGAAGCTTTGGCTGGGCACTTGAATGAAGT
CCCAGATGACTCAGTACAAGCACTTGATGTTATCACAAGACACCTTCCCTCCATGAGGTACA
CCCCAGTGGGCCGTTCCTTTTTCTCACCCCCGGAAGGTTACTACCACCCTCTGGGAGGGGGC
AGGGAGGTCTGGTTTGGTTTTCATCAGTCTGTGAGACCTGCCATGTGGAATATGATGCTCAA
CATTGATGTATCTGCAACTGCTTTCTACCGGGCTCAGCCTATCATTGAGTTCATGTGTGAGG
TTTTAGACATTCAGAACATCAATGAACAGACCAAACCTCTAACAGACTCCCAGCGTGTCAAA
TTTACCAAAGAAATCAGAGGTCTCAAAGTTGAGGTGACCCACTGTGGACAGATGAAACGAAA
ATACCGAGTTTGTAATGTGACTAGACGGCCAGCCAGTCATCAAACTTTTCCTTTGCAGCTAG
AAAACGGTCAAGCTATGGAATGTACAGTAGCTCAATATTTTAAGCAAAAGTATAGTCTGCAA
CTGAAATACCCCCATCTTCCCTGTCTCCAAGTGGGACAAGAACAAAAGCATACATACTTGCC
ACTCGAGGTCTGTAATATAGTGGCAGGACAGCGATGTATCAAGAAGCTCACAGACAATCAGA
CTTCCACAATGATCAAAGCTACAGCAAGATCTGCTCCTGACAGACAGGAAGAGATCAGTAGA
CTGGTGAAGAGCAACAGTATGGTGGGTGGACCTGATCCATACCTTAAAGAATTTGGTATTGT
TGTCCACAATGAAATGACAGAGCTCACAGGCAGGGTACTTCCAGCACCAATGCTGCAATATG
GAGGCCGGAATAAAACAGTAGCCACACCCAACCAGGGTGTCTGGGACATGCGAGGAAAGCAG
TTTTATGCTGGCATTGAAATTAAAGTTTGGGCAGTTGCTTGTTTTGCACCTCAGAAACAATG
TAGGGAAGATTTACTAAAGAGTTTCACTGACCAGCTGCGTAAAATCTCTAAGGATGCAGGAA
TGCCCATCCAGGGTCAGCCATGTTTCTGCAAGTATGCACAAGGTGCAGACAGTGTGGAGCCT
ATGTTTAAACATCTGAAAATGACTTATGTGGGCCTACAGCTAATAGTGGTTATCCTGCCTGG
AAAGACACCAGTATATGCGGAGGTGAAACGTGTTGGAGATACCCTTCTAGGTATGGCCACAC
AGTGTGTCCAGGTAAAAAATGTAGTGAAGACCTCACCTCAAACCCTTTCCAATCTTTGCCTG
AAGATAAATGCAAAACTTGGAGGAATTAACAATGTGCTTGTGCCTCATCAAAGGCCCTCGGT
GTTCCAGCAGCCTGTCATCTTCCTGGGAGCGGATGTCACACACCCCCCAGCAGGGGATGGGA
AGAAACCTTCCATTGCTGCTGTGGTTGGCAGTATGGATGGCCACCCCAGCCGGTACTGTGCC
ACCGTTCGGGTGCAGACTTCCCGGCAGGAGATCTCCCAAGAGCTCCTCTACAGTCAAGAGGT
CATCCAGGACCTGACTAACATGGTTCGAGAGCTGCTGATTCAGTTCTACAAATCCACACGCT
TCAAACCCACTCGGATCATCTATTACCGTGGAGGGGTATCTGAGGGACAAATGAAACAGGTA
GCTTGGCCAGAACTAATAGCAATTCGAAAGGCATGTATTAGCTTGGAAGAAGATTACCGGCC
AGGAATAACTTATATTGTGGTGCAAAAAAGACATCACACACGACTCTTCTGTGCAGATAAAA
CAGAAAGGGTAGGGAAAAGTGGCAATGTACCAGCAGGCACTACAGTGGATAGTACCATCACA
CATCCATCTGAGTTTGACTTTTACCTCTGTAGTCATGCAGGAATTCAGGGAACCAGCCGTCC
CTCACATTACCAGGTCTTGTGGGATGACAACTGCTTCACTGCAGATGAACTCCAGCTACTGA
CTTACCAGCTGTGTCACACCTATGTGAGGTGCACTCGCTCAGTCTCTATTCCAGCCCCTGCA
TATTATGCCCGGCTTGTAGCATTTAGGGCAAGGTATCATCTGGTGGATAAAGATCATGACAG
TGCGGAAGGCAGTCATGTGTCAGGACAGAGCAACGGCCGGGATCCTCAGGCCTTGGCTAAGG
CTGTGCAAATCCACCATGATACCCAGCACACGATGTATTTTGCC

Figure 16

>eIF2C4, cDNA sequence of predicted ORF

GCAGGACCCGCTGGGGCCCAGCCCCTACTCATGGTGCCCAGAAGACCTGGCTATGGCACCAT
GGGCAAACCCATTAAACTGCTGGCTAACTGTTTTCAAGTTGAAATCCCAAAGATTGATGTCT
ACCTCTATGAGGTAGATATTAAACCAGACAAGTGTCCTAGGAGAGTGAACAGGGAGGTGGTT
GACTCAATGGTTCAGCATTTTAAAGTAACTATATTTGGAGACCGTAGACCAGTTTATGATGG
AAAAAGAAGTCTTTACACCGCCAATCCACTTCCTGTGGCAACTACAGGGGTAGATTTAGACG
TTACTTTACCTGGGGAAGGTGGAAAAGATCGACCTTTCAAGGTGTCAATCAAATTTGTCTCT
CGGGTGAGTTGGCACCTACTGCATGAAGTACTGACAGGACGGACCTTGCCTGAGCCACTGGA
ATTAGACAAGCCAATCAGCACTAACCCTGTCCATGCCGTTGATGTGGTGCTACGACATCTGC
CCTCCATGAAATACACACCTGTGGGGCGTTCATTTTTCTCCGCTCCAGAAGGATATGACCAC
CCTCTGGGAGGGGGCAGGGAAGTGTGGTTTGGATTCCATCAGTCTGTTCGGCCTGCCATGTG
GAAAATGATGCTTAATATCGATGTTTCTGCCACTGCCTTCTACAAAGCACAACCTGTAATTC
AGTTCATGTGTGAAGTTCTTGATATTCATAATATTGATGAGCAACCAAGACCTCTGACTGAT
TCTCATCGGGTAAAATTCACCAAAGAGATAAAAGGTTTGAAGGTTGAAGTGACTCATTGTGG
AACAATGAGACGGAAATACCGTGTTTGTAATGTAACAAGGAGGCCTGCCAGTCATCAAACCT
TTCCTTTACAGTTAGAAAACGGCCAAACTGTGGAGAGAACAGTAGCGCAGTATTTCAGAGAA
AAGTATACTCTTCAGCTGAAGTACCCGCACCTTCCCTGTCTGCAAGTCGGGCAGGAACAGAA
ACACACCTACCTGCCACTAGAAGTCTGTAATATTGTGGCAGGGCAACGATGTATCAAGAAGC
TAACAGACAATCAGACTTCCACTATGATCAAGGCAACAGCAAGATCTGCACCAGATAGACAA
GAGGAAATTAGCAGATTGGTAAGAAGTGCAAATTATGAAACAGATCCATTTGTTCAGGAGTT
TCAATTTAAAGTTCGGGATGAAATGGCTCATGTAACTGGACGCGTACTTCCAGCACCTATGC
TCCAGTATGGAGGACGGAATCGGACAGTAGCAACACCGAGCCATGGAGTATGGGACATGCGA
GGGAAACAATTCCACACAGGAGTTGAAATCAAAATGTGGGCTATCGCTTGTTTTGCCACACA
GAGGCAGTGCAGAGAAGAAATATTGAAGGGTTTCACAGACCAGCTGCGTAAGATTTCTAAGG
ATGCAGGGATGCCCATCCAGGGCCAGCCATGCTTCTGCAAATATGCACAGGGGGCAGACAGC
GTAGAGCCCATGTTCCGGCATCTCAAGAACACATATTCTGGCCTACAGCTTATTATCGTCAT
CCTGCCGGGGAAGACACCAGTGTATGCGGAAGTGAAACGTGTAGGAGACACACTTTTGGGTA
TGGCTACACAATGTGTTCAAGTCAAGAATGTAATAAAAACATCTCCTCAAACTCTGTCAAAC
TTGTGCCTAAAGATAAATGTTAAACTCGGAGGGATCAATAATATTCTTGTACCTCATCAAAG
ACCTTCTGTGTTCCAGCAACCAGTGATCTTTTTGGGAGCCGATGTCACTCATCCACCTGCTG
GTGATGGAAAGAAGCCTTCTATTGCTGCTGTTGTAGGTAGTATGGATGCACACCCAAGCAGA
TACTGTGCCACAGTAAGAGTTCAGAGACCCCGACAGGAGATCATCCAGGACTTGGCCTCCAT
GGTCCGGGAACTTCTTATTCAATTTTATAAGTCAACTCGGTTCAAGCCTACTCGTATCATCT
TTTATCGGGATGGTGTTTCAGAGGGGCAGTTTAGGCAGGTATTATATTATGAACTACTAGCA
ATTCGAGAAGCCTGCATCAGTTTGGAGAAAGACTATCAACCTGGAATAACCTACATTGTAGT
TCAGAAGAGACATCACACTCGATTATTTTGTGCTGATAGGACAGAAAGGGTTGGAAGAAGTG
GCAATATCCCAGCTGGAACAACAGTTGATACAGACATTACACACCCATATGAGTTCGATTTT
TACCTCTGTAGCCATGCTGGAATACAGGGTACCAGTCGTCCTTCACACTATCATGTTTTATG
GGATGATAACTGCTTTACTGCAGATGAACTTCAGCTGCTAACTTACCAGCTCTGCCACACTT
ACGTACGCTGTACACGATCTGTTTCTATACCTGCACCAGCGTATTATGCTCACCTGGTAGCA
TTTAGAGCCAGATATCATCTTGTGGACAAAGAACATGACAGTGCTGAAGGAAGTCACGTTTC
AGGACAAAGCAATGGGCGAGATCCACAAGCTCTTGCCAAGGCTGTACAGATTCACCAAGATA
CCTTACGCACAATGTACTTCGCTTAA

Figure 16

>HILI, cDNA sequence of predicted ORF
ATATCTTCTGGTGATGCTGGAAGTACCTTCATGGAAAGAGGTGTGAAAAACAAACAGGACTT
TATGGATTTGAGTATCTGTACCAGAGAAAAATTGGCACATGTGAGAAATTGTAAAACAGGTT
CCAGTGGAATACCTGTGAAACTGGTTACAAACCTCTTTAACTTAGATTTTCCCCAAGACTGG
CAGCTATACCAGTACCATGTGACATATATTCCAGATTTAGCATCTAGAAGGCTGAGAATTGC
TTTACTTTATAGTCATAGTGAACTTTCCAACAAAGCAAAAGCATTCGACGGTGCCATCCTTT
TTCTGTCACAAAAGCTAGAAGAAAAGGTCACAGAGTTGTCAAGTGAAACTCAAAGAGGTGAG
ACTATAAAGATGACTATCACCCTGAAGAGGGAGCTGCCATCAAGTTCTCCCGTGTGCATCCA
GGTCTTCAATATCATCTTCAGAAAGATCCTCAAAAAGTTGTCCATGTACCAAATTGGACGGA
ACTTCTATAATCCTTCAGAGCCAATGGAAATTCCCCAGCACAAATTATCCCTTTGGCCTGGG
TTTGCCATTTCTGTGTCATATTTTGAAAGGAAGCTCCTGTTTAGTGCTGATGTGAGTTACAA
AGTCCTCCGGAATGAGACGGTTCTGGAATTCATGACTGCTCTCTGTCAAAGAACTGGCTTGT
CCTGTTTCACCCAGACGTGTGAGAAGCAGCTAATAGGGCTCATTGTCCTTACAAGATACAAT
AACAGAACCTACTCCATTGATGACATTGACTGGTCAGTGAAGCCCACACACACCTTTCAGAA
GCGGGATGGCACCGAGATCACCTATGTGGATTACTACAAGCAGCAGTATGATATTACTGTAT
CGGACCTGAATCAGCCCATGCTTGTTAGTCTGTTAAAGAAGAAGAGAAATGACAACAGTGAG
GCTCAGCTCGCCCACCTGATACCTGAGCTCTGCTTTCTAACAGGGCTGACTGACCAGGCAAC
ATCTGATTTCCAGCTGATGAAGGCTGTGGCTGAAAAGACACGTCTCAGTCCTTCAGGCCGGC
AGCAGCGCCTGGCCAGGCTTGTGGACAACATCCAGAGGAATACCAATGCTCGCTTTGAACTA
GAGACCTGGGGACTGCATTTTGGAAGCCAGATATCTCTGACTGGCCGGATTGTGCCTTCAGA
AAAAATATTAATGCAAGACCACATATGTCAACCTGTGTCTGCTGCTGACTGGTCCAAGGATA
TTCGAACTTGCAAGATTTTAAATGCACAGTCTTTGAATACCTGGTTGATTTTATGTAGCGAC
AGAACTGAATATGTTGCCGAGAGCTTTCTGAACTGCTTGAGAAGAGTTGCAGGTTCCATGGG
ATTTAATGTAATGTGCATTCTGCCTTCTAATCAGAAGACCTATTATGATTCCATTAAAAAAT
ATTTGAGCTCAGACTGCCCAGTCCCAAGCCAATGTGTGCTTGCTCGGACCTTGAATAAACAG
GGCATGATGATGAGTATCGCCACCAAGATCGCTATGCAGATGACTTGCAAGCTCGGAGGCGA
GCTGTGGGCTGTGGAAATACCTTTAAAGTCCCTGATGGTGGTCGGTATTGATGTCTGTAAAG
ATGCACTCAGCAAGGACGTGATGGTTGTTGGATGCGTGGCCAGTGTTAACCCCAGAATCACC
AGGTGGTTTTCCCGCTGTATCCTTCAGAGAACAATGACTGATGTTGCAGATTGCTTGAAAGT
TTTCATGACTGGAGCACTCAACAAATGGTACAAGTACAATCATGATTTGCCAGCACGGATAA
TTGTGTACCGTGCTGGTGTAGGGGATGGTCAGCTGAAAACACTTATTGAATATGAAGTCCCA
CAGCTGCTGAGCAGTGTGGCAGAATCCAGCTCAAATACCAGCTCAAGACTGTCGGTGATTGT
GGTCAGGAAGAAGTGCATGCCACGATTCTTTACCGAAATGAACCGCACTGTACAGAACCCCC
CACTTGGCACTGTTGTGGATTCAGAAGCAACACGTAACGAATGGCAGTATGACTTTTATCTG
ATCAGCCAGGTGGCCTGCCGGGGAACTGTTAGTCCTACCTACTATAATGTCATCTATGATGA
CAACGGCTTGAAGCCCGACCATATGCAGAGACTTACATTCAAATTGTGCCACCTGTACTACA
ACTGGCCGGGCATAGTCAGTGTCCCAGCACCATGTCAGTATGCTCACAAGCTGACCTTTCTG
GTGGCACAAAGCATTCATAAAGAACCCAGTCTGGAATTAGCCAACCATCTCTTCTACCTG

Figure 16

>HIWI, cDNA sequence of predicted ORF

ATGACTGGGAGAGCCCGAGCCAGAGCCAGAGGAAGGGCCCGCGGTCAGGAGACAGCGCAGCT
GGTGGGCTCCACTGCCAGTCAGCAACCTGGTTATATTCAGCCTAGGCCTCAGCCGCCACCAG
CAGAGGGGGAATTATTTGGCCGTGGACGGCAGAGAGGAACAGCAGGAGGAACAGCCAAGTCA
CAAGGACTCCAGATATCTGCTGGATTTCAGGAGTTATCGTTAGCAGAGAGAGGAGGTCGTCG
TAGAGATTTTCATGATCTTGGTGTGAATACAAGGCAGAACCTAGACCATGTTAAAGAATCAA
AAACAGGTTCTTCAGGCATTATAGTAAGGTTAAGCACTAACCATTTCCGGCTGACATCCCGT
CCCCAGTGGGCCTTATATCAGTATCACATTGACTATAACCCACTGATGGAAGCCAGAAGACT
CCGTTCAGCTCTTCTTTTTCAACACGAAGATCTAATTGGAAAGTGCCATGCTTTTGATGGAA
CGATATTATTTTTACCTAAAAGACTACAGCAAAAGGTTACTGAAGTTTTTAGTAAGACCCGG
AATGGAGAGGATGTGAGGATAACGATCACTTTAACAAATGAACTTCCACCTACATCACCAAC
TTGTTTGCAGTTCTATAATATTATTTTCAGGAGGCTTTTGAAAATCATGAATTTGCAACAAA
TTGGACGAAATTATTATAACCCAAATGACCCAATTGATATTCCAAGTCACAGGTTGGTGATT
TGGCCTGGCTTCACTACTTCCATCCTTCAGTATGAAAACAGCATCATGCTCTGCACTGACGT
TAGCCATAAAGTCCTTCGAAGTGAGACTGTTTTGGATTTCATGTTCAACTTTTATCATCAGA
CAGAAGAACATAAATTTCAAGAACAAGTTTCCAAAGAACTAATAGGTTTAGTTGTTCTTACC
AAGTATAACAATAAGACATACAGAGTGGATGATATTGACTGGGACCAGAATCCCAAGAGCAC
CTTTAAGAAAGCCGACGGCTCTGAAGTCAGCTTCTTAGAATACTACAGGAAGCAATACAACC
AAGAGATCACCGACTTGAAGCAGCCTGTCTTGGTCAGCCAGCCCAAGAGAAGGCGGGGCCCT
GGGGGGACACTGCCAGGGCCTGCCATGCTCATTCCTGAGCTCTGCTATCTTACAGGTCTAAC
TGATAAAATGCGTAATGATTTTAACGTGATGAAAGACTTAGCCGTTCATACAAGACTAACTC
CAGAGCAAAGGCAGCGTGAAGTGGGACGACTCATTGATTACATTCATAAAAACGATAATGTT
CAAAGGGAGCTTCGAGACTGGGGTTTGAGCTTTGATTCCAACTTACTGTCCTTCTCAGGAAG
AATTTTGCAAACAGAAAAGATTCACCAAGGTGGAAAAACATTTGATTACAATCCACAATTTG
CAGATTGGTCCAAAGAAACAAGAGGTGCACCATTAATTAGTGTTAAGCCACTAGATAACTGG
CTGTTGATCTATACGCGAAGAAATTATGAAGCAGCCAATTCATTGATACAAAATCTATTTAA
AGTTACACCAGCCATGGGCATGCAAATGAGAAAAGCAATAATGATTGAAGTGGATGACAGAA
CTGAAGCCTACTTAAGAGTCTTACAGCAAAAGGTCACAGCAGACACCCAGATAGTTGTCTGT
CTGTTGTCAAGTAATCGGAAGGACAAATACGATGCTATTAAAAAATACCTGTGTACAGATTG
CCCTACCCCAAGTCAGTGTGTGGTGGCCCGAACCTTAGGCAAACAGCAAACTGTCATGGCCA
TTGCTACAAAGATTGCCCTACAGATGAACTGCAAGATGGGAGGAGAGCTCTGGAGGGTGGAC
ATCCCCCTGAAGCTCGTGATGATCGTTGGCATCGATTGTTACCATGACATGACAGCTGGGCG
GAGGTCAATCGCAGGATTTGTTGCCAGCATCAATGAAGGGATGACCCGCTGGTTCTCACGCT
GCATATTTCAGGATAGAGGACAGGAGCTGGTAGATGGGCTCAAAGTCTGCCTGCAAGCGGCT
CTGAGGGCTTGGAATAGCTGCAATGAGTACATGCCCAGCCGGATCATCGTGTACCGCGATGG
CGTAGGAGACGGCCAGCTGAAAACACTGGTGAACTACGAAGTGCCACAGTTTTTGGATTGTC
TAAAATCCATTGGTAGAGGTTACAACCCTAGACTAACGGTAATTGTGGTGAAGAAAAGAGTG
AACACCAGATTTTTTGCTCAGTCTGGAGGAAGACTTCAGAATCCACTTCCTGGAACAGTTAT
TGATGTAGAGGTTACCAGACCAGAATGGTATGACTTTTTTATCGTGAGCCAGGCTGTGAGAA
GTGGTAGTGTTTCTCCCACACATTACAATGTCATCTATGACAACAGCGGCCTGAAGCCAGAC
CACATACAGCGCTTGACCTACAAGCTGTGCCACATCTATTACAACTGGCCAGGTGTCATTCG
TGTTCCTGCTCCTTGCCAGTACGCCCACAAGCTGGCTTTTCTTGTTGGCCAGAGTATTCACA
GAGAGCCAAATCTGTCACTGTCAAACCGCCTTTACTACCTC

Figure 17

A

Gene name	1st primer pair (5′-3′)	2nd primer pair (5′-3′)	Expected length (bp)
eIF2C1	GAGGTCTGTAACATTGTGGC* CGGTAGAAGATGATGCGGGT	GAGGTCTGTAACATTGTGGC* AAGTTCTTGAGCACCTCTTCTCGA	287
	GAGGTCTGTAACATTGTGGC CGGTAGAAGATGATGCGGGT	CCACACCAGCGCTCTGCC CTCACGCACCATGTAGGA	207
eIF2C2	GAGGTCTGTAACATTGTGGC CGGTAGAAGATGATGCGGGT	ATCCTGCTGCCCCAAGGG GATCTCCTGCCGGTGCTG	186
	GAGGTCTGTAACATTGTGGC* CGGTAGAAGATGATGCGGGT	GAGGTCTGTAACATTGTGGC* GATCTCCTGCCGGTGCTG	891
eIF2C3	AGAGCAACAGTATGGTGGGTGGAC TGGATGTGTGATGGTACT*	CCTCTACAGTCAAGAGGT TGGATGTGTGATGGTACT*	334
	CACTTGAATGAAGTCCCA TCCTGGATGACCTCTTGACTGTAG*	AGAGCAACAGTATGGTGGGTGGAC TCCTGGATGACCTCTTGACTGTAG*	808
eIF2C4	TCCGGCATCTCAAGAACACATATTCT GAACTCATATGGGTGTGTAATGTCTG*	ATCCAGGACTTGGCCTCC GAACTCATATGGGTGTGTAATGTCTG*	324
HILI	CAGCACAAATTATCCCTT* CGGCCTGAAGGACTGAGACGTGT	CAGCACAAATTATCCCTT* GTGTGTGGGCTTCACTGA	264
	TCTCTGTCAAAGAACTGGCTTGTCCT* CTGTACAGTGCGGTTCAT	TCTCTGTCAAAGAACTGGCTTGTCCT* CGGCCTGAAGGACTGAGACGTGT	393

* primers used in both reactions (semi-nested PCR)

B

Gene name	eIF2C1		eIF2C2		eIF2C3		eIF2C4	HILI	
Expected length (bp)	287	207	186	891	808	334	324	264	393
PCR products									

RNA-INTERFERENCE BY SINGLE-STRANDED RNA MOLECULES

[0001] This application is a divisional of U.S. Ser. No. 10/520,470 filed Jan. 7, 2005, which is a 35 U.S.C. 371 National Phase Entry Application from PCT/EP2003/007516, filed Jul. 10, 2003, which claims the benefit of European Patent Application Nos. 02015532.1 filed Jul. 10, 2002 and 02018906.4 filed Aug. 23, 2002, the disclosures of which is incorporated herein in their entirety by reference.

DESCRIPTION

[0002] The present invention relates to sequence and structural featUres of single-stranded (ss)RNA molecules required to mediate target-specific nucleic acid modifications by RNA-interference (RNAi), such as target mRNA degradation and/or DNA methylation.

[0003] Most eukaryotes possess a cellular defense system protecting their genomes against invading foreign genetic elements. Insertion of foreign elements is believed to be generally accompanied by formation of dsRNA that is interpreted by the cell as a signal for unwanted gene activity (e.g. Ahlquist, Science 296 (2002), 1270-1273; Fire et al., Nature 391 (1998), 806-811). Dicer RNase III rapidly processes dsRNA to small dsRNA fragments of distinct size and structure (e.g. Bernstein et al., Nature 409 (2001), 363-366), the small interfering RNAs (siRNAs) (Elbashir et al., Genes & Dev. 15 (2001 b), 188-200), which direct the sequence-specific degradation of the single-stranded mRNAs of the invading genes. siRNA duplexes have 2- to 3-nt 3' overhanging ends and contain 5' phosphate and free 3' hydroxyl termini (WO 02/44321). The process of posttranscriptional dsRNA-dependent gene silencing is commonly referred to as RNA interference (RNAi), and in some instances is also linked to transcriptional silencing.

[0004] Experimental introduction of siRNA duplexes into mammalian cells is now widely used to disrupt the activity of cellular genes homologous in sequence to the introduced dsRNA. Used as a reverse genetic approach, siRNA-induced gene silencing accelerates linking of gene sequence to biological function. siRNA duplexes are short enough to bypass general dsRNA-induced unspecific effects in vertebrate animal and mammalian cells. siRNAs may also be expressed intracellularly from introduced expression plasmids or viral vectors providing an alternative to chemical RNA synthesis. Therefore, an understanding of how siRNAs act in mammalian systems is important for refining this gene silencing technology and for producing gene-specific therapeutic agents.

[0005] Biochemical studies have begun to unravel the mechanistic details of RNAi. The first cell-free systems were developed using *D. melanogaster* cell or embryo extracts, and were followed by the development of in vitro systems from *C. elegans* embryo and mouse embryonal carcinoma cells. While the *D. melanogaster* lysates support the steps of dsRNA processing and sequence-specific mRNA targeting, the latter two systems only recapitulate the first step.

[0006] RNAi in *D. melanogaster* extracts is initiated by ATP-dependent processing of long dsRNA to siRNAs by Dicer RNase III (e.g. Bernstein et al., (2001), supra). Thereafter, siRNA duplexes are assembled into a multi-component complex, which guides the sequence-specific recognition of the target mRNA and catalyzes its cleavage (e.g. Elbashir (2001 b), supra). This complex is referred to as RNA-induced silencing complex (RISC) (Hammond et at., Nature 404 (2000), 293-296). siRNAs in *D. melanogaster* are predominantly 21- and 22-nt, and when paired in a manner to contain a 2-nt 3' overhanging structure effectively enter RISC (Elbashir et al., EMBO J. 20 (2001 c), 6877-6888). Mammalian systems have siRNAs of similar size, and siRNAs of 21- and 22-nt also represent the most effective sizes for silencing genes expressed in mammalian cells (e.g. Elbashir et al., Nature 411 (2001 a), 494-498, Elbashir et al., Methods 26 (2002), 199-213).

[0007] RISC assembled on siRNA duplexes in *D. melanogaster* embryo lysate targets homologous sense as well as antisense single-stranded RNAs for degradation. The cleavage sites for sense and antisense target RNAs are located in the middle of the region spanned by the siRNA duplex. Importantly, the 5'-end, and not the 3' :end, of the guide siRNA sets the ruler for the position of the target RNA cleavage. Furthermore, a 5' phosphate is required at the target-complementary strand of a siRNA duplex for RISC activity, and ATP is used to maintain the 5' phosphates of the siRNAs (Nykänen et al., Cell 107 (2001), 309-321). Synthetic siRNA duplexes with free 5' hydroxyls and 2-nt 3' overhangs are so readily phosphorylated in *D. melanogaster* embryo lysate that the RNAi efficiencies of 5'-phosphorylated and non-phosphorylated siRNAs are not significantly different (Elbashir et al. (2001 c), supra).

[0008] Unwinding of the siRNA duplex must occur prior to target RNA recognition. Analysis of ATP requirements revealed that the formation of RISC on siRNA duplexes required ATP in lysates of *D. melanogaster.* Once formed, RISC cleaves the target RNA in the absence of ATP. The need for ATP probably reflects the unwinding step and/or other conformational rearrangements. However, it is currently unknown if the unwound strands of an siRNA duplex remain associated with RISC or whether RISC only contains a single-stranded siRNA.

[0009] A component associated with RISC was identified as Argonaute2 from *D. melanogaster* Schneider 2 (S2) cells (Hammond et al., Science 293 (2001 a), 1146-1150), and is a member of a large family of proteins. The family is referred to as Argonaute or PPD family and is characterized by the presence of a PAZ domain and a C-terminal Piwi domain, both of unknown function (Cerutti et al., Trends Biochem. Sci. (2000), 481-482); Schwarz and Zamore, Genes & Dev. 16 (2002), 1025-1031). The PAZ domain is also found in Dicer. Because Dicer and Argonaute2 interact in S2 cells, PAZ may function as a protein-protein interaction motif. Possibly, the interaction between Dicer and Argonaute2 facilitates siRNA incorporation into RISC. In *D. melanogaster,* the Argonaute family has five members, most of which were shown to be involved in gene silencing and development. The mammalian members of the Argonaute family are poorly characterized, and some of them have been implicated in translational control, microRNA processing and development. The biochemical function of Argonaute proteins remains to be established and the development of more biochemical systems is crucial.

[0010] Here we report on the analysis of human RISC in extracts prepared from HeLa cells. The reconstitution of RISC and the mRNA targeting step revealed that RISC is a ribonucleoprotein complex that is composed of a single-stranded siRNA. Once RISC is formed the incorporated siRNA can no longer exchange with free siRNAs. Surprisingly, RISC can be reconstituted in HeLa S100 extracts pro-

viding single-stranded siRNAs. Introducing 5' phosphorylated single-stranded antisense siRNAs into HeLa cells potently silences an endogenous gene with similar efficiency than duplex siRNA.

[0011] The object underlying the present invention is to provide novel agents capable of mediating target-specific RNAi.

[0012] The solution of this problems is provided by the use of a single-stranded RNA molecule for the manufacture of an agent for inhibiting the expression of said target transcript. Surprisingly, it was found that single-stranded RNA molecules are capable of inhibiting the expression of target transcripts by RNA-interference (RNAi).

[0013] The length of the single-stranded RNA molecules is preferably from 14-50 nt, wherein at least the 14 to 20 5'-most nucleotides are substantially complementary to the target RNA transcript. The RNA oligonucleotides may have a free 5' hydroxyl moiety, or a moiety which is 5' phosphorylated (by means of chemical synthesis or enzymatic reactions) or which is modified by 5'-monophosphate analogues.

[0014] The inhibition of target transcript expression may occur in vitro, e.g. in eucaryotic, particularly mammalian cell cultures or cell extracts. On the other hand, the inhibition may also occur in vivo i.e. in eucaryotic, particularly mammalian organisms including human beings.

[0015] Preferably, the single-stranded RNA molecule has a length from 15-29 nucleotides. The RNA-strand may have a 3' hydroxyl group. In some cases, however, it may be preferable to modify the 3' end to make it resistant against 3' to 5' exonucleases. Tolerated 3'-modifications are for example terminal 2'-deoxy nucleotides, 3' phosphate, 2',3'-cyclic phosphate, C3 (or C6, C7, C12) aminolinker, thiol linkers, carboxyl linkers, non-nucleotidic spacers (C3, C6, C9, C12, abasic, triethylene glycol, hexaethylene glycol), biotin, fluoresceine, etc.

[0016] The 5'-terminus comprises an OH group, a phosphate group or an analogue thereof. Preferred 5' phosphate modifications are 5'-monophosphate ($(HO)_2(O)P$—O-5'), 5'-diphosphate ($(HO)_2(O)P$—O—P(HO)(O)—O-5'), 5'-triphosphate ($(HO)_2(O)$ P—O—(HO)(O)P—O—P(HO)(O)—O-5'), 5'-guanosine cap (7-methylated or non-methylated) (7m-G-O-5'-(HO)(O)P—O—(HO)(O)P—O—P(HO)(O)—O-5'), 5'-adenosine cap. (Appp), and any modified or unmodified nucleotide cap structure (N—O-5'-(HO)(O)P—O—(HO)(O)P—O—P(HO)(O)—O-5'), 5'-monothiophosphate (phosphorothioate; $(HO)_2(S)P$—O-5'), 5'-monodithiophosphate (phosphorodithioate; (HO)(HS)(S)P—O-5'), 5'-phosphorothiolate ($(HO)_2(O)P$—S-5'); any additional combination of oxgen/sulfur replaced monophosphate, diphosphate and triphosphates (e.g. 5'-alpha-thiotriphosphate, 5'-gamma-thiotriphosphate, etc.), 5'-phosphoramidates ($(HO)_2(O)P$—NH-5', (HO)(NH_2)(O)P—O-5'), 5'-alkylphosphonates (R=alkyl=methyl, ethyl, isopropyl, propyl, etc., e.g. RP(OH)(O)—O-5'-, ($(OH)_2(O)P$-5'-CH_2—), 5'-alkyletherphosphonates (R=alkylether=methoxymethyl ($MeOCH_2$—), ethoxymethyl, etc., e.g. RP(OH)(O)—O-5'-).

[0017] The sequence of the RNA molecule of the present invention has to have a sufficient identity to a nucleic acid target molecule in order to mediate target-specific RNAi. Thus the single-stranded RNA molecule of the present invention is substantially complementary to the target transcript.

[0018] The target RNA cleavage reaction guided by the single-stranded RNA molecules of the present invention is highly sequence-specific. However, no all positions of the RNA molecule contribute equally to target recognition. Mismatches, particularly at the 3'-terminus of the single-stranded RNA molecule, more particularly the residues 3' to the first 20 nt of the single-stranded RNA molecule are tolerated. Especially preferred are single-stranded RNA molecules having at the 5'-terminus at least 15 and preferably at least 20 nucleotides which are completely complementary to a predetermined target transcript or have at only mismatch and optionally up to 35 nucleotides at the 3'-terminus which may contain 1 or several, e.g. 2, 3 or more mismatches.

[0019] In order to enhance the stability of the single-stranded RNA molecules, the 3'-ends may be stabilized against degradation, e.g. they may be selected such that they consist of purine nucleotides, particularly adenosine or guanosine nucleotides. Alternatively or additionally, 3' nucleotides may be substituted by modified nucleotide analogues, including backbone modifications of ribose and/or phosphate residues.

[0020] In an especially preferred embodiment of the present invention the RNA molecule may contain at least one modified nucleotide analogue. The nucleotide analogues may be located at positions where the target-specific activity, e.g. the RNAi mediating activity is not substantially affected, e.g. in a region at the 5'-end and/or the 3'-end of the RNA molecule. Particularly, the 3'-terminus may be stabilized by incorporating modified nucleotide analogues, such as non-nucleotidic chemical derivatives such as C3 (or C6, C7, C12) arninolinker, thiol linkers, carboxyl linkers, non-nucleotidic spacers (C3, C6, C9, C12, abasic, triethylene glycol, hexaethylene glycol), biotin, fluoresceine, etc. A further modification, by which the nuclease resistance of the RNA molecule may be increased, is by covalent coupling of inverted nucleotides, e.g. 2'-deoxyribonucleotides or ribonucleotides to the 3'-end of the RNA molecule. A preferred RNA molecule structure comprises: 5'-single-stranded siRNA-3'-O—P(O)(OH)—O-3'-N, wherein N is a nucleotide, e.g. a 2'-deoxyribonucleotide or ribonucleotide, typically an inverted thymidine residue, or an inverted oligonucleotide structure, e.g. containing up to 5 nucleotides.

[0021] Preferred nucleotide analogues are selected from sugar- or backbone-modified ribonucleotides. It should be noted, however, that also nucleobase-modified ribonucleotides, i.e. ribonucleotides, containing a non-naturally occurring nucleobase instead of a naturally occurring nucleobase such as uridines or cytidines modified at the 5-position, e.g. 5-(2-amino)propyl uridine, 5-bromo uridine; 5-methyl-cytidine; adenosines and guahosines modified at the 8-position, e.g. 8-bromo guanosine; deaza nucleotides, e.g. 7-deaza-adenosine; O- and N-alkylated nucleotides, e.g. N6-methyl adenosine are suitable. In preferred sugar-modified ribonucleotides the 2' OH-group is replaced by a group selected from H, OR, R, halo, SH, SR, NH_2, NHR, NR_2 or CN, wherein R is C_1-C_6 alkyl, alkenyl, alkynyl or methoxyethoxy, and halo is F, Cl, Br or I. In preferred backbone-modified ribonucleotides the phosphoester group connecting to adjacent ribonucleotides is replaced by a modified group, e.g. a phosphorothioate, phosphorodithioate, N3'-O5'- and/or N5'-O3' phosphoramidate group. It should be noted that the above modifications may be combined. For example, complementary or non-complementary nucleotides at the 3'-terminus, particularly after at least 15, more particularly after at least 20 5'-terminal nucleotides may be modified without significant loss of activity.

[0022] The single-stranded RNA molecule of the invention may be prepared by chemical synthesis. Methods of synthesizing RNA molecules are known in the art.

[0023] The single-stranded RNAs can also be prepared by enzymatic transcription from synthetic DNA templates or from DNA plasmids isolated from recombinant bacteria and subsequent 5'-terminal modification. Typically, phage RNA polymerases are used such as T7, T3 or SP6 RNA polymerase.

[0024] A further aspect of the present invention relates to a method of mediating RNA interference in a cell or an organism comprising the steps:

[0025] (a) contacting the cell or organism with the single-stranded RNA molecule of the invention under conditions wherein target-specific nucleic acid modifications may occur and

[0026] (b) mediating a target-specific nucleic acid modification effected by the single-stranded RNA towards a target nucleic acid having a sequence portion substantially complementary to the single-stranded RNA.

[0027] Preferably the contacting step (a) comprises introducing the single-stranded RNA molecule into a target cell, e.g. an isolated target cell, e.g. in cell culture, a unicellular microorganism or a target cell or a plurality of target cells within a multicellular organism. More preferably, the introducing step comprises a carrier-mediated delivery, e.g. by liposomal carriers and/or by injection. Further suitable delivery systems include Oligofectamine (Invitrogen) and Transit-TKO siRNA Transfection reagent (Mirus)

[0028] The method of the invention may be used for determining the function of a gene in a cell or an organism or even for modulating the function of a gene in a cell or an organism, being capable of mediating RNA interference.

[0029] The cell is preferably a eukaryotic cell or a cell line, e.g. a plant cell or an animal cell, such as a mammalian cell, e.g. an embryonic cell, a pluripotent stem cell, a tumor cell, e.g. a teratocarcinoma cell or a virus-infected cell. The organism is preferably a eukaryotic organism, e.g. a plant or an animal, such as a mammal, particularly a human.

[0030] The target gene to which the RNA molecule of the invention is directed may be associated with a pathological condition. For example, the gene may be a pathogen-associated gene, e.g. a viral gene, a tumor-associated gene or an autoimmune disease-associated gene. The target gene may also be a heterologous gene expressed in a recombinant cell or a genetically altered organism. By determinating or modulating, particularly, inhibiting the function of such a gene valuable information and therapeutic benefits in the agricultural field or in the medicine or veterinary medicine field may be obtained.

[0031] The ssRNA is usually administered as a pharmaceutical composition. The administration may be carried out by known methods, wherein a nucleic acid is introduced into a desired target cell in vitro or in vivo. Commonly used gene transfer techniques include calcium phosphate, DEAE-dextran, electroporation and microinjection and viral methods (Graham, F. L. and van der Eb, A. J. (1973) Virol. 52, 456; McCutchan, J. H. and Pagano, J. S. (1968), J. Natl. Cancer Inst. 41, 351; Chu, G. et al (1987), Nucl. Acids Res. 15, 1311; Fraley, R. et al. (1980), J. Biol. Chem. 255, 10431; Capecchi, M. R. (1980), Cell 22, 479). A recent addition to this arsenal of techniques for the introduction of nucleic acids into cells is the use of cationic liposomes (Feigner, P. L. et al. (1987), Proc. Natl. Acad. Sci USA 84, 7413). Commercially available cationic lipid formulations are e.g. Tfx 50 (Promega) or Lipofectamin2000 (Life Technologies). A further preferred method for the introduction of RNA into a target organism, particularly into a mouse, is the high-pressure tail vein injection (Lewis, D. L. et al. (2002), Nat. Genet.29, 29; McCaffrey, A. P. et al. (2002), Nature 418, 38-39).

[0032] Herein, a buffered solution comprising the single-stranded RNA (e.g. about 2 ml) is injected into the tail vein of the mouse within 10 s.

[0033] Thus, the invention also relates to a pharmaceutical composition containing as an active agent at least one single-stranded RNA molecule as described above and a pharmaceutical carrier. The composition may be used for diagnostic and for therapeutic applications in human medicine or in veterinary medicine.

[0034] For diagnostic or therapeutic applications, the composition may be in form of a solution, e.g. an injectable solution, a cream, ointment, tablet, suspension or the like. The composition may be administered in any suitable way, e.g. by injection, by oral, topical, nasal, rectal application etc. The carrier may be any suitable pharmaceutical carrier. Preferably, a carrier is used, which is capable of increasing the efficacy of the RNA molecules to enter the target-cells. Suitable examples of such carriers are liposomes, particularly cationic liposomes. A further preferred administration method is injection.

[0035] A further preferred application of the RNAi method is a functional analysis of eukaryotic cells, or eukaryotic non-human organisms, preferably mammalian cells or organisms and most preferably human cells, e.g. cell lines such as HeLa or 293 or rodents, e.g. rats and mice. By transfection with suitable single-stranded RNA molecules which are homologous to a predetermined target gene or DNA molecules encoding a suitable single-stranded RNA molecule a specific knockout phenotype can be obtained in a target cell, e.g. in cell culture or in a target organism. The presence of short single-stranded RNA molecules does not result in an interferon response from the host cell or host organism.

[0036] In an especially preferred embodiment, the RNA molecule is administered associated with biodegradable polymers, e.g. polypeptides, poly(d,l-lactic-co-glycolic acid) (PLGA), polylysine or polylysine conjugates, e.g. polylysine-graft-imidazole acetic acid, or poly(beta-amino ester) or microparticles, such as microspheres, nanoparticles or nanospheres. More preferably the RNA molecule is covalently coupled to the polymer or microparticle, wherein the covalent coupling particularly is effected via the 3'-terminus of the RNA molecule.

[0037] Further, the invention relates to a pharmaceutical composition for inhibiting the expression of a target transcript by RNAi comprising as an active agent a single-stranded RNA molecule having a length from 14-50, preferably 15-29 nucleotides wherein at least the 14-20 5'most nucleotides are substantially complementary to said target transcript.

[0038] Furthermore, the invention relates to a method for the prevention or treatment of a disease associated with overexpression of at least one target gene comprising administering a subject in need thereof a single-stranded RNA molecule having a length from 14-50, preferably 15-29 nucleotides wherein at least the 14-20 5'most nucleotides are substantially complementary to a target transcript in an amount which is therapeutically effective for RNAi.

[0039] Still, a further subject matter of the invention is a eukaryotic cell or a eukaryotic non-human organism exhibit-

ing a target gene-specific knockout phenotype comprising an at least partially deficient expression of at least one endogeneous target gene wherein said cell or organism is transfected with at least one single-stranded RNA molecule capable of inhibiting the expression of at least one endogeneous target gene. It should be noted that the present invention allows the simultaneous delivery of several antisense RNAs of different sequences, which are either cognate to a different or the same target gene.

[0040] Gene-specific knockout phenotypes of cells or non-human organisms, particularly of human cells or non-human mammals may be used in analytic procedures, e.g. in the functional and/or phenotypical analysis of complex physiological processes such as analysis of gene expression profiles and/or proteomes. For example, one may prepare the knock-out phenotypes of human genes in cultured cells which are assumed to be regulators of alternative splicing processes. Among these genes are particularly the members of the SR splicing factor family, e.g. ASF/SF2, SC35, SRp2O, SRp4O or SRp55. Further, the effect of SR proteins on the mRNA profiles of predetermined alternatively spliced genes such as CD44 may be analysed. Preferably the analysis is carried out by high-throughput methods using oligonucleotide based chips.

[0041] Using RNAi based knockout technologies, the expression of an endogeneous target gene may be inhibited in a target cell or a target organism. The endogeneous gene may be complemented by an exogeneous target nucleic acid coding for the target protein or a variant or mutated form of the target protein, e.g. a gene or a cDNA, which may optionally be fused to a further nucleic acid sequence encoding a detectable peptide or polypeptide, e.g. an affinity tag, particularly a multiple affinity tag. Variants or mutated forms of the target gene differ from the endogeneous target gene in that they encode a gene product which differs from the endogeneous gene product on the amino acid level by substitutions, insertions and/or deletions of single or multiple amino acids. The variants or mutated forms may have the same biological activity as the endogeneous target gene. On the other hand, the variant or mutated target gene may also have a biological activity, which differs from the biological activity of the endogeneous target gene, e.g. a partially deleted activity, a completely deleted activity, an enhanced activity etc.

[0042] The complementation may be accomplished by coexpressing the polypeptide encoded by the exogeneous nucleic acid, e.g. a fusion protein comprising the target protein and the affinity tag and the double stranded RNA molecule for knocking out the endogeneous gene in the target cell. This coexpression may be accomplished by using a suitable expression vector expressing both the polypeptide encoded by the exogeneous nucleic acid, e.g. the tag-modified target protein and the single-stranded RNA molecule or alternatively by using a combination of expression vectors. Proteins and protein complexes which are synthesized de novo in the target cell will contain the exogeneous gene product, e.g. the modified fusion protein. In order to avoid suppression of the exogeneous gene product expression by the RNAi molecule, the nucleotide sequence encoding the exogeneous nucleic acid may be altered on the DNA level (with or without causing mutations on the amino acid level) in the part of the sequence which is homologous to the single-stranded RNA molecule. Alternatively, the endogeneous target gene may be complemented by corresponding nucleotide sequences from other species, e.g. from mouse.

[0043] Preferred applications for the cell or organism of the invention is the analysis of gene expression profiles and/or proteomes. In an especially preferred embodiment an analysis of a variant or mutant form of one or several target proteins is carried out, wherein said variant or mutant forms are reintroduced into the cell or organism by an exogeneous target nucleic acid as described above. The combination of knockout of an endogeneous gene and rescue, by using mutated, e.g. partially deleted exogeneous target has advantages compared to the use. of a knockout cell. Further, this method is particularly suitable for identifying functional domains of the target protein. In a further preferred embodiment a comparison, e.g. of gene expression profiles and/or proteomes and/or phenotypic characteristics of at least two cells or organisms is carried out. These organisms are selected from:

[0044] (i) a control cell or control organism without target gene inhibition,

[0045] (ii) a cell or organism with target gene inhibition and

[0046] (iii) a cell or organism with target gene inhibition plus target gene complementation by an exogeneous target nucleic acid.

[0047] The method and cell of the invention may also be used in a procedure for identifying and/or characterizing pharmacological agents, e.g. identifying new pharmacological agents from a collection of test substances and/or characterizing mechanisms of action and/or side effects of known pharmacological agents.

[0048] Thus, the present invention also relates to a system for identifying and/or characterizing pharmacological agents acting on at least one target protein comprising:

[0049] (a) a eukaryotic cell or a eukaryotic non-human organism capable of expressing at least one endogeneous target gene coding for said target protein,

[0050] (b) at least one single-stranded RNA molecule capable of inhibiting the expression of said at least one endogeneous target gene by RNAi and

[0051] (c) a test substance or a collection of test substances wherein pharmacological properties of said test substance or said collection are to be identified and/or characterized.

[0052] Further, the system as described above preferably comprises:

[0053] (d) at least one exogeneous target nucleic acid coding for the target protein or a variant or mutated form of the target protein wherein said exogeneous target nucleic acid differs from the endogeneous target gene on the nucleic acid level such that the expression of the exogeneous target nucleic acid is substantially less inhibited by the single-stranded RNA molecule than the expression of the endogeneons target gene.

[0054] Furthermore, the RNA knockout complementation method may be used for preparative purposes, e.g. for the affinity purification of proteins or protein complexes from eukaryotic cells, particularly mammalian cells and more particularly human cells. In this embodiment of the invention, the exogeneous target nucleic acid preferably codes for a target protein which is fused to an affinity tag.

[0055] The preparative method may be employed for the purification of high molecular weight protein complexes which preferably have a mass of ≧150 kD and more preferably of >500 kD and which optionally may contain nucleic acids such as RNA. Specific examples are the heterotrimeric protein complex consisting of the 20 kD, 60 kD and 90 kD

proteins of the U4/U6 snRNP particle, the splicing factor SF3b from the 17S U2 snRNP consisting of 5 proteins having molecular weights of 14, 49, 120, 145 and 155 kD and the 25S U4/U6/U5 tri-snRNP particle containing the U4, U5 and U6 snRNA molecules and about 30 proteins, which has a molecular weight of about 1.7 MD.

[0056] This method is suitable for functional proteome analysis in mammalian cells, particularly human cells.

[0057] Finally, the invention relates to a purified and isolated mammalian, partiCularly human RNA-induced silencing complex (RISC) having an apparent molecular weight of less than about 150-160 kDa, e.g. about 120 to 150-160 kDa. The RISC comprises polypeptide and optionally nucleic acid components, particularly single-stranded RNA molecules as described above. The RISC may be used as a target for diagnosis and/or therapy, as a diagnostic and/or therapeutic agent itself, as a molecular-biological reagent or as component in a screening procedure for the identification and/or characterization of pharmaceutical agents.

[0058] Polypeptide components of RISC preferably comprise members of the Argonaute family of proteins, and contain eIF2C1 and/or eIF2C2, and possibly at least one other expressed eIF2C family member, particularly selected from eIF2C3, eIF2C4, HILI and HIWI.

[0059] Expression or overexpression of one or several proteins present in RISC in suitable host cells, e.g. eukaryotic cells, particularly mammalian cells, is useful to assist an RNAi response. These proteins may also be expressed or overexpressed in transgenic animals, e.g. vertebrates, particularly mammals, to produce animals particularly sensitive to injected single-stranded or double-stranded siRNAs. Further, the genes encoding the proteins may be administered for therapeutic purposes, e.g. by viral or non-viral gene delivery vectors.

[0060] It is also conceivable to administer a siRNA/eIF2C1 or 2 complex directly by the assistance of protein transfection reagents (e.g. Amphoteric Protein Transfection Reagents, ProVectin protein (lmgenex), or similar products) rather than RNA/DNA transfection. This may have technical advantages over siRNA transfection that are limited to nucleic acid transfection.

[0061] Alternatively to the application of siRNAs as synthetic double-stranded or single-stranded siRNAs, it is conceivable to also administer an antisense siRNA precursor molecule in the form of a hairpin stem-loop structure comprising 19 to 29 base pairs in the stem with or without 5' or 3' overhanging ends on one side of the duplex and a nucleotide or non-nucleotide loop on the other end. Preferably, the hairpin structure has a 3' overhang of from 1-5 nucleotides. Further, the precursor may contain modified nucleotides as described above, particularly in the loop and/or in the 3' portion, particularly in the overhang. The siRNA or precursors of siRNAs may also be introduced by viral vectors or RNA expression systems into a RISC compound, e.g. eIF2C1 and/or 2 overexpressing organism or cell line. The siRNA precursors may also be generated by direct expression within an organism or cell line. This may be achieved by transformation with a suitable expression vector carrying a nucleic acid template operatively linked to an expression control sequence to express the siRNA precursor.

[0062] Further, the present invention is explained in more detail in the following figures and examples.

FIGURE LEGENDS

[0063] FIG. **1**. HeLa cytoplasmic S100 extracts show siRNA-dependent target RNA cleavage.

[0064] (A) Representation of the 177-nt ^{32}P-cap-labeled target RNA with the targeting siRNA duplex. Target RNA cleavage site and the length of the expected cleavage products is also shown. The fat black line positioned under the antisense siRNA is used in the following figures as symbol to indicate the region of the target RNA, which is complementary to the antisense siRNA sequence. (B) Comparison of the siRNA mediated target RNA cleavage using the previously established *D. melanogaster* embryo in vitro system and HeLa cell S100 cytoplasmic extract. 10 nM cap-labeled target RNA was incubated with 100 nM siRNA as described in materials. Reaction products were resolved on a 6% sequencing gel. Position markers were generated by partial RNase T1 digestion (T1) and partial alkaline hydrolysis (OH) of the cap-labeled target RNA. The arrow indicates the 5' cleavage product, the fragment is unlabeled and therefore invisible.

[0065] FIG. **2**. Chemical modification of the 5' end of the antisense but not the sense siRNAs prevents sense target RNA cleavage in HeLa S100 extracts. (A) Illustration of the possible 5' and 3' aminolinker modifications of the sense and antisense strands of a siRNA duplex. L5 represents a 6-carbon chain aminolinker connected via a 5'-phosphodiester linkage, L3 represents a 7-carbon aminolinker connected via a phosphodiester bond to the terminal 3' phosphate. s, sense; as, antisense. (B) Target RNA cleavage testing various combinations of 5' and 3' aminolinker-modified siRNA duplexes. NC (negative control) shows an incubation reaction of the target RNA in the absence of siRNA duplex. T1, RNase T1 ladder; OH, partial alkaline hydrolysis ladder.

[0066] FIG. **3**. siRNA containing 3'-terminal phosphates are subjected to ligation as well as dephosphorylation reactions.

[0067] (A) Sequence of the radiolabeled siRNA duplex. The labeled nucleotide was joined to synthetic 20-nt antisense siRNA by T4 RNA ligation of ^{32}pCp. The various combinations of 5' and 3' hydroxyl/phosphate were prepared as described in materials. X and Y indicate 5' and 3' modifications of the antisense siRNA. (B) Fate of the antisense siRNA during incubation of the modified siRNA duplexes in HeLa S100 extract in the presence of non-radiolabeled target RNA. The different phosphorylated forms of the antisense siRNA were distinguished based on their gel mobility. Identical results were obtained when using 5' phosphorylated sense siRNA or when leaving out the target RNA during incubation. Ligation products are only observed when 3' phosphates were present on the labeled antisense siRNA.

[0068] FIG. **4**: RISC is a stable complex that does not rapidly exchange bound siRNA.

[0069] Increasing concentrations of non-specific siRNA compete with target-specific RISC formation when added simultaneously to HeLa S100 extracts (lanes 4 to 7). However, when the unspecific siRNA duplex is added 15 min after pre-incubation with the specific siRNA duplex, no more competition was observed (3 lanes to the right). T1, RNase T1 ladder.

[0070] FIG. **5**. Partial purification of human RISC.

[0071] (A) Graphical representation of the structure of the biotinylated siRNA duplex used for affinity purification of siRNA-associated factors. L3 indicates a C7-aminolinker that was conjugated to a photo-cleavable biotin N-hydroxysuccinimidyl ester; UV indicates photocleavage of the UV-sensitive linkage to release affinity selected complexes under native conditions. (B) Superdex-200 gel filtration analysis of siRNA-protein complexes (siRNPs) recovered

by UV treatment/elution (UV elu) from the streptavidin affinity column. Fractions were assayed for their ability to sequence-specifically cleave the cap-labeled target RNA. The number of the 10 collected fractions and the relative positions of the aldolase (158 kDa) and BSA (66 kDa) size markers are indicated. (C) Glycerol gradient (5%-20%) sedimentation of siRNPs recovered by UV treatment/elution from the streptavidin affinity column. For legend, see (B). When monitoring the precise size of target RNA cleavage fragments using internally ^{32}P-UTP-labeled, capped mRNA, the sum is equal to the full-length transcript, thus indicating that target RNA is indeed only cleaved once in the middle of the region spanned by the siRNA.

[0072] FIG. **6**. RISC contains a single-stranded siRNA.

[0073] siRNPs were subjected to affinity selection after incubation using siRNA duplexes with one or both strands biotinylated. The eluate recovered after UV treatment or the unbound fraction after streptavidin affinity selection (flow-through) was assayed for target RNA degradation. If the antisense strand was biotinylated, all sense target RNA-cleaving RISC was bound to the streptavidin beads, while sense siRNA biotinylation resulted in RISC activity of the flow-through. The cleavage reaction in the flow-through fraction was less efficient than in the UV eluate, because affinity-selected RISC was more concentrated.

[0074] FIG. **7**. Single-stranded antisense siRNAs reconstitute RISC in HeLa S100 extracts.

[0075] Analysis of RISC reconstitution using single-stranded or duplex siRNAs comparing HeLa S100 extracts (A) and the previously described *D. melanogaster* embryo lysate (B). Different concentrations of single-stranded siRNAs (s, sense; as, antisense) and duplex siRNA (ds) were tested for specific targeting of cap-labeled substrate RNA. 100 nM concentrations of the antisense siRNA reconstituted RISC in HeLa S100 extract, although at reduced levels in comparison to the duplex siRNA. Reconstitution with single-stranded siRNAs was almost undetectable in *D. melanogaster* lysate, presumably because of the higher nuclease activity in this lysate causing rapid degradation of uncapped single-stranded RNAs.

[0076] FIG. **8**. Single-stranded antisense siRNAs mediate gene silencing in HeLa cells.

[0077] (A) Silencing of nuclear envelope protein lamin A/C. Fluorescence staining of cells transfected with lamin A/C-specific siRNAs and GL2 luciferase (control) siRNAs. Top row, staining with lamin A/C specific antibody; middle row, Hoechst staining of nuclear chromatin; bottom row, phase contrast images of fixed cells. (B) Quantification of lamin A/C knockdown after Western blot analysis. The blot was stripped after lamin A/C probing and reprobed with vimentin antibody. Quantification was performed using a Lumi-Imager (Roche) and LumiAnalyst software to quantitate the ECL signals (Amersham Biosciences), differences in gel loading were corrected relative to non-targeted vimentin protein levels. The levels of lamin A/C protein were normalized to the non-specific GL2 siRNA duplex.

[0078] FIG. **9**. Antisense siRNAs of different length direct target RNA cleavage in HeLa S100 extracts.

[0079] (A) Graphical representation of the experiment. Antisense siRNAs were extended towards the 5' side (series 1, 20 to 25-nt) or the 3' side (series 2, 20 to 23-nt).

[0080] (B) Target RNA cleavage using the antisense siRNAs described in (A). HeLa S100 extract was incubated with 10 nM cap-labeled target RNA and 100 nM antisense siRNAs at 30° C. for 2.5 h. Reaction products were resolved on a 6% sequencing gel. Position markers were generated by partial RNase T1 digestion (T1) and partial alkaline hydrolysis (OH) of the cap-labeled target RNA. Arrows indicate the position of the 5' cleavage products generated by the different antisense siRNAs. The fat black lines on the left (series 1) and the right (series 2) indicate the region of the target RNA, which is complementary to the antisense siRNA sequences.

[0081] FIG. **10**. Length dependence of antisense siRNAs and effect of terminal modifications for targeting RNA cleavage in HeLa S100 extracts.

[0082] HeLa S100 extract was incubated with 10 nM cap-labeled target RNA and 100 nM antisense siRNAs at 30° C. for 2.5h. Reaction products were resolved on a 6% sequencing get. Position markers were generated by partial RNase T1 digestion (T1) of the cap-labeled target RNA. The fat black line on the left indicates the region of the target RNA, which is complementary to the 21-nt antisense siRNA sequence. The siRNA sequences used in each experiment are listed below (sense and antisense siRNAs are listed together, they were pre-annealed to form duplex siRNAs). p, phosphate; t, 2'-deoxythymidine, c, 2'-deoxycytidine, g, 2'-deoxycytidine, g, 2'-deoxyguanosine; L, aminolinker, B, photocleavable biotin; A,C,G,U, ribonucleotides.

Lane	Sense siRNA (5'-3')	Antisense siRNA (5'-3')
1		pUCGAAGUAUUCCG CG
2		pUCGAAGUAUUCCG CGUACGUG
3		pUCGAAGUAUUCCG CGUACGUGAUGU
4		pUCGAAGUAUUCCG CGUACGUGAUGUUC
5		pUCGAAGUAUUCCG CGUACGUGAUGUUC AC
6		pUCGAAGUAUUCCG CG
7		pUCGAAGUAUUCCG CGUACGUG
8		pUCGAAGUAUUCCG CGUACGUGAUGU
9		pUCGAAGUAUUCCG CGUACGUGAUGUUC
10		pUCGAAGUAUUCCG CGUACGUGAUGUUC AC
11		pUCGAAGUAUUCCG CGUACGUG
12		pUCGAAGUAUUCCG CGUACGtg
13		pUCGAAGUAUUCCG CGUACGUU

-continued

Lane	Sense siRNA (5'-3')	Antisense siRNA (5'-3')
14		pUCGAAGUAUUCCG CGUACGtt
15		pUCGAAGUAUUCCG CGUACGUG
16		pUCGAAGUAUUCCG CGUACGtg
17		pUCGAAGUAUUCCG CGUACGUU
18		pUCGAAGUAUUCCG CGUACGtt
19	CGUACGCGGAAUACUUCG AAA	pUCGAAGUAUUCCG CGUACGUG
20	CGUACGCGGAAUACUUCG AAA	pUCGAAGUAUUCCG CGUACGtg
21	CGUACGCGGAAUACUUCG AAA	pUCGAAGUAUUCCG CGUACGUU
22	CGUACGCGGAAUACUUCG AAA	pUCGAAGUAUUCCG CGUACGtt
23		tCGAAGUAUUCCGC GUACGUULB
24	cGUACGCGGAAUACUUCG AUULB	tCGAAGUAUUCCGC GUACGUULB
25		ptCGAAGUAUUCCGC GUACGttLB
26	cGUACGCGGAAUACUUCG AttLB	ptCGAAGUAUUCCGC GUACGttLB
27		ptCGAAGUAUUCCGC GUACGttL

[0083] FIG. **11**: Single-stranded antisense siRNAs mediate gene silencing in HeLa cells.

[0084] Quantification of lamin A/C knockdown after Western blot analysis. The blot was stripped after lamin A/C probing and reprobed with vimentin antibody. Quantification was performed using a Lumi-Imager (Roche) and LumiAnalyst software to quantitate the ECL signals (Amersham Biosciences), differences in gel loading were corrected relative to non-targeted vimentin protein levels. The levels of lamin A/C protein were normalized to the non-specific GL2 s1RNA duplex.

[0085] FIG. **12**. Protein composition of affinity purified RISC.

[0086] (A) Silver-stained SDS-PAGE gel of affinity-selected ribonucleoprotein complexes after glycerol gradient (5%-20%) sedimentation. The arrow indicates the band containing eIF2C1 and eIF2C2. Molecular size markers are indicated on the left. The asterisk indicates a fraction for which the protein pellet was lost after precipitation. (B) Target RNA cleavage assay of the collected fractions. RISC activity peaked in fraction 7 and 8; bu, buffer.

[0087] FIG. **13**. Mass spectrometric characterization of eIF2C1 and eIF2C2.

[0088] The 100 kDa band was analysed by mass spectrometry. Mass spectrum indicating the peptide peaks corresponding to eIF2C2 (A) and eIF2C1 (B).

[0089] (C) Alignment of eIF2C2 and eIF2C1 amino-acid sequences indicating the position of the identified peptides. Sequence differences are indicated by yellow boxes.

[0090] FIG. **14**. Predicted amino-acid sequences of the six human Argonaute protein family members.

[0091] FIG. **15**. Alignment of the sequences of the six human Argonaute protein family members.

[0092] Predicted sequences of human eIF2C1-4, HILI and HIWI have been aligned using ClustaIX program.

[0093] FIG. **16**. Predicted cDNA sequences of the six human Argonaute protein family members.

[0094] FIG. **17**. AU members of the Argonaute family but HIWI are expressed in HeLa cells.

[0095] RT-PCR analysis on polyA RNA from HeLa cells. (A) Primers (forward and reverse) used for nested and semi-nested PCR amplification of the different Argonautes and expected length of the PCR products. (B) Agarose gel electrophoresis of the obtained PCR products, confirming the expected length. Left lanes, 100 by DNA ladder.

EXAMPLE

1. Material and Methods

[0096] 1.1 siRNA Synthesis and Biotin Conjugation

[0097] siRNAs were chemically synthesized using RNA phosphoramidites (Proligo, Hamburg, Germany) and deprotected and gel-purified as described previously. 5' aminolinkers were introduced by coupling MMT-C6-aminolinker phosphoramidite (Proligo, Hamburg), 3' C7-aminolinkers were introduced by assembling the oligoribonucleotide chain on 3'-aminomodifier (TFA) C7 lcaa control pore glass support (Cherngenes, Mass., USA). The sequences for GL2 luciferase siRNAs were as described (Elbashir et al., 2001a, supra). If 5'-phosphates were to be introduced, 50 to 100 nmoles of synthetic siRNAs were treated with T4 polynucleotide kinase (300 p1 reaction, 2.5 mM ATP, 70 mM Tris-HCl, pH 7.6, 10 mM $MgCl_2$, 5 mM DTT, 30 U T4 PNK, New England Biolabs, 45 min, 37° C.) followed by ethanol precipitation.

[0098] 3' Terminal ^{32}pCp labeling (FIG. **3**) was performed in a 30 μl reaction (17 μM siRNA, 0.5 μM ^{32}pCp (110 TBq/mmol), 15% DMSO, 20 U T4 RNA ligase, NEB, and 1× NEB-supplied reaction buffer) for 1.5 h at 37° C., and gel-purified. One half of the pCp-labeled RNA was dephosphorylated (25 μl reaction, 500 U alkaline phosphatase, Roche, and Roche-supplied buffer, 30 min, 50° C.), followed by phenol/chloroform extraction and ethanol precipitation. Half of this reaction was 5' phosphorylated (20 μl reaction, 2 units T4 polynucleotide kinase, NEB, 10 mM ATP, NEB-supplied buffer, 60 min, 37° C.). A quarter of the initial pCp-labeled siRNA was also 5' phosphorylated (10 μl reaction, 10 units 3' phosphatase-free T4 polynucleotide kinase, Roche, 10 mM ATP, Roche-supplied buffer, 3 min, 37° C.).

[0099] For conjugation to biotin, 20 to 65 nmoles of fully deprotected aminolinker-modified siRNA were dissolved in 100 μl of 100 mM sodium borate buffer (pH 8.5) and mixed with a solution of 1 mg of EZ-Link NHS-PC-LC-Biotin (Pierce, Ill., USA) in 100 μl of anhydrous dimethylformamide. The solution was incubated for 17 h at 25° C. in the dark. Subsequently, siRNAs were precipitated by the addition of 60 μl 2 M sodium acetate (pH 6.0) and 1 ml ethanol. The RNA pellet was collected by centrifugation and biotin-conjugated siRNA was separated from non-reacted siRNA on a preparative denaturing 18% acrylamide gel (40 cm length) in

the dark. The RNA bands were visualized by 254 nm UV shadowing and minimized exposure time. The bands were excised, and the RNA was eluted overnight in 0.3 M NaCl at 4° C. and recovered by ethanol precipitation. siRNA duplexes were formed as previously described (Elbashir et al., Methods 26 (2002), 199-213).

1.2 Preparation of S100 Extracts from HeLa Cells

[0100] Cytoplasm from HeLa cells adapted to grow at high density was prepared following the Dignam protocol for isolation of HeLa cell nuclei (Dignam et al., Nucleic Acids Res. 11 (1983), 1475-1489). The cytoplasmic fraction was supplemented with KCl, $MgCl_2$ and glycerol to final concentrations of 100 mM, 2 mM and 10%, respectively. At this stage, the extracts can be stored frozen at −70° C. after quick-freezing in liquid nitrogen without loss of activity. S100 extracts were prepared by ultracentrifugation at 31.500 rpm for 60 minutes at 4° C. using a Sorvall T-865 rotor. The protein concentration of HeLa S100 extract varied between 4 to 5 mg/ml as determined by Bradford assay.

1.3 Affinity Purification of RISC with 3' Biotinylated siRNA Duplexes

[0101] For affinity purification of siRNA-associated protein complexes from HeLa S100 extracts, 10 nM of a 3' double-biotinylated siRNA duplex were incubated in 0.2 mM ATP, 0.04 mM GTP, 10 U/ml RNasin, 6 μg/ml creatine kinase, and 5 mM creatine phosphate in 60% S100 extract at 30° C. for 30 to 60 min and gentle rotation. Thereafter, 1 ml slurry of Immobilized Neutravidin Biotin Binding Protein (Pierce, IL, USA) was added per 50 ml of reaction solution and the incubation was continued for another 60 to 120 min at 30° C. with gentle rotation. The Neutravidin beads were then collected at 2000 rpm for 2 minutes at 4° C. in a Heraeus Megafuge 1.0 R centrifuge using a swinging bucket rotor type 2704. Effective capturing of RISC components after affinity selection was confirmed by assaying the supernatant for residual RISC activity with and without supplementing fresh siRNA duplexes. The collected Neutravidin beads were washed with 10 volumes of buffer A relative to the bead volume (30 mM HEPES, pH 7.4, 100 mM KCl, 2 mM $MgCl_2$, 0.5 mM DTT, 10% glycerol) followed by washing with 5 volumes of buffer B (same as buffer A with only 3% glycerol content). The beads were transferred to a 0.8×4 cm Poly-Prep chromatography column (BioRad; CA, USA) by resuspending in 3 volumes of buffer B at 4° C., followed by 10 volumes of washing with buffer B. Washing of the beads was continued by 10 volumes of buffer B increased to 300 mM KCl. The column was then reequilibrated with regular buffer B. To recover native siRNA-associated complexes, the column was irradiated in the cold room by placing it at a 2 cm distance surrounded by four 312 nm UV lamps (UV-B tube, 8 W, Herotab, Germany) for 30 minutes. To recover the photocleaved siRNP solution, the column was placed into a 50 ml Falcon tube and centrifuged at 2000 rpm for 1 minute at 4° C. using again the 2704 rotor. For full recovery of siRNPs, the beads were once again resuspended in buffer B followed by a second round of UV treatment for 15 minutes. Both eluates were pooled and assayed for target RNA degradation.

1.4 Target RNA Cleavage Assays

[0102] Cap-labeled target RNA of 177 nt was generated as described (Elbashir et al., EMBO J. 20 (2001 c), 6877-6888) except that his-tagged guanylyl transferase was expressed in *E. coli* from a plasmid generously provided by J. Wilusz and purified to homogeneity. If not otherwise indicated, 5' phosphorylated siRNA or siRNA duplex was pre-incubated in supplemented HeLa S100 extract at 30° C. for 15 min prior to addition of cap-labeled target RNA. After addition of all components, final concentrations were 100 nM siRNA, 10 nM target RNA, 1 mM ATP, 0.2 mM GTP, 10 U/ml RNasin, 30 μg/ml creatine kinase, 25 mM creatine phosphate, 50% S100 extract. Incubation was continued for 2.5 h. siRNA-mediated target RNA cleavage in *D. melanogaster* embryo lysate was performed as described (Zamore et al., Cell 101 (2000), 25-33). Affinity-purified RISC in buffer B was assayed for target RNA cleavage without preincubation nor addition of extra siRNA (10 nM target RNA, 1 mM ATP, 0.2 mM GTP, 10 U/ml RNasin, 30 μg/ml creatine kinase, 25 mM creatine phosphate, 50% RISC in buffer B). Cleavage reactions were stopped by the addition of 8 vols of proteinase K buffer (200 mM Tris-HCl pH 7.5, 25 mM EDTA, 300 mM NaCl, 2% w/v SDS). Proteinase K, dissolved in 50 mM Tris-HCl pH 8.0, 5 mM $CaCl_2$, 50% glycerol, was added to a final concentration of 0.6 mg/ml and processed as described (Zamore et al. (2000), supra). Samples were s separated on 6% sequencing gels.

1.5 Analytical Gel Filtration

[0103] UV-eluates in buffer B were fractionated by gel filtration using a Superdex 200 PC 3.2/30 column (Amersham Biosciences) equilibrated with buffer A on a SMART system (Amersham Biosciences). Fractionation was performed by using a flow rate of 40 μl/minute and collecting 100 μl fractions. Fractions were assayed for specific target RNA cleavage. Size calibration was performed using molecular size markers thyroglobulin (669 kDa), ferritin (440 kDa), catalase (232 kDa), aldolase (158 kDa) and BSA (66 kDa) (Amersham Biosciences).

1.6 Glycerol Gradient Sedimentation

[0104] UV-eluates were layered on top of 4 ml linear 5% to 20% (w/w) glycerol gradient adjusted to 30 mM HEPES, pH 7.4, 100 mM KCl, 2 mM $MgCl_2$, 0.5 mM DTT. Centrifugation was performed at 35000 rpm for 14.5 h at 4° C. using a Sorvall SW 60 rotor. Twenty fractions of 0.2 ml volume were removed sequentially from the top and 15 μl aliquots were used to assay for target RNA cleavage.

2. Results

[0105] 2.1 A Human Biochemical System for siRNA Functional Analysis

[0106] We were interested in assaying siRNA-mediated target RNA degradation in human cell extracts, because siRNAs are powerful reagents to knockdown gene expression in human cells but the action of siRNAs in human cells was uncertain. To investigate whether siRNAs guide target RNA degradation in human cells with a similar mechanism to the one observed in *D. melanogaster* (e.g. Elbashir et al. (2001 b), supra), we prepared substrates for targeted mRNA degradation as described previously (Elbashir et al. (2001 c), supra). A 5═-^{32}P-cap-labeled, 177-nt RNA transcript, derived from a segment of the firefly luciferase gene, was incubated in HeLa cell S100 or *D. melanogaster* embryo extracts with a 21-nt siRNA duplex in the presence of an ATP regeneration system (FIG. **1**A, B). siRNA cleavage assays were performed at 25° C. in *D. melanogaster* lysate and at 30° C. in HeLa

S100 extracts for 2.5 h. After deproteinization using proteinase K, the reaction products were separated on a 6% sequencing gel.

[0107] Similar to the previous observation in *D. melanogaster* lysate, we observed the appearance of a cleavage product in HeLa S100 extract at exactly the same position, thus indicating that the siRNA duplex guides target RNA cleavage in the human system with the same specificity and mechanism. The cleavage reaction appeared less efficient when compared to the *D. melanogaster* system, but this could be explained by the 5-fold lower total protein concentration of HeLa S100 extracts (25 mg/ml vs. 5 mg/ml). Similar to *D. melanogaster* lysates, siRNA duplexes without 5' phosphate were rapidly 5' phosphorylated in HeLa S100 extracts (see below) and the ability to cleave the target RNA was independent of the presence of a 5' phosphate on the synthetic siRNA duplexes.

[0108] Comparative analysis of the efficiency of siRNA duplexes of different length in *D. melanogaster* lysate and in transfected mammalian cells indicated that the differences in silencing efficiencies between 20- to 25-nt siRNA duplexes were less pronounced in mammalian cells than in *D. melanogaster* (Elbashir et al. (2002), supra). Duplexes of 24- and 25-nt siRNAs were inactive in *D. melanogaster* lysate, whereas the same duplexes were quite effective for silencing when introduced by transfection into HeLa cells. We therefore asked whether siRNA duplexes of 20- to 25-nt are able to reconstitute RISC also with approximately equal efficiency. Indeed, we observed no large differences in our biochemical assay, and the position of target RNA cleavage was as predicted according to the cleavage guiding rules established in *D. melanogaster* lysate (data not shown). Our biochemical results therefore support the in vivo observations.

2.2 5' Modification of the Guide siRNA Inhibits RISC Activity

[0109] Modification of siRNAs at their termini is important for developing siRNA-based affinity purification schemes or for Conjugating reporter tags for biophysical measurements. The most common method for introducing reactive side chains into nucleic acids is by chemical synthesis using aminolinker derivatives (Eckstein (1991), Oligonucleotides and analogues, 2nd Ed., Oxford UK, Oxford University Press). After complete deprotection of the oligonucleotide, the primary amine is typically reacted with the N-hydroxysuccinimidyl ester of the desired compound. We have introduced 5' and 3' aminolinkers with six and seven methylene groups as spacers, respectively. The linker-modified siRNA duplexes were tested for mediating target RNA degradation in HeLa S100 extract (FIG. **2**A, B). Modification of the 5'-end of the antisense guide siRNA abolished target RNA cleavage, while modification of neither the sense 5'-end nor of both 3'-ends showed any inhibitory effect. In an identical experiment using *D. melanogaster* embryo lysate, we observed a similar pattern of RISC activity although the duplex carrying the 5' aminolinker-modified antisense siRNA showed some residual activity (data not shown). Presumably, introduction of additional atoms or the change in terminal phosphate electric charge at the 5'-end of the antisense siRNA interfered with its ability to function as guide RNA. The critical function of the guide siRNAs 5' end was previously documented (Elbashir et al. (2001 c), supra).

[0110] The ability to modify siRNAs at their 3'-end suggests that siRNAs do not play a major role for priming dsRNA synthesis and do not act as primers for degenerative PCR. The fate of a siRNA in HeLa S100 extracts was followed directly by incubation of an internally ^{32}pCp-radiolabeled siRNA duplexes. The radiolabeled antisense siRNA strand was also prepared with different 5' and 3' phosphate modifications (FIG. **3**A). All described combinations of siRNA duplexes were fully competent for RISC-dependent target RNA degradation (data not shown). As previously observed for *D. melanogaster* lysates (Nykänen et al. (2001), supra), rapid 5' phosphorylation of siRNA duplexes with free 5' hydroxyl termini was apparent. To our surprise, we noted that a small fraction of the 3' phosphorylated antisense siRNA could be ligated to the opposing 5' hydroxyl of the sense siRNA producing a lower mobility band. The inter-strand ligation was confirmed by changing the length of the unlabeled sense siRNA, which resulted in the expected mobility changes of the ligation product (data not shown). RNA ligase activity was previously observed in HeLa S100 extracts and it is mediated by two enzymatic activities (e.g. Vicente and Filipowicz, Eur. J. Biochem., 176 (1988), 431-439). The 3' terminal phosphate is first converted to a 2',3'-cyclic phosphate requiring ATP and 3' terminal phosphate cyclase. Thereafter, the opposing 5' hydroxyl is ligated to the cyclic phosphate end by an as yet uncharacterized RNA ligase. We chemically synthesized the predicted 5' phosphorylated, 42-nt ligation product and found that it is unable to mediate target RNA cleavage, presumably because it can not form activated RISC. The majority of the 3' phosphorylated duplexes siRNA was gradually dephosphorylated at its 3' end and emerged chemically similar to naturally generated siRNA. Together, these observations indicate that the cell has a mechanism to preserve the integrity of siRNAs. We were unable to detect a proposed siRNA-primed polymerization product (FIG. **3**B), suggesting that siRNAs do not function as primers for template-dependent dsRNA synthesis in our system. However, we acknowledge that a proposed RNA-dependent polymerase activity may have been inactivated during preparation of our extracts.

2.3 siRNAs Incorporated into RISC do not Compete with a Pool of Free siRNAs

[0111] In order to analyze RISC assembly and stability, we tested whether target-unspecific siRNA duplexes were able to compete with target-specific siRNA duplexes. When specific and non-specific siRNA duplexes were co-incubated in HeLa S100 extracts, increasing concentrations of unspecific siRNA duplex competed with the formation of target-specific RISC (FIG. **4**, left lanes). However, when target-specific siRNAs were pre-incubated in HeLa S100 extract for 15 min in the absence of competitor siRNA duplex, the assembled siRNA in the target-specific RISC could no longer be competed with the target-unspecific siRNA duplex (FIG. **4**, right lanes). This result suggests that RISC is formed during the first 15 minutes of incubation and that siRNAs were irreversibly associated with the protein components of RISC during the 2.5 h time window of the experiment.

2.4 Purification of Human RISC

[0112] After having the 3' termini of siRNAs defined as the most suitable position for chemical modification, a photocleavable biotin derivative was conjugated to the 3' aminolinker-modified siRNAs. A photo-cleavable biotin derivative was selected because of the advantage of recovering RISC under non-denaturing conditions after capturing complexes on streptavidin-coated affinity supports. 3' Conjugation of biotin to the sense, antisense or to both of the strands did not

affect target RNA cleavage when compared to non-biotinylated siRNAs (data not shown). siRNA duplexes with biotin residues on both 3' ends were therefore used for affinity purification (FIG. **5**A). The double biotinylated siRNA duplex was incubated in HeLa S100 extracts in the presence of ATP, GTP, creatine phosphate, and creatine kinase for ATP regeneration. Thereafter, streptavidin-conjugated agarose beads were added to capture the biotinylated siRNA ribonucleoprotein complexes (siRNPs) including RISC. After extensive washing of the collected beads, the siRNPs were released by UV irradiation at 312 nm. The eluate cleaved target RNA sequence-specifically, thus indicating that RISC was recovered in its native state from the resin. (FIG. **5**B, C, lane UV elu). The flow-through from the affinity selection showed no detectable RISC activity indicating complete binding of RISC by the beads (FIG. **6**). The affinity eluate was further analyzed by applying it onto a Superdex 200 gel filtration column (FIG. **5**B) as well as a 5%-20% glycerol gradient ultra-centrifugation (FIG. **5**C). Individual fractions were collected and assayed for target RNA cleavage without the addition of any further siRNA. RISC activity appeared between the molecular size markers aldolase (158 kDa) and BSA (66 kDa) after gel filtration or glycerol gradient centrifugation (FIG. **5**B, C). The molecular size of human RISC is therefore estimated to be between 90 and 160 kDa, significantly smaller than the complex previously analyzed in *D. melanogaster* lysates (Hammond et al. (2000), supra; Nykänen et al. (2001), supra). The small size of RISC suggests that Dicer (210 kDa) is not contained in RISC and that the formation of RISC from synthetic siRNAs may occur independently of Dicer. While these results do not rule out a role for Dicer during assembly of RISC, they emphasize the absence of Dicer in RISC.

2.5 RISC Contains a Single siRNA Strand and can be Reconstituted Using Single-Stranded siRNAs

[0113] Two models are currently discussed concerning the siRNA strand composition of RISC. The first model suggests that both strands of the initially added siRNA duplex are physically present in RISC, but in an unwound conformation. The second model proposes that RISC carries only a single siRNA strand, implying loss of one of the siRNA strands during assembly. The latter model has been favored based on the analogy to miRNA precursor processing, where only one 21-nt strand accumulated from a dsRNA hairpin precursor. The molecular basis for the asymmetry of the miRNA precursor processing reaction is not yet understood. Because siRNAs have symmetric 2-nt 3'-overhangs it is assumed that siRNA duplexes enter RISC with equal probability for both orientations, thus giving rise to distinct sense and antisense targeting RISCs.

[0114] To address the constitution of siRNAs in RISC, we affinity selected the assembled complexes with siRNA duplexes that were biotinylated at only one of the two constituting strands or both (FIG. **6**). If both strands were present together in RISC, the cleavage activity should be affinity selected on Neutravidin independently of the position of the biotin residue. In contrast, we observed target RNA cleavage from UV eluates after streptavidin selection only for siRNA duplexes with biotin conjugated to the antisense strand, but not the sense strand (FIG. **6**). RISC activity, assembled on siRNA duplexes with only the sense siRNA biotinylated, remained in the flow-through. These data suggest that RISC contains only a single-stranded RNA molecule.

[0115] To assess whether single-stranded siRNAs may be able to reconstitute RISC, single-stranded 5' phosphorylated siRNAs as well as the siRNA duplex were incubated at concentrations between 1 to 100 nM with cap-labeled target RNA in HeLa S100 extract (FIG. **7**A). At 100 nM single-stranded antisense siRNA, we detected RISC-specific target RNA cleavage, thus confirming that single-stranded siRNAs are present in RISC. At lower concentrations of single-stranded siRNAs, RISC formation remained undetectable while duplex siRNAs were effectively forming RISC even at 1 nM concentration. Therefore, a specific pathway exists which converts double-stranded siRNA into single-stranded siRNA containing RISC. Using *D. melanogaster* embryo lysate, we were unable to detect RISC activity from antisense siRNA (FIG. **78**), presumably because of the high load of single-strand specific ribonucleases (Elbashir et al. (2001 b), supra). Furthermore, 5' phosphorylated 20- to 25-nt antisense siRNAs were able to mediate RISC-specific target RNA degradation in HeLa S100 extract producing the same target RNA cleavage sites as duplex siRNAs of this length (data not shown).

[0116] Finally, we tested single-stranded and duplex siRNAs for targeting of an endogenous gene in HeLa cells following our standard protocol previously established for silencing of lamin A/C. 200 nM concentrations of single-stranded siRNAs with and without 5' phosphate and 100 nM concentrations of duplex siRNAs were transfected into HeLa cells. Lamin A/C levels were monitored 48 h later using immunofluorescence (FIG. **8**A) and quantitative luminescence-based Western blot analysis (FIG. **8**B). non-phosphorylated antisense siRNA caused a substantial knockdown of lamin A/C to about 25% of its normal level while 5' phosphoryled siRNAs reduced the lamin A/C content to less than 5%, similar to the reduction observed with the lamin A/C 5' phosphorylated (data not shown) or non-phosphorylated duplex siRNA (FIG. **8**). Sense siRNA and GL2 unspecific siRNA did not affect lamin A/C levels. The levels of non-targeted vimentin protein were monitored and used for normalizing of the loading of the lanes of the lamin A/C Western blots.

[0117] Gene silencing was also observed with phosphorylated as well as non-phosphorylated antisense siRNAs ranging in size between 19 to 29 nt. The phosphorylated antisense siRNAs were consistently better performing than the non-phosphorylated antisense, and their silencing efficiencies were comparable to that of the conventional duplex siRNA (FIG. **11**).

2.6 Protein Composition of RISC

[0118] In order to identify the protein components of the RNA-induced silencing complex (RISC) in HeLa S100 extract, the specific affinity selection previously outlined was used. UV eluates were fractionated on a 5-20% glycerol gradient, fractions were recovered from the gradient and analysed for protein composition and target RNA endonucleolytic activity. Two proteins of approximately 100 kDa were identified by mass spectrometry in the peak fraction of the endonucleolytic activity (FIG. **12**, fractions 7 and 8), corresponding to eIF2C1 and eIF2C2/GERp95 (FIGS. **13**A and B). These proteins are 82% similar and are both members of the Argonaute family (FIG. **13**C). The first evidence that Argonaute proteins are part of RISC was provided by classical biochemical fractionation studies using dsRNA-transfected *D. melanogaster* S2 cells (Hammond et al., 2001, supra). The closest relative to *D. melanogaster* Argonaute2,

D. melanogaster Argonaute1, was recently shown to be required for RNAI (Williams and Rubin, PNAS USA 99 (2002), 6889-6894).

[0119] Mass spectrometry analysis also revealed the presence of three peptides belonging exclusively to the HILI member of the Argonaute family of proteins. The sequences of those peptides are: NKQDFMDLSICTR, is corresponding to positions 17-29 of the protein; TEYVAESFLNCLRR, corresponding to positions 436-449 of the protein, and; YNHDLPARIIVYR, corresponding to positions 591-603 of the protein. This finding suggests that the protein HILI may also be part of RISC.

[0120] In human, the Argonaute family is composed of 6 members, eIF2C1, eIF2C2, eIF2C3, eIF2C4, HILI and HMI (FIG. **14**). The alignment of the six predicted amino-acid sequences show a high conservation, in particular between the eIF2C members, and HILI and HIWI (FIG. **15**). Predicted cDNA sequences encoding the Argonaute proteins are also shown (FIG. **16**).

[0121] The expression of the human Argonaute proteins was also investigated in HeLa cells by RT-PCR analysis using total and poly (A) selected RNA. All members of the family but HIWI were detected (FIG. **17**).

3. Discussion

[0122] The development of a human biochemical system for analysis of the mechanism of RNAi is important given the recent success of siRNA duplexes for silencing genes expressed in human cultured cells and the potential for becoming a sequence-specific therapeutic agent. Biochemical systems are useful for defining the individual steps of the RNAi process and for evaluating the constitution and molecular requirements of the participating macromolecular complexes. For the analysis of RNAi, several systems were developed, with the *D. melanogaster* systems being the most comprehensive as they enable to reconstitute dsRNA processing as well as the mRNA targeting. For mammalian systems, reconstitution of the mRNA targeting reaction has not yet been accomplished. Here, we describe the development and application of a biochemical system prepared from the cytoplasmic fraction of human HeLa cells, which is able to reconstitute the human mRNA-targeting RNA-induced silencing complex (RISC). Formation of RISC was accomplished using either 5' phosphorylated or non-phosphorylated siRNA duplexes; as well as single-stranded antisense siRNAs; non-phosphorylated siRNA duplexes and presumably also single-stranded antisense siRNAs are rapidly 5' phosphorylated in HeLa cell extracts (FIG. **3**).

Biochemical Characterization of siRNA Function

[0123] Reconstitution of RISC activity was only observed using cytoplasmic HeLa extracts. HeLa nuclear extracts assayed under the same conditions did not support siRNA-specific target RNA cleavage, thus suggesting that RISC components are located predominantly in the cytoplasm (data not shown).

[0124] Modifications of the 5' and 3' termini of siRNAs were tested in order to assess the importance of the siRNA termini for the targeting step. It was found that the 5' end modification of the guide siRNA was more inhibitory for target RNA cleavage than 3' end modification. Introduction of the 3' biotin affinity tag into the target-complementary guide siRNA enabled us to affinity select sense-RNA-targeting RISC, whereas 3' biotinylation of the sense siRNA strand resulted in RISC activity in the flowthrough. Furthermore, the single RNA strand composition of RISC was confirmed by reconstituting the sequence-specific endonuclease complex using 5'-phosphorylated single-stranded guide siRNA. The reconstitution of RISC from single-stranded siRNA was however less effective and required 10- to 100-fold higher concentrations compared to duplex siRNA. Reconstitution of RISC from single-stranded siRNA was undetectable using *D. melanogaster* embryo lysate, which is most likely explained by the high content of 5' to 3' exonucleases in embryo lysate.

[0125] The size of RISC in HeLa lysate was determined by gel filtration as well as glycerol gradient ultracentrifugation after streptavidin affinity purification with 3' biotinylated siRNA duplexes. Sizes for RISC in *D. melanogaster* systems have been reported within a range of less than 230 to 500 kDa, however size determinations were conducted without having affinity purified RISC. Our affinity-purified RISC sediments in a narrow range between the size makers of 66 and 158 kDa. The differences to the reported sizes for RISC are not species-specific as we observed a similar size for RISC in *D. melanogaster* S2 cell cytoplasmic extracts after affinity purification (data not shown).

[0126] It has previously been proposed that siRNAs act as primers for target RNA-templated dsRNA synthesis (Lipardi et al., Cell 107 (2001), 297-307) although homologs for such RNA-dependent RNA polymerases known to participate in gene silencing in other systems are not identified in *D. melanogaster* or mammalian genomes. Analysis of the fate of siRNA duplexes in the HeLa cell system did not provide evidence for such a siRNA-primed activity (FIG. **3**), but indicates that the predominant pathway for siRNA-mediated gene silencing is sequence-specific endonucleolytic target RNA degradation.

Single-Stranded 5' Phosphorylated Antisense siRNAs as Triggers of Mammalian Gene Silencing

[0127] It was previously noted that introduction of sense and antisense RNAs of several hundred nucleotides in length into *C. elegans* was able to sequence-specifically silence homologous genes (Guo and Kemphues, Cell 81 (1995), 611-620). Later, it was suggested that the sense and antisense RNA preparation were contaminated with a small amount of dsRNA, which was responsible for the silencing effect and is a much more potent inducer of gene silencing (Fire et al. (1998), supra). It is however conceivable that antisense RNA directly contributed to initiation of silencing. Indeed, most recently it was shown that antisense RNAs between 22 and 40 nt, but not sense RNAs were able to activate gene silencing in *C. elegans* (Tijsterman et al., Science 295 (2002), 694-697). The authors, however, favored the hypothesis of siRNA-primed dsRNA synthesis.

[0128] We have shown that modification of the 3' ends of antisense siRNA did not interfere with reconstitution of RISC in the human system. Together, these observations suggest that the driving forces for gene silencing in *C. elegans* may be predominantly dsRNA synthesis followed by Dicer cleavage, while in human and possibly also in *D. melanogaster* RISC-specific target mRNA degradation predominates.

[0129] Targeting of endogenously expressed lamin A/C by transfection of duplex siRNA into HeLa cells was the first reported example of siRNA-induced gene silencing. Lamin A/C protein was drastically reduced by a lamin A/C-specific siRNA duplex within two days post transfection, while unspecific siRNA duplexes showed no effect. At the time, transfection of non-phosphorylated sense or antisense siRNA did not reveal a substantial effect on lamin A/C levels,

although more recently a minor reduction upon antisense siRNA transfection was noticed when similar concentrations of antisense siRNA were delivered as described in this study. However, the effect was not interpreted as RISC-specific effect. Assaying 5'-phosphorylated antisense siRNAs revealed a substantial increase in lamin A/C silencing. Probably, 5' phosphorylated siRNAs are more stable or enter RISC more rapidly. Alternatively, the 5' end of transfected single-stranded s1RNA may be less rapidly phosphorylated in the cell in comparison to duplex siRNAs.

[0130] Finally, it should be noted that HeLa cells are generally poor in nucleases and represent one of the preferred mammalian systems for studying RNA-processing or transcription reactions in vivo and in vitro. However, it can be expected that 5' phosphorylated single-stranded antisense siRNAs are suitable to knockdown gene expression in other cell types or tissues with a different content of nucleases, since chemical strategies to improve nuclease resistance of single stranded RNA are available. The general silencing ability of various cell types may also depend on the relative levels of siRNA/miRNA-free eIF2C1 and eIF2C2 proteins capable of associating with exogenously delivered siRNAs.

[0131] In summary, single-stranded 5'-phosphorylated antisense siRNAs of 19- to 29-nt in size broaden the use of RNA molecules for gene silencing because they can enter the mammalian RNAi pathway in vitro as well as in vivo through reconstitution of RISC. Human eIF2C1 and/or eIF2C2 seem to play a critical. role in this process. Considering the feasibility of modulating the stability and uptake properties of single-stranded RNAs, 5'-phosphorylated single-stranded antisense siRNAs may further expand the utility of RNAi-based gene silencing technology as tool for functional genomics as well as therapeutic applications.

[0132] Argonaute proteins are a distinct class of proteins, containing a PAZ and Piwi domain (Cerutti et al., 2000, supra) and have been implicated in many processes previously linked to post-transcriptional silencing, however only limited biochemical information is available.

[0133] Human eIF2C2 is the ortholog of rat GERp95, which was identified as a component of the Golgi complex or the endoplasmic reticulum and copurified with intracellular membranes (Cikaluk et al., Mol. Biol. Cell 10 (1999), 3357-3722). More recently, HeLa cell eIF2C2 was shown to be associated with microRNAs and components of the SMN complex, a regulator of ribonucleoprotein assembly, suggesting that eIF2C2 plays a role in miRNA precursor processing or miRNA function (Mourelatos et al., Genes & Dev. 16 (2002), 720-728). A more provocative hypothesis is that miRNAs are also in a RISC-like complex, which could potentially mediate target RNA degradation, if only perfectly matched miRNA target mRNAs existed. Sequence analysis using cloned human and mouse, however, did not reveal the presence of such perfectly complementary sequences in the genomes (Lagos-Quintana et al., Science 294 (2001), 853-858). Therefore, miRNPs may only function as translational regulators of partially mismatched target mRNAs, probably by recruiting additional factors that prevent dissociation from mismatched target mRNAs.

[0134] Human eIF2C1 has not been linked to gene silencing previously, but it is more than 80% similar in sequence to eIF2C2 (Koesters et al., Genomics 61 (1999), 210-218). This similarity may indicate functional redundancy, but it is also conceivable that functional RISC may contain eIF2C1 and eIF2C2 heterodimers. The predicted molecular weight of this heterodimeric complex would be slightly larger than the observed size of 90-160 kDa, but because size fractionation is based on globular shape, we can not disregard this possibility at this time.

[0135] Due to the high conservation between the members of the Argonaute family, it is possible that peptides that derive from regions 100% conserved in the 6 predicted proteins, may belong to members others than eIF2C1 and eIF2C2. In this respect, three peptides were identified with masses corresponding to HILI, meaning that this protein might be also a component of RISC.

[0136] To precisely assess the protein composition of RISC, reconstitution of the siRNA-mediated target RNA cleavage must be achieved by using recombinant proteins which may be obtained by cloning and expression in suitable bacterial or eukaryotic systems.

[0137] We expect that the biochemical characterization or the siRNA-mediated target RNA degradation process will have immediate applications, such as the development of cell lines or transgenic animals overexpressing RISC components. The efficiency in targeting endogenous genes in those lines or organisms will be enhanced. Furthermore, a reconstituted in vitro system for RNAi will allow the design of more potent and specific siRNA to achieve gene silencing.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 115

<210> SEQ ID NO 1
<211> LENGTH: 15
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 1

ucgaaguauu ccgcg 15

<210> SEQ ID NO 2

-continued

<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 2

ucgaaguauu ccgcguacgu g 21

<210> SEQ ID NO 3
<211> LENGTH: 25
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 3

ucgaaguauu ccgcguacgu gaugu 25

<210> SEQ ID NO 4
<211> LENGTH: 27
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 4

ucgaaguauu ccgcguacgu gauguuc 27

<210> SEQ ID NO 5
<211> LENGTH: 29
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 5

ucgaaguauu ccgcguacgu gauguucac 29

<210> SEQ ID NO 6
<211> LENGTH: 15
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 6

ucgaaguauu ccgcg 15

<210> SEQ ID NO 7
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100

-continued

antisense siRNA (5'-3')

<400> SEQUENCE: 7

ucgaaguauu ccgcguacgu g 21

<210> SEQ ID NO 8
<211> LENGTH: 25
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 8

ucgaaguauu ccgcguacgu gaugu 25

<210> SEQ ID NO 9
<211> LENGTH: 27
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 9

ucgaaguauu ccgcguacgu gauguuc 27

<210> SEQ ID NO 10
<211> LENGTH: 29
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 10

ucgaaguauu ccgcguacgu gauguucac 29

<210> SEQ ID NO 11
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 11

ucgaaguauu ccgcguacgu g 21

<210> SEQ ID NO 12
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: RNA/DNA hybrid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')
<220> FEATURE:

-continued

<221> NAME/KEY: misc_feature
<222> LOCATION: (20)..(20)
<223> OTHER INFORMATION: n = 2'-deoxythymidine
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (21)..(21)
<223> OTHER INFORMATION: n = 2'-deoxyguanosine

<400> SEQUENCE: 12

ucgaaguauu ccgcguacgn n 21

<210> SEQ ID NO 13
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 13

ucgaaguauu ccgcguacgu u 21

<210> SEQ ID NO 14
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: RNA/DNA hybrid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (20)..(21)
<223> OTHER INFORMATION: n = 2'-deoxythymidine

<400> SEQUENCE: 14

ucgaaguauu ccgcguacgn n 21

<210> SEQ ID NO 15
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 15

ucgaaguauu ccgcguacgu g 21

<210> SEQ ID NO 16
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: RNA/DNA hybrid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100 cells
antisense siRNA (5'-3')
<220> FEATURE:

-continued

<221> NAME/KEY: misc_feature
<222> LOCATION: (20)..(20)
<223> OTHER INFORMATION: n = 2'-deoxythymidine
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (21)..(21)
<223> OTHER INFORMATION: n = 2'-deoxyguanosine

<400> SEQUENCE: 16

ucgaaguauu ccgcguacgn n 21

<210> SEQ ID NO 17
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 17

ucgaaguauu ccgcguacgu u 21

<210> SEQ ID NO 18
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: RNA/DNA hybrid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (20)..(21)
<223> OTHER INFORMATION: n = 2'-deoxythymidine

<400> SEQUENCE: 18

ucgaaguauu ccgcguacgn n 21

<210> SEQ ID NO 19
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
sense siRNA (5'-3')

<400> SEQUENCE: 19

cguacgcgga auacuucgaa a 21

<210> SEQ ID NO 20
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 20

ucgaaguauu ccgcguacgu g 21

-continued

<210> SEQ ID NO 21
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
sense siRNA (5'-3')

<400> SEQUENCE: 21

cguacgcgga auacuucgaa a 21

<210> SEQ ID NO 22
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: RNA/DNA hybrid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (20)..(20)
<223> OTHER INFORMATION: n = 2'-deoxythymidine
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (21)..(21)
<223> OTHER INFORMATION: n = 2'-deoxyguanosine

<400> SEQUENCE: 22

ucgaaguauu ccgcguacgn n 21

<210> SEQ ID NO 23
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
sense siRNA (5'-3')

<400> SEQUENCE: 23

cguacgcgga auacuucgaa a 21

<210> SEQ ID NO 24
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')

<400> SEQUENCE: 24

ucgaaguauu ccgcguacgu u 21

<210> SEQ ID NO 25
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100

-continued

sense siRNA (5'-3')

<400> SEQUENCE: 25

cguacgcgga auacuucgaa a 21

<210> SEQ ID NO 26
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: RNA/DNA hybrid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (20)..(21)
<223> OTHER INFORMATION: n = 2'-deoxythymidine

<400> SEQUENCE: 26

ucgaaguauu ccgcguacgn n 21

<210> SEQ ID NO 27
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: RNA/DNA hybrid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: n = 2'-deoxythymidine

<400> SEQUENCE: 27

ncgaaguauu ccgcguacgu u 21

<210> SEQ ID NO 28
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: RNA/DNA hybrid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
sense siRNA (5'-3')
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: n = 2'-deoxycytidine

<400> SEQUENCE: 28

nguacgcgga auacuucgau u 21

<210> SEQ ID NO 29
<211> LENGTH: 21
<212> TYPE: DNA

-continued

<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: RNA/DNA hybrid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: n = 2'-deoxythymidine

<400> SEQUENCE: 29

ncgaaguauu ccgcguacgu u 21

<210> SEQ ID NO 30
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: RNA/DNA hybrid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100 cells
antisense siRNA (5'-3')
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: n = 2'-deoxythymidine

<400> SEQUENCE: 30

ncgaaguauu ccgcguacgn n 21

<210> SEQ ID NO 31
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: RNA/DNA hybrid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
sense siRNA (5'-3')
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: n = 2'-deoxycytidine
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (20)..(21)
<223> OTHER INFORMATION: n = 2'-deoxythymidine

<400> SEQUENCE: 31

nguacgcgga auacuucgan n 21

<210> SEQ ID NO 32
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: RNA/DNA hybrid
<220> FEATURE:

-continued

<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: n = 2'-deoxythymidine

<400> SEQUENCE: 32

ncgaaguauu ccgcguacgn n 21

<210> SEQ ID NO 33
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: RNA/DNA hybrid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
antisense siRNA (5'-3')
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: n = 2'-deoxythymidine

<400> SEQUENCE: 33

ncgaaguauu ccgcguacgn n 21

<210> SEQ ID NO 34
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of HILI, corresponding to
position 17-29 of the protein

<400> SEQUENCE: 34

Asn Lys Gln Asp Phe Met Asp Leu Ser Ile Cys Thr Arg
1 5 10

<210> SEQ ID NO 35
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of HILI, corresponding to
position 436-449 of the protein

<400> SEQUENCE: 35

Thr Glu Tyr Val Ala Glu Ser Phe Leu Asn Cys Leu Arg Arg
1 5 10

<210> SEQ ID NO 36
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of HILI, corresponding to
position 591-603 of the protein

<400> SEQUENCE: 36

-continued

Tyr Asn His Asp Leu Pro Ala Arg Ile Ile Val Tyr Arg
1 5 10

<210> SEQ ID NO 37
<211> LENGTH: 35
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
target RNA

<400> SEQUENCE: 37

aacaucacgu acgcggaaua cuucgaaaug uccgu 35

<210> SEQ ID NO 38
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
strand of siRNA duplex

<400> SEQUENCE: 38

cguacgcgga auacuucgau u 21

<210> SEQ ID NO 39
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
strand of siRNA duplex

<400> SEQUENCE: 39

ucgaaguauu ccgcguacgu u 21

<210> SEQ ID NO 40
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
strand of siRNA duplex

<400> SEQUENCE: 40

cguacgcgga auacuucgaa a 21

<210> SEQ ID NO 41
<211> LENGTH: 20
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HeLa S100
strand of siRNA duplex

<400> SEQUENCE: 41

ucgaaguauu ccgcguacgu 20

<210> SEQ ID NO 42
<211> LENGTH: 12

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C2, obtained by mass spectrometry

<400> SEQUENCE: 42

Val Leu Gln Pro Pro Ser Ile Leu Tyr Gly Gly Arg
1 5 10

<210> SEQ ID NO 43
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C2, obtained by mass spectrometry

<400> SEQUENCE: 43

Gln Glu Ile Ile Gln Asp Leu Ala Ala Met Val Arg
1 5 10

<210> SEQ ID NO 44
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C2, obtained by mass spectrometry

<400> SEQUENCE: 44

His Leu Pro Ser Met Arg Tyr Thr Pro Val Gly Arg
1 5 10

<210> SEQ ID NO 45
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C2, obtained by mass spectrometry

<400> SEQUENCE: 45

Lys Leu Thr Asp Asn Gln Thr Ser Thr Met Ile Arg
1 5 10

<210> SEQ ID NO 46
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C2, obtained by mass spectrometry

<400> SEQUENCE: 46

Tyr Ala Gln Gly Ala Asp Ser Val Glu Pro Met Phe Arg
1 5 10

<210> SEQ ID NO 47
<211> LENGTH: 14
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C2, obtained by mass spectrometry

<400> SEQUENCE: 47

Asp Lys Val Glu Leu Glu Val Thr Leu Pro Gly Glu Gly Lys
1 5 10

<210> SEQ ID NO 48
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C2, obtained by mass spectrometry

<400> SEQUENCE: 48

Asp Ala Gly Met Pro Ile Gln Gly Gln Pro Cys Phe Cys Lys
1 5 10

<210> SEQ ID NO 49
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C2, obtained by mass spectrometry

<400> SEQUENCE: 49

Thr Gln Ile Phe Gly Asp Arg Lys Pro Val Phe Asp Gly Arg
1 5 10

<210> SEQ ID NO 50
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C2, obtained by mass spectrometry

<400> SEQUENCE: 50

Ala Thr Ala Arg Ser Ala Pro Asp Arg Gln Glu Glu Ile Ser Lys
1 5 10 15

<210> SEQ ID NO 51
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C2, obtained by mass spectrometry

<400> SEQUENCE: 51

Asp Tyr Gln Pro Gly Ile Thr Phe Ile Val Val Gln Lys Arg
1 5 10

<210> SEQ ID NO 52
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

-continued

<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C2, obtained by mass spectrometry

<400> SEQUENCE: 52

Ser Ala Pro Asp Arg Gln Glu Glu Ile Ser Lys Leu Met Arg
1 5 10

<210> SEQ ID NO 53
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C2, obtained by mass spectrometry

<400> SEQUENCE: 53

Tyr Pro His Leu Pro Cys Leu Gln Val Gly Gln Glu Gln Lys
1 5 10

<210> SEQ ID NO 54
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C2, obtained by mass spectrometry

<400> SEQUENCE: 54

Ser Phe Phe Thr Ala Ser Glu Gly Cys Ser Asn Pro Leu Gly Gly Gly
1 5 10 15

Arg

<210> SEQ ID NO 55
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C2, obtained by mass spectrometry

<400> SEQUENCE: 55

Tyr His Leu Val Asp Lys Glu His Asp Ser Ala Glu Gly Ser His Thr
1 5 10 15

Ser Gly Gln Ser Asn Gly Arg
20

<210> SEQ ID NO 56
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C1, obtained by mass spectrometry

<400> SEQUENCE: 56

Val Leu Pro Ala Pro Ile Leu Gln Tyr Gly Gly Arg
1 5 10

-continued

<210> SEQ ID NO 57
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C1, obtained by mass spectrometry

<400> SEQUENCE: 57

Ser Val Ser Ile Pro Ala Pro Ala Tyr Tyr Ala Arg
1 5 10

<210> SEQ ID NO 58
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C1, obtained by mass spectrometry

<400> SEQUENCE: 58

Thr Ser Pro Gln Thr Leu Ser Asn Leu Cys Leu Lys
1 5 10

<210> SEQ ID NO 59
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C1, obtained by mass spectrometry

<400> SEQUENCE: 59

Tyr Ala Gln Gly Ala Asp Ser Val Glu Pro Met Phe Arg
1 5 10

<210> SEQ ID NO 60
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C1, obtained by mass spectrometry

<400> SEQUENCE: 60

Asn Ile Tyr Thr Val Thr Ala Leu Pro Ile Gly Asn Glu Arg
1 5 10

<210> SEQ ID NO 61
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C1, obtained by mass spectrometry

<400> SEQUENCE: 61

Val Asp Phe Glu Val Thr Ile Pro Gly Glu Gly Lys Asp Arg
1 5 10

<210> SEQ ID NO 62

-continued

<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: HeLa S100 cells
peptide fragment of eIF2C1 obtained by mass spectrometry

<400> SEQUENCE: 62

Asp Ala Gly Met Pro Ile Gln Gly Gln Pro Cys Phe Cys Lys
1 5 10

<210> SEQ ID NO 63
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C1, obtained by mass spectrometry

<400> SEQUENCE: 63

Asn Ile Asp Glu Gln Pro Lys Pro Leu Thr Asp Ser Gln Arg
1 5 10

<210> SEQ ID NO 64
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C1, obtained by mass spectrometry

<400> SEQUENCE: 64

Ser Ala Pro Asp Arg Gln Glu Glu Ile Ser Arg Leu Met Lys
1 5 10

<210> SEQ ID NO 65
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C1, obtained by mass spectrometry

<400> SEQUENCE: 65

Asp Tyr Gln Pro Gly Ile Thr Tyr Ile Val Val Gln Lys Arg
1 5 10

<210> SEQ ID NO 66
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C1, obtained by mass spectrometry

<400> SEQUENCE: 66

Tyr Pro His Leu Pro Cys Leu Gln Val Gly Gln Glu Gln Lys
1 5 10

<210> SEQ ID NO 67
<211> LENGTH: 17

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: peptide fragment of eIF2C1, obtained by mass spectrometry

<400> SEQUENCE: 67

Ser Phe Phe Ser Pro Pro Glu Gly Tyr Tyr His Pro Leu Gly Gly Gly
1 5 10 15

Arg

<210> SEQ ID NO 68
<211> LENGTH: 857
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: eIF2C1, predicted protein sequence

<400> SEQUENCE: 68

Met Glu Ala Gly Pro Ser Gly Ala Ala Ala Gly Ala Tyr Leu Pro Pro
1 5 10 15

Leu Gln Gln Val Phe Gln Ala Pro Arg Arg Pro Gly Ile Gly Thr Val
20 25 30

Gly Lys Pro Ile Lys Leu Leu Ala Asn Tyr Phe Glu Val Asp Ile Pro
35 40 45

Lys Ile Asp Val Tyr His Tyr Glu Val Asp Ile Lys Pro Asp Lys Cys
50 55 60

Pro Arg Arg Val Asn Arg Glu Val Val Glu Tyr Met Val Gln His Phe
65 70 75 80

Lys Pro Gln Ile Phe Gly Asp Arg Lys Pro Val Tyr Asp Gly Lys Lys
85 90 95

Asn Ile Tyr Thr Val Thr Ala Leu Pro Ile Gly Asn Glu Arg Val Asp
100 105 110

Phe Glu Val Thr Ile Pro Gly Glu Gly Lys Asp Arg Ile Phe Lys Val
115 120 125

Ser Ile Lys Trp Leu Ala Ile Val Ser Trp Arg Met Leu His Glu Ala
130 135 140

Leu Val Ser Gly Gln Ile Pro Val Pro Leu Glu Ser Val Gln Ala Leu
145 150 155 160

Asp Val Ala Met Arg His Leu Ala Ser Met Arg Tyr Thr Pro Val Gly
165 170 175

Arg Ser Phe Phe Ser Pro Pro Glu Gly Tyr Tyr His Pro Leu Gly Gly
180 185 190

Gly Arg Glu Val Trp Phe Gly Phe His Gln Ser Val Arg Pro Ala Met
195 200 205

Trp Lys Met Met Leu Asn Ile Asp Val Ser Ala Thr Ala Phe Tyr Lys
210 215 220

Ala Gln Pro Val Ile Glu Phe Met Cys Glu Val Leu Asp Ile Arg Asn
225 230 235 240

Ile Asp Glu Gln Pro Lys Pro Leu Thr Asp Ser Gln Arg Val Arg Phe
245 250 255

Thr Lys Glu Ile Lys Gly Leu Lys Val Glu Val Thr His Cys Gly Gln
260 265 270

-continued

```
Met Lys Arg Lys Tyr Arg Val Cys Asn Val Thr Arg Arg Pro Ala Ser
        275                 280                 285

His Gln Thr Phe Pro Leu Gln Leu Glu Ser Gly Gln Thr Val Glu Cys
    290                 295                 300

Thr Val Ala Gln Tyr Phe Lys Gln Lys Tyr Asn Leu Gln Leu Lys Tyr
305                 310                 315                 320

Pro His Leu Pro Cys Leu Gln Val Gly Gln Glu Gln Lys His Thr Tyr
                325                 330                 335

Leu Pro Leu Glu Val Cys Asn Ile Val Ala Gly Gln Arg Cys Ile Lys
            340                 345                 350

Lys Leu Thr Asp Asn Gln Thr Ser Thr Met Ile Lys Ala Thr Ala Arg
        355                 360                 365

Ser Ala Pro Asp Arg Gln Glu Glu Ile Ser Arg Leu Met Lys Asn Ala
    370                 375                 380

Ser Tyr Asn Leu Asp Pro Tyr Ile Gln Glu Phe Gly Ile Lys Val Lys
385                 390                 395                 400

Asp Asp Met Thr Glu Val Thr Gly Arg Val Leu Pro Ala Pro Ile Leu
                405                 410                 415

Gln Tyr Gly Gly Arg Asn Arg Ala Ile Ala Thr Pro Asn Gln Gly Val
            420                 425                 430

Trp Asp Met Arg Gly Lys Gln Phe Tyr Asn Gly Ile Glu Ile Lys Val
        435                 440                 445

Trp Ala Ile Ala Cys Phe Ala Pro Gln Lys Gln Cys Arg Glu Glu Val
    450                 455                 460

Leu Lys Asn Phe Thr Asp Gln Leu Arg Lys Ile Ser Lys Asp Ala Gly
465                 470                 475                 480

Met Pro Ile Gln Gly Gln Pro Cys Phe Cys Lys Tyr Ala Gln Gly Ala
                485                 490                 495

Asp Ser Val Glu Pro Met Phe Arg His Leu Lys Asn Thr Tyr Ser Gly
            500                 505                 510

Leu Gln Leu Ile Ile Val Ile Leu Pro Gly Lys Thr Pro Val Tyr Ala
        515                 520                 525

Glu Val Lys Arg Val Gly Asp Thr Leu Leu Gly Met Ala Thr Gln Cys
    530                 535                 540

Val Gln Val Lys Asn Val Val Lys Thr Ser Pro Gln Thr Leu Ser Asn
545                 550                 555                 560

Leu Cys Leu Lys Ile Asn Val Lys Leu Gly Gly Ile Asn Asn Ile Leu
                565                 570                 575

Val Pro His Gln Arg Ser Ala Val Phe Gln Gln Pro Val Ile Phe Leu
            580                 585                 590

Gly Ala Asp Val Thr His Pro Pro Ala Gly Asp Gly Lys Lys Pro Ser
        595                 600                 605

Ile Thr Ala Val Val Gly Ser Met Asp Ala His Pro Ser Arg Tyr Cys
    610                 615                 620

Ala Thr Val Arg Val Gln Arg Pro Arg Gln Glu Ile Ile Glu Asp Leu
625                 630                 635                 640

Ser Tyr Met Val Arg Glu Leu Leu Ile Gln Phe Tyr Lys Ser Thr Arg
                645                 650                 655

Phe Lys Pro Thr Arg Ile Ile Phe Tyr Arg Asp Gly Val Pro Glu Gly
            660                 665                 670

Gln Leu Pro Gln Ile Leu His Tyr Glu Leu Leu Ala Ile Arg Asp Ala
```

-continued

```
        675                 680                 685

Cys Ile Lys Leu Glu Lys Asp Tyr Gln Pro Gly Ile Thr Tyr Ile Val
    690                 695                 700

Val Gln Lys Arg His His Thr Arg Leu Phe Cys Ala Asp Lys Asn Glu
705                 710                 715                 720

Arg Ile Gly Lys Ser Gly Asn Ile Pro Ala Gly Thr Thr Val Asp Thr
                725                 730                 735

Asn Ile Thr His Pro Phe Glu Phe Asp Phe Tyr Leu Cys Ser His Ala
            740                 745                 750

Gly Ile Gln Gly Thr Ser Arg Pro Ser His Tyr Tyr Val Leu Trp Asp
        755                 760                 765

Asp Asn Arg Phe Thr Ala Asp Glu Leu Gln Ile Leu Thr Tyr Gln Leu
    770                 775                 780

Cys His Thr Tyr Val Arg Cys Thr Arg Ser Val Ser Ile Pro Ala Pro
785                 790                 795                 800

Ala Tyr Tyr Ala Arg Leu Val Ala Phe Arg Ala Arg Tyr His Leu Val
                805                 810                 815

Asp Lys Glu His Asp Ser Gly Glu Gly Ser His Ile Ser Gly Gln Ser
            820                 825                 830

Asn Gly Arg Asp Pro Gln Ala Leu Ala Lys Ala Val Gln Val His Gln
        835                 840                 845

Asp Thr Leu Arg Thr Met Tyr Phe Ala
    850                 855


<210> SEQ ID NO 69
<211> LENGTH: 860
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: eIF2C2, predicted protein sequence

<400> SEQUENCE: 69

Met Gly Val Leu Ser Ala Ile Pro Ala Leu Ala Pro Pro Ala Pro Pro
1               5                   10                  15

Pro Pro Ile Gln Gly Tyr Ala Phe Lys Pro Pro Pro Arg Pro Asp Phe
            20                  25                  30

Gly Thr Ser Gly Arg Thr Ile Lys Leu Gln Ala Asn Phe Phe Glu Met
        35                  40                  45

Asp Ile Pro Lys Ile Asp Ile Tyr His Tyr Glu Leu Asp Ile Lys Pro
    50                  55                  60

Glu Lys Cys Pro Arg Arg Val Asn Arg Glu Ile Val Glu His Met Val
65                  70                  75                  80

Gln His Phe Lys Thr Gln Ile Phe Gly Asp Arg Lys Pro Val Phe Asp
                85                  90                  95

Gly Arg Lys Asn Leu Tyr Thr Ala Met Pro Leu Pro Ile Gly Arg Asp
            100                 105                 110

Lys Val Glu Leu Glu Val Thr Leu Pro Gly Glu Gly Lys Asp Arg Ile
        115                 120                 125

Phe Lys Val Ser Ile Lys Trp Val Ser Cys Val Ser Leu Gln Ala Leu
    130                 135                 140

His Asp Ala Leu Ser Gly Arg Leu Pro Ser Val Pro Phe Glu Thr Ile
145                 150                 155                 160
```

-continued

```
Gln Ala Leu Asp Val Val Met Arg His Leu Pro Ser Met Arg Tyr Thr
                165                 170                 175

Pro Val Gly Arg Ser Phe Phe Thr Ala Ser Glu Gly Cys Ser Asn Pro
            180                 185                 190

Leu Gly Gly Gly Arg Glu Val Trp Phe Gly Phe His Gln Ser Val Arg
        195                 200                 205

Pro Ser Leu Trp Lys Met Met Leu Asn Ile Asp Val Ser Ala Thr Ala
    210                 215                 220

Phe Tyr Lys Ala Gln Pro Val Ile Glu Phe Val Cys Glu Val Leu Asp
225                 230                 235                 240

Phe Lys Ser Ile Glu Glu Gln Gln Lys Pro Leu Thr Asp Ser Gln Arg
                245                 250                 255

Val Lys Phe Thr Lys Glu Ile Lys Gly Leu Lys Val Glu Ile Thr His
            260                 265                 270

Cys Gly Gln Met Lys Arg Lys Tyr Arg Val Cys Asn Val Thr Arg Arg
        275                 280                 285

Pro Ala Ser His Gln Thr Phe Pro Leu Gln Gln Glu Ser Gly Gln Thr
    290                 295                 300

Val Glu Cys Thr Val Ala Gln Tyr Phe Lys Asp Arg His Lys Leu Val
305                 310                 315                 320

Leu Arg Tyr Pro His Leu Pro Cys Leu Gln Val Gly Gln Glu Gln Lys
                325                 330                 335

His Thr Tyr Leu Pro Leu Glu Val Cys Asn Ile Val Ala Gly Gln Arg
            340                 345                 350

Cys Ile Lys Lys Leu Thr Asp Asn Gln Thr Ser Thr Met Ile Arg Ala
        355                 360                 365

Thr Ala Arg Ser Ala Pro Asp Arg Gln Glu Glu Ile Ser Lys Leu Met
    370                 375                 380

Arg Ser Ala Ser Phe Asn Thr Asp Pro Tyr Val Arg Glu Phe Gly Ile
385                 390                 395                 400

Met Val Lys Asp Glu Met Thr Asp Val Thr Gly Arg Val Leu Gln Pro
                405                 410                 415

Pro Ser Ile Leu Tyr Gly Gly Arg Asn Lys Ala Ile Ala Thr Pro Val
            420                 425                 430

Gln Gly Val Trp Asp Met Arg Asn Lys Gln Phe His Thr Gly Ile Glu
        435                 440                 445

Ile Lys Val Trp Ala Ile Ala Cys Phe Ala Pro Gln Arg Gln Cys Thr
    450                 455                 460

Glu Val His Leu Lys Ser Phe Thr Glu Gln Leu Arg Lys Ile Ser Arg
465                 470                 475                 480

Asp Ala Gly Met Pro Ile Gln Gly Gln Pro Cys Phe Cys Lys Tyr Ala
                485                 490                 495

Gln Gly Ala Asp Ser Val Glu Pro Met Phe Arg His Leu Lys Asn Thr
            500                 505                 510

Tyr Ala Gly Leu Gln Leu Val Val Val Ile Leu Pro Gly Lys Thr Pro
        515                 520                 525

Val Tyr Ala Glu Val Lys Arg Val Gly Asp Thr Val Leu Gly Met Ala
    530                 535                 540

Thr Gln Cys Val Gln Met Lys Asn Val Gln Arg Thr Thr Pro Gln Thr
545                 550                 555                 560

Leu Ser Asn Leu Cys Leu Lys Ile Asn Val Lys Leu Gly Gly Val Asn
```

-continued

```
               565                 570                 575

Asn Ile Leu Leu Pro Gln Gly Arg Pro Pro Val Phe Gln Gln Pro Val
            580                 585                 590

Ile Phe Leu Gly Ala Asp Val Thr His Pro Pro Ala Gly Asp Gly Lys
        595                 600                 605

Lys Pro Ser Ile Ala Ala Val Val Gly Ser Met Asp Ala His Pro Asn
    610                 615                 620

Arg Tyr Cys Ala Thr Val Arg Val Gln Gln His Arg Gln Glu Ile Ile
625                 630                 635                 640

Gln Asp Leu Ala Ala Met Val Arg Glu Leu Leu Ile Gln Phe Tyr Lys
                645                 650                 655

Ser Thr Arg Phe Lys Pro Thr Arg Ile Ile Phe Tyr Arg Asp Gly Val
            660                 665                 670

Ser Glu Gly Gln Phe Gln Gln Val Leu His His Glu Leu Leu Ala Ile
        675                 680                 685

Arg Glu Ala Cys Ile Lys Leu Glu Lys Asp Tyr Gln Pro Gly Ile Thr
    690                 695                 700

Phe Ile Val Val Gln Lys Arg His His Thr Arg Leu Phe Cys Thr Asp
705                 710                 715                 720

Lys Asn Glu Arg Val Gly Lys Ser Gly Asn Ile Pro Ala Gly Thr Thr
                725                 730                 735

Val Asp Thr Lys Ile Thr His Pro Thr Glu Phe Asp Phe Tyr Leu Cys
            740                 745                 750

Ser His Ala Gly Ile Gln Gly Thr Ser Arg Pro Ser His Tyr His Val
        755                 760                 765

Leu Trp Asp Asp Asn Arg Phe Ser Ser Asp Glu Leu Gln Ile Leu Thr
    770                 775                 780

Tyr Gln Leu Cys His Thr Tyr Val Arg Cys Thr Arg Ser Val Ser Ile
785                 790                 795                 800

Pro Ala Pro Ala Tyr Tyr Ala His Leu Val Ala Phe Arg Ala Arg Tyr
                805                 810                 815

His Leu Val Asp Lys Glu His Asp Ser Ala Glu Gly Ser His Thr Ser
            820                 825                 830

Gly Gln Ser Asn Gly Arg Asp His Gln Ala Leu Ala Lys Ala Val Gln
        835                 840                 845

Val His Gln Asp Thr Leu Arg Thr Met Tyr Phe Ala
    850                 855                 860


<210> SEQ ID NO 70
<211> LENGTH: 924
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: eIF2C3, predicted protein sequence

<400> SEQUENCE: 70

Ser Arg Ser Arg Val Pro Val Pro Gly Pro Gly Ala Ala Ala Ala Pro
1               5                   10                  15

Cys Pro Ala Pro Ala Ser Pro Arg Arg His Pro Ser Ala Asn Ile Pro
            20                  25                  30

Glu Ile Lys Arg Tyr Ala Ala Ala Ala Ala Ala Ala Ala Gly Pro Gly
        35                  40                  45
```

-continued

```
Ala Gly Gly Ala Gly Asp Arg Gly Glu Ala Ala Pro Ala Ala Ala Met
    50                  55                  60

Glu Ala Leu Gly Pro Gly Pro Pro Ala Ser Leu Phe Gln Pro Pro Arg
65                  70                  75                  80

Arg Pro Gly Leu Gly Thr Val Gly Lys Pro Ile Arg Leu Leu Ala Asn
                85                  90                  95

His Phe Gln Val Gln Ile Pro Lys Ile Asp Val Tyr His Tyr Asp Val
            100                 105                 110

Asp Ile Lys Pro Glu Lys Arg Pro Arg Arg Val Asn Arg Glu Val Val
        115                 120                 125

Asp Thr Met Val Arg His Phe Lys Met Gln Ile Phe Gly Asp Arg Gln
    130                 135                 140

Pro Gly Tyr Asp Gly Lys Arg Asn Met Tyr Thr Ala His Pro Leu Pro
145                 150                 155                 160

Ile Gly Arg Asp Arg Val Asp Met Glu Val Thr Leu Pro Gly Glu Gly
                165                 170                 175

Lys Asp Gln Thr Phe Lys Val Ser Val Gln Trp Val Ser Val Val Ser
            180                 185                 190

Leu Gln Leu Leu Leu Glu Ala Leu Ala Gly His Leu Asn Glu Val Pro
        195                 200                 205

Asp Asp Ser Val Gln Ala Leu Asp Val Ile Thr Arg His Leu Pro Ser
    210                 215                 220

Met Arg Tyr Thr Pro Val Gly Arg Ser Phe Phe Ser Pro Pro Glu Gly
225                 230                 235                 240

Tyr Tyr His Pro Leu Gly Gly Gly Arg Glu Val Trp Phe Gly Phe His
                245                 250                 255

Gln Ser Val Arg Pro Ala Met Trp Asn Met Met Leu Asn Ile Asp Val
            260                 265                 270

Ser Ala Thr Ala Phe Tyr Arg Ala Gln Pro Ile Ile Glu Phe Met Cys
        275                 280                 285

Glu Val Leu Asp Ile Gln Asn Ile Asn Glu Gln Thr Lys Pro Leu Thr
    290                 295                 300

Asp Ser Gln Arg Val Lys Phe Thr Lys Glu Ile Arg Gly Leu Lys Val
305                 310                 315                 320

Glu Val Thr His Cys Gly Gln Met Lys Arg Lys Tyr Arg Val Cys Asn
                325                 330                 335

Val Thr Arg Arg Pro Ala Ser His Gln Thr Phe Pro Leu Gln Leu Glu
            340                 345                 350

Asn Gly Gln Ala Met Glu Cys Thr Val Ala Gln Tyr Phe Lys Gln Lys
        355                 360                 365

Tyr Ser Leu Gln Leu Lys Tyr Pro His Leu Pro Cys Leu Gln Val Gly
    370                 375                 380

Gln Glu Gln Lys His Thr Tyr Leu Pro Leu Glu Val Cys Asn Ile Val
385                 390                 395                 400

Ala Gly Gln Arg Cys Ile Lys Lys Leu Thr Asp Asn Gln Thr Ser Thr
                405                 410                 415

Met Ile Lys Ala Thr Ala Arg Ser Ala Pro Asp Arg Gln Glu Glu Ile
            420                 425                 430

Ser Arg Leu Val Lys Ser Asn Ser Met Val Gly Gly Pro Asp Pro Tyr
        435                 440                 445

Leu Lys Glu Phe Gly Ile Val Val His Asn Glu Met Thr Glu Leu Thr
```

-continued

```
    450                 455                 460

Gly Arg Val Leu Pro Ala Pro Met Leu Gln Tyr Gly Gly Arg Asn Lys
465                 470                 475                 480

Thr Val Ala Thr Pro Asn Gln Gly Val Trp Asp Met Arg Gly Lys Gln
                485                 490                 495

Phe Tyr Ala Gly Ile Glu Ile Lys Val Trp Ala Val Ala Cys Phe Ala
            500                 505                 510

Pro Gln Lys Gln Cys Arg Glu Asp Leu Leu Lys Ser Phe Thr Asp Gln
        515                 520                 525

Leu Arg Lys Ile Ser Lys Asp Ala Gly Met Pro Ile Gln Gly Gln Pro
    530                 535                 540

Cys Phe Cys Lys Tyr Ala Gln Gly Ala Asp Ser Val Glu Pro Met Phe
545                 550                 555                 560

Lys His Leu Lys Met Thr Tyr Val Gly Leu Gln Leu Ile Val Val Ile
                565                 570                 575

Leu Pro Gly Lys Thr Pro Val Tyr Ala Glu Val Lys Arg Val Gly Asp
            580                 585                 590

Thr Leu Leu Gly Met Ala Thr Gln Cys Val Gln Val Lys Asn Val Val
        595                 600                 605

Lys Thr Ser Pro Gln Thr Leu Ser Asn Leu Cys Leu Lys Ile Asn Ala
    610                 615                 620

Lys Leu Gly Gly Ile Asn Asn Val Leu Val Pro His Gln Arg Pro Ser
625                 630                 635                 640

Val Phe Gln Gln Pro Val Ile Phe Leu Gly Ala Asp Val Thr His Pro
                645                 650                 655

Pro Ala Gly Asp Gly Lys Lys Pro Ser Ile Ala Ala Val Val Gly Ser
            660                 665                 670

Met Asp Gly His Pro Ser Arg Tyr Cys Ala Thr Val Arg Val Gln Thr
        675                 680                 685

Ser Arg Gln Glu Ile Ser Gln Glu Leu Leu Tyr Ser Gln Glu Val Ile
    690                 695                 700

Gln Asp Leu Thr Asn Met Val Arg Glu Leu Leu Ile Gln Phe Tyr Lys
705                 710                 715                 720

Ser Thr Arg Phe Lys Pro Thr Arg Ile Ile Tyr Tyr Arg Gly Gly Val
                725                 730                 735

Ser Glu Gly Gln Met Lys Gln Val Ala Trp Pro Glu Leu Ile Ala Ile
            740                 745                 750

Arg Lys Ala Cys Ile Ser Leu Glu Glu Asp Tyr Arg Pro Gly Ile Thr
        755                 760                 765

Tyr Ile Val Val Gln Lys Arg His His Thr Arg Leu Phe Cys Ala Asp
    770                 775                 780

Lys Thr Glu Arg Val Gly Lys Ser Gly Asn Val Pro Ala Gly Thr Thr
785                 790                 795                 800

Val Asp Ser Thr Ile Thr His Pro Ser Glu Phe Asp Phe Tyr Leu Cys
                805                 810                 815

Ser His Ala Gly Ile Gln Gly Thr Ser Arg Pro Ser His Tyr Gln Val
            820                 825                 830

Leu Trp Asp Asp Asn Cys Phe Thr Ala Asp Glu Leu Gln Leu Leu Thr
        835                 840                 845

Tyr Gln Leu Cys His Thr Tyr Val Arg Cys Thr Arg Ser Val Ser Ile
    850                 855                 860
```

-continued

```
Pro Ala Pro Ala Tyr Tyr Ala Arg Leu Val Ala Phe Arg Ala Arg Tyr
865                 870                 875                 880

His Leu Val Asp Lys Asp His Asp Ser Ala Glu Gly Ser His Val Ser
                885                 890                 895

Gly Gln Ser Asn Gly Arg Asp Pro Gln Ala Leu Ala Lys Ala Val Gln
            900                 905                 910

Ile His His Asp Thr Gln His Thr Met Tyr Phe Ala
        915                 920


<210> SEQ ID NO 71
<211> LENGTH: 855
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: eIF2C4, predicted protein sequence

<400> SEQUENCE: 71

Ala Gly Pro Ala Gly Ala Gln Pro Leu Leu Met Val Pro Arg Arg Pro
1               5                   10                  15

Gly Tyr Gly Thr Met Gly Lys Pro Ile Lys Leu Leu Ala Asn Cys Phe
            20                  25                  30

Gln Val Glu Ile Pro Lys Ile Asp Val Tyr Leu Tyr Glu Val Asp Ile
        35                  40                  45

Lys Pro Asp Lys Cys Pro Arg Arg Val Asn Arg Glu Val Val Asp Ser
    50                  55                  60

Met Val Gln His Phe Lys Val Thr Ile Phe Gly Asp Arg Arg Pro Val
65                  70                  75                  80

Tyr Asp Gly Lys Arg Ser Leu Tyr Thr Ala Asn Pro Leu Pro Val Ala
                85                  90                  95

Thr Thr Gly Val Asp Leu Asp Val Thr Leu Pro Gly Glu Gly Gly Lys
            100                 105                 110

Asp Arg Pro Phe Lys Val Ser Ile Lys Phe Val Ser Arg Val Ser Trp
        115                 120                 125

His Leu Leu His Glu Val Leu Thr Gly Arg Thr Leu Pro Glu Pro Leu
    130                 135                 140

Glu Leu Asp Lys Pro Ile Ser Thr Asn Pro Val His Ala Val Asp Val
145                 150                 155                 160

Val Leu Arg His Leu Pro Ser Met Lys Tyr Thr Pro Val Gly Arg Ser
                165                 170                 175

Phe Phe Ser Ala Pro Glu Gly Tyr Asp His Pro Leu Gly Gly Gly Arg
            180                 185                 190

Glu Val Trp Phe Gly Phe His Gln Ser Val Arg Pro Ala Met Trp Lys
        195                 200                 205

Met Met Leu Asn Ile Asp Val Ser Ala Thr Ala Phe Tyr Lys Ala Gln
    210                 215                 220

Pro Val Ile Gln Phe Met Cys Glu Val Leu Asp Ile His Asn Ile Asp
225                 230                 235                 240

Glu Gln Pro Arg Pro Leu Thr Asp Ser His Arg Val Lys Phe Thr Lys
                245                 250                 255

Glu Ile Lys Gly Leu Lys Val Glu Val Thr His Cys Gly Thr Met Arg
            260                 265                 270

Arg Lys Tyr Arg Val Cys Asn Val Thr Arg Arg Pro Ala Ser His Gln
```

-continued

```
        275                 280                 285

Thr Phe Pro Leu Gln Leu Glu Asn Gly Gln Thr Val Glu Arg Thr Val
    290                 295                 300

Ala Gln Tyr Phe Arg Glu Lys Tyr Thr Leu Gln Leu Lys Tyr Pro His
305                 310                 315                 320

Leu Pro Cys Leu Gln Val Gly Gln Glu Gln Lys His Thr Tyr Leu Pro
                325                 330                 335

Leu Glu Val Cys Asn Ile Val Ala Gly Gln Arg Cys Ile Lys Lys Leu
            340                 345                 350

Thr Asp Asn Gln Thr Ser Thr Met Ile Lys Ala Thr Ala Arg Ser Ala
        355                 360                 365

Pro Asp Arg Gln Glu Glu Ile Ser Arg Leu Val Arg Ser Ala Asn Tyr
    370                 375                 380

Glu Thr Asp Pro Phe Val Gln Glu Phe Gln Phe Lys Val Arg Asp Glu
385                 390                 395                 400

Met Ala His Val Thr Gly Arg Val Leu Pro Ala Pro Met Leu Gln Tyr
                405                 410                 415

Gly Gly Arg Asn Arg Thr Val Ala Thr Pro Ser His Gly Val Trp Asp
            420                 425                 430

Met Arg Gly Lys Gln Phe His Thr Gly Val Glu Ile Lys Met Trp Ala
        435                 440                 445

Ile Ala Cys Phe Ala Thr Gln Arg Gln Cys Arg Glu Glu Ile Leu Lys
    450                 455                 460

Gly Phe Thr Asp Gln Leu Arg Lys Ile Ser Lys Asp Ala Gly Met Pro
465                 470                 475                 480

Ile Gln Gly Gln Pro Cys Phe Cys Lys Tyr Ala Gln Gly Ala Asp Ser
                485                 490                 495

Val Glu Pro Met Phe Arg His Leu Lys Asn Thr Tyr Ser Gly Leu Gln
            500                 505                 510

Leu Ile Ile Val Ile Leu Pro Gly Lys Thr Pro Val Tyr Ala Glu Val
        515                 520                 525

Lys Arg Val Gly Asp Thr Leu Leu Gly Met Ala Thr Gln Cys Val Gln
    530                 535                 540

Val Lys Asn Val Ile Lys Thr Ser Pro Gln Thr Leu Ser Asn Leu Cys
545                 550                 555                 560

Leu Lys Ile Asn Val Lys Leu Gly Gly Ile Asn Asn Ile Leu Val Pro
                565                 570                 575

His Gln Arg Pro Ser Val Phe Gln Gln Pro Val Ile Phe Leu Gly Ala
            580                 585                 590

Asp Val Thr His Pro Pro Ala Gly Asp Gly Lys Lys Pro Ser Ile Ala
        595                 600                 605

Ala Val Val Gly Ser Met Asp Ala His Pro Ser Arg Tyr Cys Ala Thr
    610                 615                 620

Val Arg Val Gln Arg Pro Arg Gln Glu Ile Ile Gln Asp Leu Ala Ser
625                 630                 635                 640

Met Val Arg Glu Leu Leu Ile Gln Phe Tyr Lys Ser Thr Arg Phe Lys
                645                 650                 655

Pro Thr Arg Ile Ile Phe Tyr Arg Asp Gly Val Ser Glu Gly Gln Phe
            660                 665                 670

Arg Gln Val Leu Tyr Tyr Glu Leu Leu Ala Ile Arg Glu Ala Cys Ile
        675                 680                 685
```

-continued

```
Ser Leu Glu Lys Asp Tyr Gln Pro Gly Ile Thr Tyr Ile Val Val Gln
    690                 695                 700

Lys Arg His His Thr Arg Leu Phe Cys Ala Asp Arg Thr Glu Arg Val
705                 710                 715                 720

Gly Arg Ser Gly Asn Ile Pro Ala Gly Thr Thr Val Asp Thr Asp Ile
                725                 730                 735

Thr His Pro Tyr Glu Phe Asp Phe Tyr Leu Cys Ser His Ala Gly Ile
            740                 745                 750

Gln Gly Thr Ser Arg Pro Ser His Tyr His Val Leu Trp Asp Asp Asn
        755                 760                 765

Cys Phe Thr Ala Asp Glu Leu Gln Leu Leu Thr Tyr Gln Leu Cys His
    770                 775                 780

Thr Tyr Val Arg Cys Thr Arg Ser Val Ser Ile Pro Ala Pro Ala Tyr
785                 790                 795                 800

Tyr Ala His Leu Val Ala Phe Arg Ala Arg Tyr His Leu Val Asp Lys
                805                 810                 815

Glu His Asp Ser Ala Glu Gly Ser His Val Ser Gly Gln Ser Asn Gly
            820                 825                 830

Arg Asp Pro Gln Ala Leu Ala Lys Ala Val Gln Ile His Gln Asp Thr
        835                 840                 845

Leu Arg Thr Met Tyr Phe Ala
    850                 855


<210> SEQ ID NO 72
<211> LENGTH: 764
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: HILI, predicted protein sequence

<400> SEQUENCE: 72

Ile Ser Ser Gly Asp Ala Gly Ser Thr Phe Met Glu Arg Gly Val Lys
1               5                   10                  15

Asn Lys Gln Asp Phe Met Asp Leu Ser Ile Cys Thr Arg Glu Lys Leu
            20                  25                  30

Ala His Val Arg Asn Cys Lys Thr Gly Ser Ser Gly Ile Pro Val Lys
        35                  40                  45

Leu Val Thr Asn Leu Phe Asn Leu Asp Phe Pro Gln Asp Trp Gln Leu
    50                  55                  60

Tyr Gln Tyr His Val Thr Tyr Ile Pro Asp Leu Ala Ser Arg Arg Leu
65                  70                  75                  80

Arg Ile Ala Leu Leu Tyr Ser His Ser Glu Leu Ser Asn Lys Ala Lys
                85                  90                  95

Ala Phe Asp Gly Ala Ile Leu Phe Leu Ser Gln Lys Leu Glu Glu Lys
            100                 105                 110

Val Thr Glu Leu Ser Ser Glu Thr Gln Arg Gly Glu Thr Ile Lys Met
        115                 120                 125

Thr Ile Thr Leu Lys Arg Glu Leu Pro Ser Ser Ser Pro Val Cys Ile
    130                 135                 140

Gln Val Phe Asn Ile Ile Phe Arg Lys Ile Leu Lys Lys Leu Ser Met
145                 150                 155                 160

Tyr Gln Ile Gly Arg Asn Phe Tyr Asn Pro Ser Glu Pro Met Glu Ile
```

-continued

```
                165                 170                 175

Pro Gln His Lys Leu Ser Leu Trp Pro Gly Phe Ala Ile Ser Val Ser
            180                 185                 190

Tyr Phe Glu Arg Lys Leu Leu Phe Ser Ala Asp Val Ser Tyr Lys Val
        195                 200                 205

Leu Arg Asn Glu Thr Val Leu Glu Phe Met Thr Ala Leu Cys Gln Arg
    210                 215                 220

Thr Gly Leu Ser Cys Phe Thr Gln Thr Cys Glu Lys Gln Leu Ile Gly
225                 230                 235                 240

Leu Ile Val Leu Thr Arg Tyr Asn Asn Arg Thr Tyr Ser Ile Asp Asp
                245                 250                 255

Ile Asp Trp Ser Val Lys Pro Thr His Thr Phe Gln Lys Arg Asp Gly
            260                 265                 270

Thr Glu Ile Thr Tyr Val Asp Tyr Tyr Lys Gln Gln Tyr Asp Ile Thr
        275                 280                 285

Val Ser Asp Leu Asn Gln Pro Met Leu Val Ser Leu Leu Lys Lys Lys
    290                 295                 300

Arg Asn Asp Asn Ser Glu Ala Gln Leu Ala His Leu Ile Pro Glu Leu
305                 310                 315                 320

Cys Phe Leu Thr Gly Leu Thr Asp Gln Ala Thr Ser Asp Phe Gln Leu
                325                 330                 335

Met Lys Ala Val Ala Glu Lys Thr Arg Leu Ser Pro Ser Gly Arg Gln
            340                 345                 350

Gln Arg Leu Ala Arg Leu Val Asp Asn Ile Gln Arg Asn Thr Asn Ala
        355                 360                 365

Arg Phe Glu Leu Glu Thr Trp Gly Leu His Phe Gly Ser Gln Ile Ser
    370                 375                 380

Leu Thr Gly Arg Ile Val Pro Ser Glu Lys Ile Leu Met Gln Asp His
385                 390                 395                 400

Ile Cys Gln Pro Val Ser Ala Ala Asp Trp Ser Lys Asp Ile Arg Thr
                405                 410                 415

Cys Lys Ile Leu Asn Ala Gln Ser Leu Asn Thr Trp Leu Ile Leu Cys
            420                 425                 430

Ser Asp Arg Thr Glu Tyr Val Ala Glu Ser Phe Leu Asn Cys Leu Arg
        435                 440                 445

Arg Val Ala Gly Ser Met Gly Phe Asn Val Met Cys Ile Leu Pro Ser
    450                 455                 460

Asn Gln Lys Thr Tyr Tyr Asp Ser Ile Lys Lys Tyr Leu Ser Ser Asp
465                 470                 475                 480

Cys Pro Val Pro Ser Gln Cys Val Leu Ala Arg Thr Leu Asn Lys Gln
                485                 490                 495

Gly Met Met Met Ser Ile Ala Thr Lys Ile Ala Met Gln Met Thr Cys
            500                 505                 510

Lys Leu Gly Gly Glu Leu Trp Ala Val Glu Ile Pro Leu Lys Ser Leu
        515                 520                 525

Met Val Val Gly Ile Asp Val Cys Lys Asp Ala Leu Ser Lys Asp Val
    530                 535                 540

Met Val Val Gly Cys Val Ala Ser Val Asn Pro Arg Ile Thr Arg Trp
545                 550                 555                 560

Phe Ser Arg Cys Ile Leu Gln Arg Thr Met Thr Asp Val Ala Asp Cys
                565                 570                 575
```

-continued

```
Leu Lys Val Phe Met Thr Gly Ala Leu Asn Lys Trp Tyr Lys Tyr Asn
            580                 585                 590

His Asp Leu Pro Ala Arg Ile Ile Val Tyr Arg Ala Gly Val Gly Asp
        595                 600                 605

Gly Gln Leu Lys Thr Leu Ile Glu Tyr Glu Val Pro Gln Leu Leu Ser
    610                 615                 620

Ser Val Ala Glu Ser Ser Ser Asn Thr Ser Ser Arg Leu Ser Val Ile
625                 630                 635                 640

Val Val Arg Lys Lys Cys Met Pro Arg Phe Phe Thr Glu Met Asn Arg
                645                 650                 655

Thr Val Gln Asn Pro Pro Leu Gly Thr Val Val Asp Ser Glu Ala Thr
            660                 665                 670

Arg Asn Glu Trp Gln Tyr Asp Phe Tyr Leu Ile Ser Gln Val Ala Cys
        675                 680                 685

Arg Gly Thr Val Ser Pro Thr Tyr Tyr Asn Val Ile Tyr Asp Asp Asn
    690                 695                 700

Gly Leu Lys Pro Asp His Met Gln Arg Leu Thr Phe Lys Leu Cys His
705                 710                 715                 720

Leu Tyr Tyr Asn Trp Pro Gly Ile Val Ser Val Pro Ala Pro Cys Gln
                725                 730                 735

Tyr Ala His Lys Leu Thr Phe Leu Val Ala Gln Ser Ile His Lys Glu
            740                 745                 750

Pro Ser Leu Glu Leu Ala Asn His Leu Phe Tyr Leu
        755                 760


<210> SEQ ID NO 73
<211> LENGTH: 861
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: HIWI, predicted protein sequence

<400> SEQUENCE: 73

Met Thr Gly Arg Ala Arg Ala Arg Ala Arg Gly Arg Ala Arg Gly Gln
1               5                   10                  15

Glu Thr Ala Gln Leu Val Gly Ser Thr Ala Ser Gln Gln Pro Gly Tyr
            20                  25                  30

Ile Gln Pro Arg Pro Gln Pro Pro Pro Ala Glu Gly Glu Leu Phe Gly
        35                  40                  45

Arg Gly Arg Gln Arg Gly Thr Ala Gly Gly Thr Ala Lys Ser Gln Gly
    50                  55                  60

Leu Gln Ile Ser Ala Gly Phe Gln Glu Leu Ser Leu Ala Glu Arg Gly
65                  70                  75                  80

Gly Arg Arg Arg Asp Phe His Asp Leu Gly Val Asn Thr Arg Gln Asn
                85                  90                  95

Leu Asp His Val Lys Glu Ser Lys Thr Gly Ser Ser Gly Ile Ile Val
            100                 105                 110

Arg Leu Ser Thr Asn His Phe Arg Leu Thr Ser Arg Pro Gln Trp Ala
        115                 120                 125

Leu Tyr Gln Tyr His Ile Asp Tyr Asn Pro Leu Met Glu Ala Arg Arg
    130                 135                 140

Leu Arg Ser Ala Leu Leu Phe Gln His Glu Asp Leu Ile Gly Lys Cys
```

-continued

```
145                 150                 155                 160

His Ala Phe Asp Gly Thr Ile Leu Phe Leu Pro Lys Arg Leu Gln Gln
                165                 170                 175

Lys Val Thr Glu Val Phe Ser Lys Thr Arg Asn Gly Glu Asp Val Arg
            180                 185                 190

Ile Thr Ile Thr Leu Thr Asn Glu Leu Pro Pro Thr Ser Pro Thr Cys
        195                 200                 205

Leu Gln Phe Tyr Asn Ile Ile Phe Arg Arg Leu Leu Lys Ile Met Asn
    210                 215                 220

Leu Gln Gln Ile Gly Arg Asn Tyr Tyr Asn Pro Asn Asp Pro Ile Asp
225                 230                 235                 240

Ile Pro Ser His Arg Leu Val Ile Trp Pro Gly Phe Thr Thr Ser Ile
                245                 250                 255

Leu Gln Tyr Glu Asn Ser Ile Met Leu Cys Thr Asp Val Ser His Lys
            260                 265                 270

Val Leu Arg Ser Glu Thr Val Leu Asp Phe Met Phe Asn Phe Tyr His
        275                 280                 285

Gln Thr Glu Glu His Lys Phe Gln Glu Gln Val Ser Lys Glu Leu Ile
    290                 295                 300

Gly Leu Val Val Leu Thr Lys Tyr Asn Asn Lys Thr Tyr Arg Val Asp
305                 310                 315                 320

Asp Ile Asp Trp Asp Gln Asn Pro Lys Ser Thr Phe Lys Lys Ala Asp
                325                 330                 335

Gly Ser Glu Val Ser Phe Leu Glu Tyr Tyr Arg Lys Gln Tyr Asn Gln
            340                 345                 350

Glu Ile Thr Asp Leu Lys Gln Pro Val Leu Val Ser Gln Pro Lys Arg
        355                 360                 365

Arg Arg Gly Pro Gly Gly Thr Leu Pro Gly Pro Ala Met Leu Ile Pro
    370                 375                 380

Glu Leu Cys Tyr Leu Thr Gly Leu Thr Asp Lys Met Arg Asn Asp Phe
385                 390                 395                 400

Asn Val Met Lys Asp Leu Ala Val His Thr Arg Leu Thr Pro Glu Gln
                405                 410                 415

Arg Gln Arg Glu Val Gly Arg Leu Ile Asp Tyr Ile His Lys Asn Asp
            420                 425                 430

Asn Val Gln Arg Glu Leu Arg Asp Trp Gly Leu Ser Phe Asp Ser Asn
        435                 440                 445

Leu Leu Ser Phe Ser Gly Arg Ile Leu Gln Thr Glu Lys Ile His Gln
    450                 455                 460

Gly Gly Lys Thr Phe Asp Tyr Asn Pro Gln Phe Ala Asp Trp Ser Lys
465                 470                 475                 480

Glu Thr Arg Gly Ala Pro Leu Ile Ser Val Lys Pro Leu Asp Asn Trp
                485                 490                 495

Leu Leu Ile Tyr Thr Arg Arg Asn Tyr Glu Ala Ala Asn Ser Leu Ile
            500                 505                 510

Gln Asn Leu Phe Lys Val Thr Pro Ala Met Gly Met Gln Met Arg Lys
        515                 520                 525

Ala Ile Met Ile Glu Val Asp Asp Arg Thr Glu Ala Tyr Leu Arg Val
    530                 535                 540

Leu Gln Gln Lys Val Thr Ala Asp Thr Gln Ile Val Val Cys Leu Leu
545                 550                 555                 560
```

-continued

```
Ser Ser Asn Arg Lys Asp Lys Tyr Asp Ala Ile Lys Lys Tyr Leu Cys
                565                 570                 575

Thr Asp Cys Pro Thr Pro Ser Gln Cys Val Val Ala Arg Thr Leu Gly
            580                 585                 590

Lys Gln Gln Thr Val Met Ala Ile Ala Thr Lys Ile Ala Leu Gln Met
        595                 600                 605

Asn Cys Lys Met Gly Gly Glu Leu Trp Arg Val Asp Ile Pro Leu Lys
    610                 615                 620

Leu Val Met Ile Val Gly Ile Asp Cys Tyr His Asp Met Thr Ala Gly
625                 630                 635                 640

Arg Arg Ser Ile Ala Gly Phe Val Ala Ser Ile Asn Glu Gly Met Thr
                645                 650                 655

Arg Trp Phe Ser Arg Cys Ile Phe Gln Asp Arg Gly Gln Glu Leu Val
            660                 665                 670

Asp Gly Leu Lys Val Cys Leu Gln Ala Ala Leu Arg Ala Trp Asn Ser
        675                 680                 685

Cys Asn Glu Tyr Met Pro Ser Arg Ile Ile Val Tyr Arg Asp Gly Val
    690                 695                 700

Gly Asp Gly Gln Leu Lys Thr Leu Val Asn Tyr Glu Val Pro Gln Phe
705                 710                 715                 720

Leu Asp Cys Leu Lys Ser Ile Gly Arg Gly Tyr Asn Pro Arg Leu Thr
                725                 730                 735

Val Ile Val Val Lys Lys Arg Val Asn Thr Arg Phe Phe Ala Gln Ser
            740                 745                 750

Gly Gly Arg Leu Gln Asn Pro Leu Pro Gly Thr Val Ile Asp Val Glu
        755                 760                 765

Val Thr Arg Pro Glu Trp Tyr Asp Phe Phe Ile Val Ser Gln Ala Val
    770                 775                 780

Arg Ser Gly Ser Val Ser Pro Thr His Tyr Asn Val Ile Tyr Asp Asn
785                 790                 795                 800

Ser Gly Leu Lys Pro Asp His Ile Gln Arg Leu Thr Tyr Lys Leu Cys
                805                 810                 815

His Ile Tyr Tyr Asn Trp Pro Gly Val Ile Arg Val Pro Ala Pro Cys
            820                 825                 830

Gln Tyr Ala His Lys Leu Ala Phe Leu Val Gly Gln Ser Ile His Arg
        835                 840                 845

Glu Pro Asn Leu Ser Leu Ser Asn Arg Leu Tyr Tyr Leu
    850                 855                 860


<210> SEQ ID NO 74
<211> LENGTH: 2571
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C1, cDNA sequence of predicted ORF

<400> SEQUENCE: 74

atggaagcgg gaccctcggg agcagctgcg ggcgcttacc tgccccccct gcagcaggtg     60

ttccaggcac ctcgccggcc tggcattggc actgtgggga aaccaatcaa gctcctggcc    120

aattactttg aggtggacat ccctaagatc gacgtgtacc actacgaggt ggacatcaag    180

ccggataagt gtccccgtag agtcaaccgg gaagtggtgg aatacatggt ccagcatttc    240
```

-continued

aagcctcaga tctttggtga tcgcaagcct gtgtatgatg gaaagaagaa catttacact 300

gtcacagcac tgcccattgg caacgaacgg gtcgactttg aggtgacaat ccctggggaa 360

gggaaggatc gaatctttaa ggtctccatc aagtggctag ccattgtgag ctggcgaatg 420

ctgcatgagg ccctggtcag cggccagatc cctgttccct tggagtctgt gcaagccctg 480

gatgtggcca tgaggcacct ggcatccatg aggtacaccc ctgtgggccg ctccttcttc 540

tcaccgcctg agggctacta ccacccgctg gggggtgggc gcgaggtctg gttcggcttt 600

caccagtctg tgcgccctgc catgtggaag atgatgctca acattgatgt ctcagccact 660

gccttttata aggcacagcc agtgattgag ttcatgtgtg aggtgctgga catcaggaac 720

atagatgagc agcccaagcc cctcacggac tctcagcgcg ttcgcttcac caaggagatc 780

aagggcctga aggtggaagt cacccactgt ggacagatga agaggaagta ccgcgtgtgt 840

aatgttaccc gtcgccctgc tagccatcag acattcccct tacagctgga gagtggacag 900

actgtggagt gcacagtggc acagtatttc aagcagaaat ataaccttca gctcaagtat 960

ccccatctgc cctgcctaca agttggccag gaacaaaagc atacctacct tcccctagag 1020

gtctgtaaca ttgtggctgg gcagcgctgt attaaaaagc tgaccgacaa ccagacctcg 1080

accatgataa aggccacagc tagatccgct ccagacagac aggaggagat cagtcgcctg 1140

atgaagaatg ccagctacaa cttagatccc tacatccagg aatttgggat caaagtgaag 1200

gatgacatga cggaggtgac agggcgagtg ctgccggcgc ccatcttgca gtacggcggc 1260

cggaaccggg ccattgccac acccaatcag ggtgtctggg acatgcgggg gaaacagttc 1320

tacaatggga ttgagatcaa agtctgggcc atcgcctgct tcgcacccca aaaacagtgt 1380

cgagaagagg tgctcaagaa cttcacagac cagctgcgga agatttccaa ggatgcgggg 1440

atgcctatcc agggtcaacc ttgtttctgc aaatatgcac agggggcaga cagcgtggag 1500

cctatgttcc ggcatctcaa gaacacctac tcagggctgc agctcattat tgtcatcctg 1560

ccagggaaga cgccggtgta tgctgaggtg aaacgtgtcg gagatacact cttgggaatg 1620

gctacgcagt gtgtgcaggt gaagaacgtg gtcaagacct cacctcagac tctgtccaac 1680

ctctgcctca agatcaatgt caaacttggt ggcattaaca acatcctagt cccacaccag 1740

cgctctgccg tttttcaaca gccagtgata ttcctgggag cagatgttac acacccccca 1800

gcaggggatg ggaaaaaacc ttctatcaca gcagtggtag gcagtatgga tgcccacccc 1860

agccgatact gtgctactgt gcgggtacag cgaccacggc aagagatcat tgaagacttg 1920

tcctacatgg tgcgtgagct cctcatccaa ttctacaagt ccacccgttt caagcctacc 1980

cgcatcatct tctaccgaga tggggtgcct gaaggccagc taccccagat actccactat 2040

gagctactgg ccattcgtga tgcctgcatc aaactggaaa aggactacca gcctgggatc 2100

acttatattg tggtgcagaa acgccatcac acccgccttt tctgtgctga caagaatgag 2160

cgaattggga agagtggtaa catcccagct gggaccacag tggacaccaa catcacccac 2220

ccatttgagt ttgacttcta tctgtgcagc cacgcaggca tccagggcac cagccgacca 2280

tcccattact atgttctttg ggatgacaac cgtttcacag cagatgagct ccagatcctg 2340

acgtaccagc tgtgccacac ttacgtacga tgcacacgct ctgtctctat cccagcacct 2400

gcctactatg cccgcctggt ggctttccgg gcacgatacc acctggtgga caaggagcat 2460

gacagtggag aggggagcca catatcgggg cagagcaatg ggcgggaccc ccaggccctg 2520

-continued

gccaaagccg tgcaggttca ccaggatact ctgcgcacca tgtacttcgc t 2571

<210> SEQ ID NO 75
<211> LENGTH: 2580
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C2, cDNA sequence of predicted ORF

<400> SEQUENCE: 75

atgggtgttc tctctgccat tcccgcactt gcacctcctg cgccgccgcc ccccatccaa 60

ggatatgcct tcaagcctcc acctagaccc gactttggga cctccgggag aacaatcaaa 120

ttacaggcca atttcttcga aatggacatc cccaaaattg acatctatca ttatgaattg 180

gatatcaagc cagagaagtg cccgaggaga gttaacaggg aaatcgtgga acacatggtc 240

cagcacttta aaacacagat ctttggggat cggaagcccg tgtttgacgg caggaagaat 300

ctatacacag ccatgcccct tccgattggg agggacaagg tggagctgga ggtcacgctg 360

ccaggagaag gcaaggatcg catcttcaag gtgtccatca agtgggtgtc ctgcgtgagc 420

ttgcaggcgt tacacgatgc actttcaggg cggctgccca gcgtcccttt tgagacgatc 480

caggccctgg acgtggtcat gaggcacttg ccatccatga ggtacacccc cgtgggccgc 540

tccttcttca ccgcgtccga aggctgctct aaccctcttg gcgggggccg agaagtgtgg 600

tttggcttcc atcagtccgt ccggccttct ctctggaaaa tgatgctgaa tattgatgtg 660

tcagcaacag cgttttacaa ggcacagcca gtaatcgagt ttgtttgtga agttttggat 720

tttaaaagta ttgaagaaca acaaaaacct ctgacagatt cccaaagggt aaagtttacc 780

aaagaaatta aaggtctaaa ggtggagata acgcactgtg ggcagatgaa gaggaagtac 840

cgtgtctgca atgtgacccg gcggcccgcc agtcaccaaa cattcccgct gcagcaggag 900

agcgggcaga cggtggagtg cacggtggcc cagtatttca aggacaggca caagttggtt 960

ctgcgctacc cccacctccc atgtttacaa gtcggacagg agcagaaaca cacctacctt 1020

cccctggagg tctgtaacat tgtggcagga caaagatgta ttaaaaaatt aacggacaat 1080

cagacctcaa ccatgatcag agcaactgct aggtcggcgc ccgatcggca agaagagatt 1140

agcaaattga tgcgaagtgc aagtttcaac acagatccat acgtccgtga atttggaatc 1200

atggtcaaag atgagatgac agacgtgact gggcgggtgc tgcagccgcc ctccatcctc 1260

tacgggggca ggaataaagc tattgcgacc cctgtccagg gcgtctggga catgcggaac 1320

aagcagttcc acacgggcat cgagatcaag gtgtgggcca ttgcgtgctt cgccccccag 1380

cgccagtgca cggaagtcca tctgaagtcc ttcacagagc agctcagaaa gatctcgaga 1440

gacgctggca tgcccatcca gggccagccg tgcttctgca aatacgcgca gggggcggac 1500

agcgtggagc ccatgttccg gcacctgaag aacacgtatg cgggcctgca gctggtggtg 1560

gtcatcctgc ccggcaagac gcccgtgtac gccgaggtca agcgcgtggg agacacggtg 1620

ctggggatgg ccacgcagtg cgtgcagatg aagaacgtgc agaggaccac gccacagacc 1680

ctgtccaacc tttgcctgaa gatcaacgtc aagctgggag gcgtgaacaa catcctgctg 1740

ccccagggca ggccgccggt gttccagcag cccgtcatct ttctgggagc agacgtcact 1800

caccccccg ccggggatgg gaagaagccc tccattgccg ccgtggtggg cagcatggac 1860

-continued

gcccacccca atcgctactg cgccaccgtg cgcgtgcagc agcaccggca ggagatcata 1920

caagacctgg ccgccatggt ccgcgagctc ctcatccagt tctacaagtc cacgcgcttc 1980

aagcccaccc gcatcatctt ctaccgcgac ggtgtctctg aaggccagtt ccagcaggtt 2040

ctccaccacg agttgctggc catccgtgag gcctgtatca agctagaaaa agactaccag 2100

cccgggatca ccttcatcgt ggtgcagaag aggcaccaca cccggctctt ctgcactgac 2160

aagaacgagc gggttgggaa aagtggaaac attccagcag gcacgactgt ggacacgaaa 2220

atcacccacc ccaccgagtt cgacttctac ctgtgtagtc acgctggcat ccaggggaca 2280

agcaggcctt cgcactatca cgtcctctgg gacgacaatc gtttctcctc tgatgagctg 2340

cagatcctaa cctaccagct gtgtcacacc tacgtgcgct gcacacgctc cgtgtccatc 2400

ccagcgccag catactacgc tcacctggtg gccttccggg ccaggtacca cctggtggat 2460

aaggaacatg acagtgctga aggaagccat acctctgggc agagtaacgg gcgagaccac 2520

caagcactgg ccaaggcggt ccaggttcac caagacactc tgcgcaccat gtactttgct 2580

<210> SEQ ID NO 76
<211> LENGTH: 2772
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C3, cDNA sequence of predicted ORF

<400> SEQUENCE: 76

agccggagcc gggtccctgt ccccgggccg ggcgccgccg ccgccccctg cccagcgccc 60

gcgtctccgc ggcgccaccc cagcgccaat attccggaga tcaagcgtta cgcggcggcg 120

gcggcggcgg cggcggggcc cggagcggga ggcgccgggg accggggcga ggcggccccc 180

gccgccgcca tggaggcgct gggacccgga cctccggcta gcctgtttca gccacctcgt 240

cgtcctggcc ttggaactgt tggaaaacca attcgactgt tagccaatca ttttcaggtt 300

cagattccta aaatagatgt gtatcactat gatgtggata ttaagcctga aaaacggcct 360

cgtagagtca acagggaggt agtagataca atggtgcggc acttcaagat gcaaatattt 420

ggtgatcggc agcctgggta tgatggcaaa agaaacatgt acacagcaca tccactacca 480

attggacggg atagggttga tatggaggtg actcttccag gcgagggtaa agaccaaaca 540

tttaaagtgt ctgttcagtg ggtgtcagtt gtgagccttc agttgctttt agaagctttg 600

gctgggcact tgaatgaagt cccagatgac tcagtacaag cacttgatgt tatcacaaga 660

caccttccct ccatgaggta caccccagtg ggccgttcct ttttctcacc cccggaaggt 720

tactaccacc ctctgggagg gggcagggag gtctggtttg gttttcatca gtctgtgaga 780

cctgccatgt ggaatatgat gctcaacatt gatgtatctg caactgcttt ctaccgggct 840

cagcctatca ttgagttcat gtgtgaggtt ttagacattc agaacatcaa tgaacagacc 900

aaacctctaa cagactccca gcgtgtcaaa tttaccaaag aaatcagagg tctcaaagtt 960

gaggtgaccc actgtggaca gatgaaacga aaataccgag tttgtaatgt gactagacgg 1020

ccagccagtc atcaaacttt tcctttgcag ctagaaaacg gtcaagctat ggaatgtaca 1080

gtagctcaat attttaagca aaagtatagt ctgcaactga aataccccca tcttccctgt 1140

ctccaagtgg gacaagaaca aaagcataca tacttgccac tcgaggtctg taatatagtg 1200

gcaggacagc gatgtatcaa gaagctcaca gacaatcaga cttccacaat gatcaaagct 1260

-continued

acagcaagat ctgctcctga cagacaggaa gagatcagta gactggtgaa gagcaacagt 1320

atggtgggtg gacctgatcc ataccttaaa gaatttggta ttgttgtcca caatgaaatg 1380

acagagctca caggcagggt acttccagca ccaatgctgc aatatggagg ccggaataaa 1440

acagtagcca cacccaacca gggtgtctgg gacatgcgag gaaagcagtt ttatgctggc 1500

attgaaatta aagtttgggc agttgcttgt tttgcacctc agaaacaatg tagggaagat 1560

ttactaaaga gtttcactga ccagctgcgt aaaatctcta aggatgcagg aatgcccatc 1620

cagggtcagc catgtttctg caagtatgca caaggtgcag acagtgtgga gcctatgttt 1680

aaacatctga aaatgactta tgtgggccta cagctaatag tggttatcct gcctggaaag 1740

acaccagtat atgcggaggt gaaacgtgtt ggagataccc ttctaggtat ggccacacag 1800

tgtgtccagg taaaaaatgt agtgaagacc tcacctcaaa ccctttccaa tctttgcctg 1860

aagataaatg caaaacttgg aggaattaac aatgtgcttg tgcctcatca aaggccctcg 1920

gtgttccagc agcctgtcat cttcctggga gcggatgtca cacacccccc agcaggggat 1980

gggaagaaac cttccattgc tgctgtggtt ggcagtatgg atggccaccc cagccggtac 2040

tgtgccaccg ttcgggtgca gacttcccgg caggagatct cccaagagct cctctacagt 2100

caagaggtca tccaggacct gactaacatg gttcgagagc tgctgattca gttctacaaa 2160

tccacacgct tcaaacccac tcggatcatc tattaccgtg gaggggtatc tgagggacaa 2220

atgaaacagg tagcttggcc agaactaata gcaattcgaa aggcatgtat tagcttggaa 2280

gaagattacc ggccaggaat aacttatatt gtggtgcaaa aaagacatca cacacgactc 2340

ttctgtgcag ataaaacaga aagggtaggg aaaagtggca atgtaccagc aggcactaca 2400

gtggatagta ccatcacaca tccatctgag tttgactttt acctctgtag tcatgcagga 2460

attcagggaa ccagccgtcc ctcacattac caggtcttgt gggatgacaa ctgcttcact 2520

gcagatgaac tccagctact gacttaccag ctgtgtcaca cctatgtgag gtgcactcgc 2580

tcagtctcta ttccagcccc tgcatattat gcccggcttg tagcatttag ggcaaggtat 2640

catctggtgg ataaagatca tgacagtgcg gaaggcagtc atgtgtcagg acagagcaac 2700

ggccgggatc ctcaggcctt ggctaaggct gtgcaaatcc accatgatac ccagcacacg 2760

atgtattttg cc 2772

<210> SEQ ID NO 77
<211> LENGTH: 2568
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C4, cDNA sequence of predicted ORF

<400> SEQUENCE: 77

gcaggacccg ctggggccca gcccctactc atggtgccca gaagacctgg ctatggcacc 60

atgggcaaac ccattaaact gctggctaac tgttttcaag ttgaaatccc aaagattgat 120

gtctacctct atgaggtaga tattaaacca gacaagtgtc ctaggagagt gaacagggag 180

gtggttgact caatggttca gcattttaaa gtaactatat ttggagaccg tagaccagtt 240

tatgatggaa aaagaagtct ttacaccgcc aatccacttc ctgtggcaac tacaggggta 300

gatttagacg ttactttacc tggggaaggt ggaaaagatc gacctttcaa ggtgtcaatc 360

-continued

aaatttgtct ctcgggtgag ttggcaccta ctgcatgaag tactgacagg acggaccttg 420

cctgagccac tggaattaga caagccaatc agcactaacc ctgtccatgc cgttgatgtg 480

gtgctacgac atctgccctc catgaaatac acacctgtgg ggcgttcatt tttctccgct 540

ccagaaggat atgaccaccc tctgggaggg ggcagggaag tgtggtttgg attccatcag 600

tctgttcggc ctgccatgtg gaaaatgatg cttaatatcg atgtttctgc cactgccttc 660

tacaaagcac aacctgtaat tcagttcatg tgtgaagttc ttgatattca taatattgat 720

gagcaaccaa gacctctgac tgattctcat cgggtaaaat tcaccaaaga gataaaaggt 780

ttgaaggttg aagtgactca ttgtggaaca atgagacgga aataccgtgt ttgtaatgta 840

acaaggaggc ctgccagtca tcaaaccttt cctttacagt tagaaaacgg ccaaactgtg 900

gagagaacag tagcgcagta tttcagagaa aagtatactc ttcagctgaa gtacccgcac 960

cttccctgtc tgcaagtcgg gcaggaacag aaacacacct acctgccact agaagtctgt 1020

aatattgtgg cagggcaacg atgtatcaag aagctaacag acaatcagac ttccactatg 1080

atcaaggcaa cagcaagatc tgcaccagat agacaagagg aaattagcag attggtaaga 1140

agtgcaaatt atgaaacaga tccatttgtt caggagtttc aatttaaagt tcgggatgaa 1200

atggctcatg taactggacg cgtacttcca gcacctatgc tccagtatgg aggacggaat 1260

cggacagtag caacaccgag ccatggagta tgggacatgc gagggaaaca attccacaca 1320

ggagttgaaa tcaaaatgtg ggctatcgct tgttttgcca cacagaggca gtgcagagaa 1380

gaaatattga agggtttcac agaccagctg cgtaagattt ctaaggatgc agggatgccc 1440

atccagggcc agccatgctt ctgcaaatat gcacaggggg cagacagcgt agagcccatg 1500

ttccggcatc tcaagaacac atattctggc ctacagctta ttatcgtcat cctgccgggg 1560

aagacaccag tgtatgcgga agtgaaacgt gtaggagaca cacttttggg tatggctaca 1620

caatgtgttc aagtcaagaa tgtaataaaa acatctcctc aaactctgtc aaacttgtgc 1680

ctaaagataa atgttaaact cggagggatc aataatattc ttgtacctca tcaaagacct 1740

tctgtgttcc agcaaccagt gatctttttg ggagccgatg tcactcatcc acctgctggt 1800

gatggaaaga agccttctat tgctgctgtt gtaggtagta tggatgcaca cccaagcaga 1860

tactgtgcca cagtaagagt tcagagaccc cgacaggaga tcatccagga cttggcctcc 1920

atggtccggg aacttcttat tcaatttttat aagtcaactc ggttcaagcc tactcgtatc 1980

atcttttatc gggatggtgt ttcagagggg cagtttaggc aggtattata ttatgaacta 2040

ctagcaattc gagaagcctg catcagtttg gagaaagact atcaacctgg aataacctac 2100

attgtagttc agaagagaca tcacactcga ttattttgtg ctgataggac agaaagggtt 2160

ggaagaagtg gcaatatccc agctggaaca acagttgata cagacattac acacccatat 2220

gagttcgatt tttacctctg tagccatgct ggaatacagg gtaccagtcg tccttcacac 2280

tatcatgttt tatgggatga taactgcttt actgcagatg aacttcagct gctaacttac 2340

cagctctgcc acacttacgt acgctgtaca cgatctgttt ctatacctgc accagcgtat 2400

tatgctcacc tggtagcatt tagagccaga tatcatcttg tggacaaaga acatgacagt 2460

gctgaaggaa gtcacgtttc aggacaaagc aatgggcgag atccacaagc tcttgccaag 2520

gctgtacaga ttcaccaaga taccttacgc acaatgtact tcgcttaa 2568

<210> SEQ ID NO 78

-continued

<211> LENGTH: 2292
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HILI, cDNA sequence of predicted ORF

<400> SEQUENCE: 78

atatcttctg gtgatgctgg aagtaccttc atggaaagag gtgtgaaaaa caaacaggac 60

tttatggatt tgagtatctg taccagagaa aaattggcac atgtgagaaa ttgtaaaaca 120

ggttccagtg gaatacctgt gaaactggtt acaaacctct ttaacttaga ttttccccaa 180

gactggcagc tataccagta ccatgtgaca tatattccag atttagcatc tagaaggctg 240

agaattgctt tactttatag tcatagtgaa ctttccaaca aagcaaaagc attcgacggt 300

gccatccttt ttctgtcaca aaagctagaa gaaaaggtca cagagttgtc aagtgaaact 360

caaagaggtg agactataaa gatgactatc accctgaaga gggagctgcc atcaagttct 420

cccgtgtgca tccaggtctt caatatcatc ttcagaaaga tcctcaaaaa gttgtccatg 480

taccaaattg gacggaactt ctataatcct tcagagccaa tggaaattcc ccagcacaaa 540

ttatcccttt ggcctgggtt tgccatttct gtgtcatatt ttgaaaggaa gctcctgttt 600

agtgctgatg tgagttacaa agtcctccgg aatgagacgg ttctggaatt catgactgct 660

ctctgtcaaa gaactggctt gtcctgtttc acccagacgt gtgagaagca gctaataggg 720

ctcattgtcc ttacaagata caataacaga acctactcca ttgatgacat tgactggtca 780

gtgaagccca cacacacctt tcagaagcgg gatggcaccg agatcaccta tgtggattac 840

tacaagcagc agtatgatat tactgtatcg gacctgaatc agcccatgct tgttagtctg 900

ttaaagaaga agagaaatga caacagtgag gctcagctcg cccacctgat acctgagctc 960

tgctttctaa cagggctgac tgaccaggca acatctgatt tccagctgat gaaggctgtg 1020

gctgaaaaga cacgtctcag tccttcaggc cggcagcagc gcctggccag gcttgtggac 1080

aacatccaga ggaataccaa tgctcgcttt gaactagaga cctggggact gcattttgga 1140

agccagatat ctctgactgg ccggattgtg ccttcagaaa aaatattaat gcaagaccac 1200

atatgtcaac ctgtgtctgc tgctgactgg tccaaggata ttcgaacttg caagatttta 1260

aatgcacagt ctttgaatac ctggttgatt ttatgtagcg acagaactga atatgttgcc 1320

gagagctttc tgaactgctt gagaagagtt gcaggttcca tgggatttaa tgtaatgtgc 1380

attctgcctt ctaatcagaa gacctattat gattccatta aaaaatattt gagctcagac 1440

tgcccagtcc caagccaatg tgtgcttgct cggaccttga ataaacaggg catgatgatg 1500

agtatcgcca ccaagatcgc tatgcagatg acttgcaagc tcggaggcga gctgtgggct 1560

gtggaaatac ctttaaagtc cctgatggtg gtcggtattg atgtctgtaa agatgcactc 1620

agcaaggacg tgatggttgt tggatgcgtg gccagtgtta accccagaat caccaggtgg 1680

ttttcccgct gtatccttca gagaacaatg actgatgttg cagattgctt gaaagttttc 1740

atgactggag cactcaacaa atggtacaag tacaatcatg atttgccagc acggataatt 1800

gtgtaccgtg ctggtgtagg ggatggtcag ctgaaaacac ttattgaata tgaagtccca 1860

cagctgctga gcagtgtggc agaatccagc tcaaatacca gctcaagact gtcggtgatt 1920

gtggtcagga agaagtgcat gccacgattc tttaccgaaa tgaaccgcac tgtacagaac 1980

cccccacttg gcactgttgt ggattcagaa gcaacacgta acgaatggca gtatgacttt 2040

-continued

tatctgatca gccaggtggc ctgccgggga actgttagtc ctacctacta taatgtcatc 2100

tatgatgaca acggcttgaa gcccgaccat atgcagagac ttacattcaa attgtgccac 2160

ctgtactaca actggccggg catagtcagt gtcccagcac catgtcagta tgctcacaag 2220

ctgacctttc tggtggcaca aagcattcat aaagaaccca gtctggaatt agccaaccat 2280

ctcttctacc tg 2292

<210> SEQ ID NO 79
<211> LENGTH: 2583
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HIWI, cDNA sequence of predicted ORF

<400> SEQUENCE: 79

atgactggga gagcccgagc cagagccaga ggaagggccc gcggtcagga gacagcgcag 60

ctggtgggct ccactgccag tcagcaacct ggttatattc agcctaggcc tcagccgcca 120

ccagcagagg gggaattatt tggccgtgga cggcagagag gaacagcagg aggaacagcc 180

aagtcacaag gactccagat atctgctgga tttcaggagt tatcgttagc agagagagga 240

ggtcgtcgta gagattttca tgatcttggt gtgaatacaa ggcagaacct agaccatgtt 300

aaagaatcaa aaacaggttc ttcaggcatt atagtaaggt taagcactaa ccatttccgg 360

ctgacatccc gtccccagtg ggccttatat cagtatcaca ttgactataa cccactgatg 420

gaagccagaa gactccgttc agctcttctt tttcaacacg aagatctaat tggaaagtgc 480

catgcttttg atggaacgat attatttta cctaaaagac tacagcaaaa ggttactgaa 540

gtttttagta agacccggaa tggagaggat gtgaggataa cgatcacttt aacaaatgaa 600

cttccaccta catcaccaac ttgtttgcag ttctataata ttattttcag gaggcttttg 660

aaaatcatga atttgcaaca aattggacga aattattata acccaaatga cccaattgat 720

attccaagtc acaggttggt gatttggcct ggcttcacta cttccatcct tcagtatgaa 780

aacagcatca tgctctgcac tgacgttagc cataaagtcc ttcgaagtga gactgttttg 840

gatttcatgt tcaactttta tcatcagaca gaagaacata aatttcaaga acaagtttcc 900

aaagaactaa taggtttagt tgttcttacc aagtataaca ataagacata cagagtggat 960

gatattgact gggaccagaa tcccaagagc acctttaaga aagccgacgg ctctgaagtc 1020

agcttcttag aatactacag gaagcaatac aaccaagaga tcaccgactt gaagcagcct 1080

gtcttggtca gccagcccaa gagaaggcgg ggccctgggg ggacactgcc agggcctgcc 1140

atgctcattc ctgagctctg ctatcttaca ggtctaactg ataaaatgcg taatgatttt 1200

aacgtgatga aagacttagc cgttcataca agactaactc cagagcaaag gcagcgtgaa 1260

gtgggacgac tcattgatta cattcataaa aacgataatg ttcaaaggga gcttcgagac 1320

tggggtttga gctttgattc caacttactg tccttctcag gaagaatttt gcaaacagaa 1380

aagattcacc aaggtggaaa aacatttgat tacaatccac aatttgcaga ttggtccaaa 1440

gaaacaagag gtgcaccatt aattagtgtt aagccactag ataactggct gttgatctat 1500

acgcgaagaa attatgaagc agccaattca ttgatacaaa atctatttaa agttacacca 1560

gccatgggca tgcaaatgag aaaagcaata atgattgaag tggatgacag aactgaagcc 1620

-continued

tacttaagag tcttacagca aaaggtcaca gcagacaccc agatagttgt ctgtctgttg 1680

tcaagtaatc ggaaggacaa atacgatgct attaaaaaat acctgtgtac agattgccct 1740

accccaagtc agtgtgtggt ggcccgaacc ttaggcaaac agcaaactgt catggccatt 1800

gctacaaaga ttgccctaca gatgaactgc aagatgggag gagagctctg gagggtggac 1860

atccccctga agctcgtgat gatcgttggc atcgattgtt accatgacat gacagctggg 1920

cggaggtcaa tcgcaggatt tgttgccagc atcaatgaag ggatgacccg ctggttctca 1980

cgctgcatat ttcaggatag aggacaggag ctggtagatg ggctcaaagt ctgcctgcaa 2040

gcggctctga gggcttggaa tagctgcaat gagtacatgc ccagccggat catcgtgtac 2100

cgcgatggcg taggagacgg ccagctgaaa acactggtga actacgaagt gccacagttt 2160

ttggattgtc taaaatccat tggtagaggt tacaacccta gactaacggt aattgtggtg 2220

aagaaaagag tgaacaccag atttttgct cagtctggag gaagacttca gaatccactt 2280

cctggaacag ttattgatgt agaggttacc agaccagaat ggtatgactt ttttatcgtg 2340

agccaggctg tgagaagtgg tagtgtttct cccacacatt acaatgtcat ctatgacaac 2400

agcggcctga agccagacca catacagcgc ttgacctaca agctgtgcca catctattac 2460

aactggccag gtgtcattcg tgttcctgct ccttgccagt acgcccacaa gctggctttt 2520

cttgttggcc agagtattca cagagagcca aatctgtcac tgtcaaaccg cctttactac 2580

ctc 2583

<210> SEQ ID NO 80
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C1, primer (5'-3')

<400> SEQUENCE: 80

gaggtctgta acattgtggc 20

<210> SEQ ID NO 81
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C1, primer (5'-3')

<400> SEQUENCE: 81

cggtagaaga tgatgcgggt 20

<210> SEQ ID NO 82
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature

-continued

<223> OTHER INFORMATION: eIF2C1, primer (5'-3')

<400> SEQUENCE: 82

gaggtctgta acattgtggc 20

<210> SEQ ID NO 83
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C1, primer (5'-3')

<400> SEQUENCE: 83

aagttcttga gcacctcttc tcga 24

<210> SEQ ID NO 84
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C1, primer (5'-3')

<400> SEQUENCE: 84

gaggtctgta acattgtggc 20

<210> SEQ ID NO 85
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C1, primer (5'-3')

<400> SEQUENCE: 85

cggtagaaga tgatgcgggt 20

<210> SEQ ID NO 86
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C1, primer (5'-3')

<400> SEQUENCE: 86

ccacaccagc gctctgcc 18

<210> SEQ ID NO 87
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C1, primer (5'-3')

<400> SEQUENCE: 87

ctcacgcacc atgtagga 18

<210> SEQ ID NO 88
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C2, primer (5'-3')

<400> SEQUENCE: 88

gaggtctgta acattgtggc 20

<210> SEQ ID NO 89
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C2, primer (5'-3')

<400> SEQUENCE: 89

cggtagaaga tgatgcgggt 20

<210> SEQ ID NO 90
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C2, primer (5'-3')

<400> SEQUENCE: 90

atcctgctgc cccaaggg 18

<210> SEQ ID NO 91
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C2, primer (5'-3')

<400> SEQUENCE: 91

gatctcctgc cggtgctg 18

<210> SEQ ID NO 92

-continued

<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C2, primer (5'-3')

<400> SEQUENCE: 92

gaggtctgta acattgtggc 20

<210> SEQ ID NO 93
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C2, primer (5'-3')

<400> SEQUENCE: 93

cggtagaaga tgatgcgggt 20

<210> SEQ ID NO 94
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C2, primer (5'-3')

<400> SEQUENCE: 94

gaggtctgta acattgtggc 20

<210> SEQ ID NO 95
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C2, primer (5'-3')

<400> SEQUENCE: 95

gatctcctgc cggtgctg 18

<210> SEQ ID NO 96
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C3, primer (5'-3')

<400> SEQUENCE: 96

-continued

agagcaacag tatggtgggt ggac 24

<210> SEQ ID NO 97
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C3, primer (5'-3')

<400> SEQUENCE: 97

tggatgtgtg atggtact 18

<210> SEQ ID NO 98
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C3, primer (5'-3')

<400> SEQUENCE: 98

cctctacagt caagaggt 18

<210> SEQ ID NO 99
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C3, primer (5'-3')

<400> SEQUENCE: 99

tggatgtgtg atggtact 18

<210> SEQ ID NO 100
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C3, primer (5'-3')

<400> SEQUENCE: 100

cacttgaatg aagtccca 18

<210> SEQ ID NO 101
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature

-continued

<223> OTHER INFORMATION: eIF2C3, primer (5'-3')

<400> SEQUENCE: 101

tcctggatga cctcttgact gtag 24

<210> SEQ ID NO 102
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C3, primer (5'-3')

<400> SEQUENCE: 102

agagcaacag tatggtgggt ggac 24

<210> SEQ ID NO 103
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C3, primer (5'-3')

<400> SEQUENCE: 103

tcctggatga cctcttgact gtag 24

<210> SEQ ID NO 104
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C4, primer (5'-3')

<400> SEQUENCE: 104

tccggcatct caagaacaca tattct 26

<210> SEQ ID NO 105
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C4, primer (5'-3')

<400> SEQUENCE: 105

gaactcatat gggtgtgtaa tgtctg 26

<210> SEQ ID NO 106
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C4, primer (5'-3')

<400> SEQUENCE: 106

atccaggact tggcctcc 18

<210> SEQ ID NO 107
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: eIF2C4, primer (5'-3')

<400> SEQUENCE: 107

gaactcatat gggtgtgtaa tgtctg 26

<210> SEQ ID NO 108
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HILI, primer (5'-3')

<400> SEQUENCE: 108

cagcacaaat tatccctt 18

<210> SEQ ID NO 109
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HILI, primer (5'-3')

<400> SEQUENCE: 109

cggcctgaag gactgagacg tgt 23

<210> SEQ ID NO 110
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HILI, primer (5'-3')

<400> SEQUENCE: 110

cagcacaaat tatccctt 18

<210> SEQ ID NO 111

-continued

<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HILI, primer (5'-3')

<400> SEQUENCE: 111

gtgtgtgggc ttcactga 18

<210> SEQ ID NO 112
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HILI, primer (5'-3')

<400> SEQUENCE: 112

tctctgtcaa agaactggct tgtcct 26

<210> SEQ ID NO 113
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HILI, primer (5'-3')

<400> SEQUENCE: 113

ctgtacagtg cggttcat 18

<210> SEQ ID NO 114
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HILI, primer (5'-3')

<400> SEQUENCE: 114

tctctgtcaa agaactggct tgtcct 26

<210> SEQ ID NO 115
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligodeoxynucleotide with homology to human gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: HILI, primer (5'-3')

-continued

<400> SEQUENCE: 115

cggcctgaag gactgagacg tgt 23

1. Purified human RISC having a molecular weight of from up to about 150-160 kDa.

2. The RISC of claim 1 comprising at least one member of the Argonaute family of proteins.

3. The RISC of claim 1 containing eIF2C1 and/or eIFC2 and optionally at least one of eIFC3, eIFC4, HILI and HIWI.

4. The RISC of claim 1, further containing an RNA component, particularly a single-stranded RNA molecule.

5. The RISC of claim 4, wherein the single-stranded RNA molecule has a length from 14-50 nucleotides wherein at least the 14-20 5' most nucleotides are substantially complementary to a target transcript.

6. The RISC of claim 4, wherein said RNA molecule has a length from 15-29 nucleotides.

7. The RISC of claim 4, wherein said RNA molecule has a free 5' hydroxyl moiety or a moiety selected from phosphate groups or analogues thereof.

8. The RISC of claim 7, wherein said RNA molecule has a 5'-moiety selected from 5'-monophosphate ((HO)2(O)P—O-5'), 5'-diphosphate ((HO)2(O)P—O—P(HO)(O)—O-5'), 5'-triphosphate ((HO)2(O)P—O—(HO)(O) P—O—P(HO)(O)—O-5'), 5'-guanosine cap (7-methylated or non-methylated) (7m-G-0-5'-(HO)(O)P—O—(HO)(O)P—O—P(HO)(O)—O-5'), 5'-adenosine cap (Appp), and any modified or unmodified nucleotide cap structure (N—O-5'-(HO)(O)P—O—(HO)(O)P—O—P(HO)(O)—O-5'), 5'-monothiophosphate (phosphorothioate; (HO)2(S)P—O-5'), 5'-monodithiophosphate (phosphorodithioate; (HO)(HS)(S)P—O-5'), 5'-phosphorothiolate ((HO)2(O)P—S-5'); any additional combination of oxygen/sulfur replaced monophosphate, diphosphate and triphosphates (e.g. 5'-alpha-thiotriphosphate, 5'-gamma-thiotriphosphate, etc.), 5'-phosphoramidates ((HO)2(O)P—NH-5', (HO)(NH2)(O)P—O-5'), 5'-alkylphosphonates (R=alkyl=methyl, ethyl, isopropyl, propyl, etc., e.g. RP(OH)(O)—O-5'-, (OH)2(O)P-5'-CH2-), 5'-alkyletherphosphonates (R=alkylether=methoxymethyl (MeOCH2-), ethoxymethyl, etc., e.g. RP(OH)(O)—O-5'-).

9. The RISC of claim 1, wherein said RNA molecule is completely complementary to said target transcript, optionally with the exception of nucleotides that extend beyond position 20 (counted from the 5' terminus).

10. The RISC of claim 1, wherein said RNA molecule comprises at least one modified nucleotide analogue, which is preferably selected from sugar-backbone- and nucleobase-modified ribonucleotides and combinations thereof.

11. The RISC of claim 1, wherein said RNA molecule is associated with biodegradable polymers or microparticles, preferably wherein said association comprises a covalent coupling, in particular a covalent coupling via the 3'-terminus of the RNA molecule.

12. A host cell or non-human host organism capable of overexpressing RISC according to claim 1.

13. A method of enhancing RNAi in a cell or an organism comprising causing said cell or organism to overexpress at least one component of RISC according to claim 1.

14. The RISC molecule according to claim 1 for use as a target for diagnosis and/or therapy.

15. The RISC according to claim 1 for use as a diagnostic and/or therapeutic agent itself, as a molecular-biological reagent or as component in a screening procedure for identification and/or characterization of pharmaceutical agents.

* * * * *